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Abstract 
 
Anti-Beta2-Glycoprotein I antibodies (anti-β2GPI) are strongly associated 
with thrombosis in patients with primary antiphospholipid syndrome (PAPS). 
Anti-β2GPI activate endothelial cells (EC) resulting in a pro-thrombotic and 
pro-inflammatory phenotype. In order to characterise EC gene regulation in 
response to anti-β2GPI, early global gene expression was assessed in human 
umbilical vein endothelial cells (HUVEC) in response to affinity purified 
anti-β2GPI. Sera were collected from patients with PAPS and IgG was 
purified using HiTrap Protein G Sepharose columns. Polyclonal anti-β2GPI 
were prepared by passing patient IgG through NHS activated sepharose 
coupled to human β2GPI. Anti-β2GPI preparations were characterized by 
confirming their β2GPI co-factor dependence, binding to β2GPI and ability to 
induce leukocyte adhesion molecule expression and IL-8 production in vitro. 
Two microarray experiments tested differential global gene expression in 6 
individual HUVEC donors in response to 5 different PAPS polyclonal anti-
β2GPI (50 µg/ml) compared to 5 normal control IgG (50 µg/ml) after 4 hours 
incubation . Total HUVEC RNA was extracted and cRNA was prepared and 
hybridised to Affymetrix HG-133A (Exp.1) and HG-133A_2 (Exp.2) gene 
chips. Data were analyzed using a combination of the MAS 5.0 (Affymetrix) 
and GeneSpring (Agilent) software programmes. Significant change in gene 
expression was defined as greater than two fold increase or decrease in 
expression (p<0.05).  
Novel genes not previously associated with PAPS were induced including 
chemokines CCL20, CXCL3, CX3CL1, CXCL5, CXCL2 and CXCL1, the 
receptors Tenascin C, OLR1, IL-18 receptor 1 and growth factors, CSF2, 
CSF3, IL-6, IL1β and FGF18. Downregulated genes were transcription 
factors/signaling molecules including ID2. Microarray results were 
confirmed for selected genes (CSF3, CX3CL1, FGF18, ID2, SOD2, Tenascin 
C) using quantitative real-time RT-PCR analysis. This study revealed a 
complex anti-β2GPI-regulated gene expression profile in HUVEC in vitro. 
The novel chemokines and pro-inflammatory cytokines identified in this 
study may contribute to the vasculopathy associated with PAPS. 
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Chapter 1 
General Introduction 
 21
1.1 History of APS 
 In 1906, A.P. vonWasserman developed the first serologic test for a complement-
fixing antibody in the sera of patients with syphilis. Antibodies in the sera of such 
patients reacted with extracts of syphilitic tissues but were also found to interact 
with normal human and animal tissues. The antigen was later identified in 1941 by 
Pangborn as a mitochondrial phospholipid called cardiolipin 
(diphosphatidylglycerol)(Levine, Branch, & Rauch 2002; Hanly 2003) and the 
antigen used in the test was an extract from bovine hearts. In an effort to control 
the infection, the Wasserman test facilitated the widespread screening of the 
population using serologic tests for syphilis. These tests became the basis of the 
Venereal Disease Research Laboratory (VDRL) test for syphilis in the 1930s, a 
rapid serum flocculation procedure similar to that still in use for monitoring of 
treatment rather than diagnosis (Levine, Branch, & Rauch 2002; Hanly 2003). 
 
Widespread use of the VDRL test included screening of military personnel at the 
onset of World War II and premarital testing required by State Boards of Health 
identified numbers of individuals who tested positive in the VDRL test but had no 
history of sexually transmitted disease. It was found that many patients with 
systemic lupus erythematosus (SLE) had a positive VDRL test but no clinical or 
serological evidence of infection with syphilis (Triplett 2000). As the result of the 
high rate of false positives, the more specific Treponema Pallidum Immobilization 
(TPI) diagnostic test for syphilis was introduced in the late 1940s. TPI confirmed 
that the VDRL test was detecting antibodies secondary to infections other that 
syphilis. In 1952, Moore and Mohr divided biologic false positive serologic test 
results for syphilis into two groups, acute (transient) or chronic. Transient false 
positives could follow acute viral infections and vaccination but persistent 
positive results over a period of 6 months or greater were consistent with 
autoimmune disorders such as SLE, Sjogren’s syndrome and rheumatoid arthritis 
(Hanly 2003). They also made the association between false positivity and 
increased incidence of thrombosis and thrombocytopenia in young women. 
Conley and Hartmann were the first to describe a circulating anticoagulant in the 
plasma of two patients with SLE (Conley & Hartmann, 1952). The patients’ 
plasma demonstrated a prolongation of the whole blood clotting time and 
prothrombin time and no coagulation factor deficiency then measurable. This was 
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the first reference to the “lupus anticoagulant” (LA) and its association with 
prolongation of phospholipid dependent coagulation tests. In 1957 Laurell and 
Nilsson (1957) demonstrated that the cardiolipin in the Kahn flocculation test 
could adsorb out LA activity suggesting that LA activity was due to an anti-
phospholipid antibody. Feinstein and Rapaport applied the term lupus LA to these 
antibodies twenty years later because LA’s were originally found in patients with 
SLE (Feinstein & Rapaport 1972).  
 
Preliminary work by Hughes et al. investigating CNS Lupus in patients with 
“Jamaican neuropathy” identified numerous patients who showed false positive 
VDRL tests (Wilson & Hughes, 1975). This finding led to subsequent extensive 
investigation of antibodies to phospholipids in these patients. In this way the strong 
link between LA and increased incidence of thrombosis was recognized. 
Investigation of increasing numbers of patients revealed numerous instances of anti-
DNA negative or atypical SLE patients associated with thrombosis, cerebral 
disease, and/or recurrent miscarriages. In 1983, Harris and Hughes (with colleagues 
Asherson, Gharavi) at the Hammersmith Hospital (London, U.K.) developed a solid 
phase radioimmunoassay for the detection of anticardiolipin antibodies (aCL). This 
assay was approximately 400 times more sensitive than the conventional VDRL test 
(Harris et al., 1983). Using this assay, they reported correlation between the 
presence of aCL and the incidence of both arterial and venous thrombosis, recurrent 
pregnancy loss and thrombocytopenia. The development of an enzyme-linked 
immunosorbent assay (ELISA) for aCL determination and quantitation followed in 
1984 (Koike et al., 1984). The proposal of the “anticardiolipin” or “antiphospholipid 
syndrome” (APS) as a new clinical entity in 1985 was facilitated by subsequent 
clinical and epidemiological studies utilizing the new assay (Hughes 1985).  
 
 
1.2 Clinical features of APS 
Primary antiphospholipid syndrome (PAPS) occurs in patients when clinical 
evidence of another autoimmune disease is absent, and accounts for about 50 
percent of cases of APS. It is characterized by recurrent arterial and/or venous 
thrombosis, recurrent pregnancy loss and thrombocytopenia in association with 
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the presence of antiphospholipid antibodies (aPL). APS, in association with 
another autoimmune disease such as SLE, is referred to as secondary APS. 
Since APS was first described in 1983 and recognized as an entity apart from the 
LA associated phenomenon, the spectrum of associated clinical manifestations has 
grown considerably. In addition to thrombosis, recurrent fetal loss and 
thrombocytopenia, they encompass neurological disorders (epilepsy, atypical 
migraine, chorea, transverse myelopathy, dementia), obstetric complications (fetal 
distress, preeclampsia and pregnancy induced hypertension), valvular heart 
disease and cutaneous features (livedo reticularis, leg ulcers, gangrene skin ulcers) 
(Koike et al., 1984; Hojnik et al., 1996; Durrani, Gordon, & Murray 2002). 
Accelerated atherosclerosis is also associated with APS (Harats et al., 1999; Tak 
& Firestein 2001; Cervera et al., 2002).  
 
aPL have been associated with both valvular and ischaemic heart disease. Up to 4 
percent of patients with APS have at least one heart valve abnormality (Vianna et 
al., 1994). PAPS is associated with a high incidence of cardiac valvular disease 
(35-60% of patients) (Badui et al., 1995; Garcia-Torres et al.,1996; Espanola-
Zavaleta et al., 1999; Turiel et al., 2000). Pathological findings in PAPS include 
mitral and/or aortic valve lesions and/or thickening, intravascular or coronary 
thrombosis or myocardial infarction. A significant correlation between aPL titre, 
degree of valvular thickening and thrombotic events has been identified (Turiel et 
al., 2000). Other pathological findings include fibrin deposits and vascular 
proliferation in the absence of inflammation (Garcia-Torres et al., 1996). Using 
immunohistochemical methods, sub-endothelial deposits of immunoglobulins 
containing aPL are consistently present in cardiac valves of patients with APS 
(Hojnik et al., 1996). APL have been associated with an increased risk of 
cardiovascular events. Hamsten (1986) noted that 21 percent of men who had 
myocardial infarcts under the age of 45 had elevated levels of aPL, and a higher 
incidence of another cardiovascular event in the next five years compared to 
patients with no antibodies. A prospective study of middle-aged men identified 
increased aPL level was an independent risk factor for myocardial infarction 
(Vaarala et al., 1995). A prospective study of 1150 patients with acute myocardial 
infarction however showed that elevated IgG aPL and low IgM aPL were 
independent risk factors for recurrent cardiac events (Bili et al., 2000).  
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1.3 Diagnostic criteria for the diagnosis of APS 
In an attempt to consolidate consensus, clarify diagnosis and treatment of the 
syndrome, an international and multidisciplinary symposium has been held every 
two years since 1984. Formulation of the preliminary classification criteria for 
APS (“Sopporo criteria”) was undertaken during a post-conference workshop that 
took place in Sopporo, Japan on October 10, 1998 following the Eighth 
International Symposium on Antiphospholipid Antibodies. Extensive review of 
clinical and experimental evidence has reinforced the widespread opinion that 
aPL are significantly associated with arterial and venous thrombosis and recurrent 
miscarriage. Results of prospective studies and the strong experimental evidence 
defined vascular thrombosis and/or recurrent pregnancy loss as the clinical 
criteria for APS. The diagnosis of APS requires that aPL must be present in a 
medium to high titre and persistently present on two or more occasions at least six 
weeks apart (Wilson W.A. et al., 1999; Carreras, Forasterio, & Martinuzzo 2000). 
Definite APS is considered to be present in a given patient when at least 1 of the 
laboratory criteria (detection of either aCL or LA) and at least one of the 
diagnostic criteria (vascular thrombosis or fetal loss) are met (Table 1.1). Patients 
with either PAPS or secondary APS experience no major differences in clinical 
symptoms as a consequence of aPL (Levine, Branch, & Rauch 2002). Definite 
APS is considered to be present if at least 1 of the clinical criteria and 1 of the 
laboratory criteria are met (see Table 1.1). 
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Table 1.1: Criteria for the classification of definite antiphospholipid syndrome 
 
Clinical criteria 
 
1. Vascular thrombosis 
One or more clinical episodes of arterial, venous or small-vessel thrombosis in any tissue 
or organ. 
Thrombosis must be confirmed by imaging or Doppler studies or histopathology, with the 
exception of superficial venous thrombosis. For histopathologic confirmation, thrombosis 
should be present without significant inflammation in the vessel wall. 
2. Pregnancy morbidity 
a) One or more unexplained deaths of a morphologically normal fetus at or beyond the 
10th week of gestation, with normal fetal morphology documented by ultrasonography or 
by direct examination of the fetus, or 
b) One or more premature births of a morphologically normal neonate at or before the 34th 
week of gestation because of severe pre-eclampsia or eclampsia, or severe placental 
insufficiency, or 
c) Three or more unexplained consecutive spontaneous abortions before the 10th week of 
gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal 
chromosomal causes excluded. In studies of populations of patients who have more than 1 
type of pregnancy morbidity, investigators are strongly encouraged to stratify groups of 
subjects according to a, b or c above. 
 
 
 
 
Laboratory criteria 
 
1. Anticardiolipin antibody of IgG and/or IgM isotype in blood, present in medium or 
high titre, on 2 or more occasions, at least 12 weeks apart, measured by a standardized 
enzyme-linked immunosorbent assay for β2-glycoprotein-I–dependent anticardiolipin 
antibodies.  
2. Anti-β2 GPI antibodies of IgG or IgM isotype in blood (in titre above 99th percentile), 
present on two or more occasions, at least 12 weeks apart, measured by a standardized 
ELISA, according to recommended procedures (Miyakis et al., 2006). 
3. Lupus anticoagulant present in plasma, on 2 or more occasions at least 6 weeks 
apart, detected according to the guidelines of the International Society of Thrombosis and 
Hemostasis (ScientificSubcommittee on Lupus Anticoagulants/Phospholipid-Dependent 
Antibodies) in the following steps: 
a) Prolonged phospholipid-dependent coagulation demonstrated on a screening test, e.g., 
activated partial lthromboplastin time, kaolin clotting time, dilute Russell’s viper venom 
time, dilute prothrombin time, Textarin time. 
b) Failure to correct the prolonged coagulation time on the screening test by mixing with 
normal platelet poor plasma. 
c) Shortening or correction of the prolonged coagulation time on the screening test by 
addition of excess phospholipid. 
d) Exclusion of other coagulopathies, e.g., factor VIII inhibitor or heparin, as appropriate. 
Note: Ig = immunoglobulin. 
                                              (Arthritis Rheumatism 1999; 42(7):1309-11) 
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1.4 Incidence of aPL in healthy individuals 
The incidence of aPL measured in the healthy population have indicated that 4.7 
percent of healthy young people and up to 52 percent of elderly are positive for 
aPL. Antibody titres are low-positive and transient usually in response to 
infection (Durrani, Gordon, & Murray, 2002). It is highly unlikely for individuals 
to go on to develop clinical symptoms of APS when antibody titres are low. 
Additional risk factors should be assessed if such individuals go on to develop 
thrombosis. aPL are likely part of the natural repertoire of antibody production in 
these individuals and are not implicated in autoimmune disease.  
 
aPL can be present in numerous other conditions such as cancer, they can be 
drug-induced or found in patients undergoing hemodialysis, or with infections 
such as HIV (Greaves et al., 2000). These antibodies are not usually implicated in 
association with thrombosis since they are usually IgM, transient, and present in 
low concentration.  
 
 
1.5 The catastrophic antiphospholipid syndrome 
In most patients with APS, thrombosis occurs as a singular event in one 
anatomical site. A small number of patients may however present with an acute 
syndrome characterized by multiple vascular occlusions throughout the body. The 
catastrophic antiphospholipid syndrome presents as any combination of 
thrombocytopenia, disseminated intravascular coagulation (DIC), adult 
respiratory distress syndrome, liver failure, multi-organ involvement and often 
results in death (Asherson 1992). Its onset has been associated with infection, 
surgical procedures and withdrawal of anticoagulant therapy. It often results in 
widespread microvascular coagulopathy and has been coined a “thrombotic 
storm”.  Diagnosis requires arbitrary involvement of at least three different organ 
systems over a period of days to several weeks. The syndrome typically involves 
acute thrombotic microangiopathy that affects small vessels in multiple organs 
including the kidneys, lungs, central nervous system, heart and skin (Levine, 
Branch, & Rauch 2002). Catastrophic APS results in DIC in 25% of cases 
characterized by bleeding or thrombosis, increased activated partial 
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thromboplastin time (aPTT), decreased fibrinogen, antithrombin III, Protein C 
and increased D-dimer. 
 
 
1.6 Anti-endothelial cell antibodies (AECA) 
Anti-endothelial cell antibodies (AECA) are present in a number of autoimmune 
disorders where endothelial cell (EC) damage is common and AECA alter the 
procoagulant and anticoagulant phenotype of EC in vitro (reviewed in Praprotnik 
et al., 2001). AECA can bind directly to structural antigens on the EC surface itself 
or to extraneous antigens bound to the EC surface. AECA from one individual can 
show variation in binding affinities to EC of different phenotypes resulting in 
disease pathology within different parts of the vasculature (Hill et al., 1998). Their 
presence is well-documented in SLE-associated vasculitis and anti-neutrophil 
cytoplasmic antibody (ANCA)-positive vasculitis (Meroni et al., 2005). Numerous 
studies have attempted to identify AECA antigens by examining membrane lysate 
preparations but results are seldom conclusive due to the heterogeneity of these 
antibodies. AECA may have specificity for antigens on the EC membrane, the 
nucleus or cytoplasmic antigens. Methods for detection of AECA are also poorly 
standardized and give discrepant results (Praprotnik et al., 2001). AECA are found 
in sera of APS patients, of which aPL are a sub-group (Cines et al., 1998). 
 
 
1.7 Detection of antiphospholipid antibodies 
APL immunoglobulins (IgG, IgM and occasionally IgA) are generally divided into 
sub-groups based on the method by which they are detected. Pathogenic aPL are 
mainly IgG1 and IgG3 isotypes (Loizou et al., 1992). The antibodies are 
heterogeneous and adequate screening for their presence requires more than one 
type of assay. The two methods used for detection are: (1) solid phase 
immunoassays (ELISA) and (2) phospholipid dependent clotting tests. aPL are 
generally divided into lupus anticoagulant (LA) antibodies and anticardiolipin 
antibodies (aCL) where aCL represent aPL detected in the conventional ELISA 
assay that incorporates the negatively charged phospholipid cardiolipin as the 
antigen. Commercial aCL assays detect both infection and autoimmune derived 
antibodies. The original standard used to measure aCL was a cardiolipin affinity 
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purified standard (Harris et al., 1987). Isotype concentrations are expressed as (Ig) 
GPL, MPL or APL units where one unit is defined as the binding activity of 1µg/ml 
of affinity purified aCL. Reference sera for the measurement of aCL in ELISA 
assays have improved inter-laboratory reproducibility when quantitating the 
antibodies and helped in the standardization of assays. The formation of the 
European Forum for the standardization of aPL has improved standardization for 
antibody measurement between centres (Tincani, Allegri, & Sanmarco 2001). LA 
are detected in phospholipid-dependent coagulation tests where they interfere with 
phospholipid dependent coagulation reactions resulting in prolonged clotting times 
(Koike et al., 1984; Triplett 1994). A single patient may have aCL, LA or a 
combination of both and there may be some overlap in their antigenic specificities. 
 
 
1.8 Beta2 -Glycoprotein I: Co-factor for aPL 
Autoimmune aPL were thought to bind to negatively charged phospholipids, but it 
has become apparent that they are antibodies which bind to plasma proteins which 
bind to phospholipid and other anionic surfaces. In 1990, independent groups 
determined that a co-factor, Beta2–Glycoprotein I (β2GPI or apolipoprotein H) 
was necessary for autoimmune aPL to bind to acidic phospholipids such as 
cardiolipin and phosphatidylserine in ELISA (Galli et al., 1990; Matsuura et al., 
1990; McNeil et al., 1990; Triplett 1994). β2GPI was also found to be necessary 
for some LA’s to express their anticoagulant activity in vitro (Roubey et al., 
1995). It should be noted that both ELISA and clot based assays are required for 
adequate screening for the presence of aPL. The aCL ELISA detects both 
autoimmune aPL that are β2GPI-dependent and infection mediated PL antibodies. 
LA tests detect antibodies to β2GPI or prothrombin in association with 
phospholipids. 
 
β2GPI is a plasma glycoprotein with a molecular mass of 50 kDa that circulates at 
a concentration of ~200µg/ml. It is composed of five short-consensus-repeat 
domains (sushi domains) that are also common to complement factors and 
selectins (Takeya et al., 1997) (see Figure 1.1). β2GPI is highly conserved 
between species implying an important biological function in vivo. It binds to 
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negatively charged phospholipids (Roubey 1996). The positively charged 
phospholipid- binding site of the protein also known as the lysine binding region, 
is located in the fifth domain of the molecule. β2GPI also binds to the surface of 
EC through its fifth domain (Del Papa et al., 1998). The protein is largely 
synthesized in the liver but β2GPI mRNA has been isolated from different cell 
types involved in the pathology of APS (Caronti et al., 1999). β2GPI has 
anticoagulant properties in vitro including the inhibition of ADP-induced 
aggregation of platelets (Nimpf, Wurm & Kostner 1985) and inhibition of the 
prothrombinase complex (Roubay et al., 1995). An anticoagulant role for this 
protein in vivo has been suggested due to its ability to bind to negatively charged 
phospholipids, potentially blocking the molecules required for the activation of 
coagulation (Schousboe 1985). However, deficiency of the protein does not cause 
a thrombotic tendency and β2GPI–knockout mice were not distinguishable from 
normal mice indicating that the protein may not serve a physiologically significant 
role associated with thrombosis (Bansci, van der Linden, & Bertina 1992). 
  
In 1994, Matsura was able to show that some aPL could recognise β2GPI in the 
absence of cardiolipin, indeed aCL and anti-β2GPI were identified as two distinct 
populations of autoantibodies in that infection mediated aCL do not require the 
cofactor in order to bind to phospholipid (Roubey, Eisenberg, Harper & Winfield 
1995; Sorice, Circella & Griggi 1996). Anti-β2GPI have been found to have greater 
specificity and predictive value for clinical complications in APS when compared to 
assays for aCL (McNally et al., 1995; Amengual et al., 1996; Sanmarco et al., 
1997). Indeed β2GPI is now regarded as the most appropriate candidate antigen for 
clinically significant aPL (Hojnik et al., 1996; Roubey, Eisenberg, Harper & 
Winfield 1995; Triplett 1994). Like aCL, anti-β2GPI antibodies can be measured 
using an ELISA but both assays have proven difficult to standardize between 
laboratories. (McNally et al., 1995; Amengual et al., 1996; Carreras, Forasterio & 
Martinuzzo 2000). A number of commercial ELISA kits are available for 
measurement of IgG anti-β2GPI. The assay for anti-β2GPI is valuable since it can 
distinguish between β2GPI dependent and independent aPL (McNally et al., 1995). 
Testing for aCL and LA still remain the methods of choice in the diagnosis of APS 
(Greaves et al., 2000). 
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Figure 1.1  Beta 2 Glycoprotein I Structure  Picture A shows two molecules of 
β2GPI. The protein consists of a fish-hook like chain of five short consensus 
repeats (SCR), also called Complement Control Protein domains or Sushi domains. 
Each domain (I-IV) consists of around 60 amino acids (AA) and two di-sulphide 
bonds. Picture B- Domain V contains 82 AA including a six residue insertion and a 
19 residue C-terminal extension which together form the PL binding site. Shown in 
B are the 14 positively charges AAs that allow interaction with negatively charged 
PLs. C- A hydrophobic loop (Ser311-Lys317) anchors the protein when it is 
inserted into the membrane. Taken from: The EMBO Journal (1999) vol. 18, 5166-
5174 . 
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1.9 Antigenicity of anti-β2GPI antibodies 
The exact nature of the antigen/antibody interaction between aPL/anti-β2GPI and 
β2GPI has long been subject to debate. Opinions have differed as to whether the 
antibodies bind to the β2-GPI/phospholipids (PL) complex or to an epitope formed 
when the protein binds to negatively charged PLs or specially treated synthetic 
surfaces. γ-Irradiation of polystyrene plates increases the net negative charge 
enabling more β2GPI to bind. It was proposed that the binding of β2GPI to the PL 
surface caused a conformational change in the protein resulting in the formation of 
neo or cryptic epitope(s) for antibody binding. Preliminary studies in support of a 
cryptic epitope demonstrated that aPL were able to bind to β2GPI coated on an 
oxidized polystyrene surface in the absence of cardiolipin, but did not bind to non-
irradiated plates (Matsuura et al., 1994; Chamley et al., 1999). Binding of anti-
β2GPI to CL was inhibited by the simultaneous addition of CL-coated latex beads 
and β2GPI but not addition of β2GPI alone. This observation provided evidence 
that a cryptic epitope was formed as the result of conformational change in β2GPI 
when the protein interacted with PL or irradiated plates. 
 
In a ground-breaking study, Tincani and co-workers purified polyclonal anti-β2GPI 
preparations from 5 patients with APS and characterized them in detail. They 
found that anti-β2GPI were able to bind to β2GPI in solution and in the absence of 
PLs. The study defined anti-β2GPI as mono-reactive low-avidity auto-antibodies 
which react with epitopes located on β2GPI (Tincani et al., 1996). Two other 
groups of investigators provided the first evidence that anti-β2GPI bind to wild 
type protein and binding is dependent upon antigen density and bivalency of the 
antibody and not formation of a neo-epitope. Importantly, they showed that aPL 
and anti-β2GPI bound to the protein in the absence of PL. Experiments 
demonstrated little detectable binding of anti-β2GPI to fluid phase β2GPI at low 
physiological concentrations or β2GPI bound to ELISA plates at low density 
(Roubey et al., 1995; Sheng et al., 1998). Bivalent F(ab’)2  fragments bound more 
efficiently to immobilized β2GPI than monovalent Fab’. Roubay concluded that 
low affinity aPL bind bivalently to β2GPI on an irradiated plate or PL surface only 
when it was present at a sufficient concentration (Roubey et al., 1995). This 
observation is consistent with the more recent recognition of a threshold for β2GPI 
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ELISA antigen coating concentration below which polyclonal anti-β2GPI do not 
bind (Reddel, Wang, & Krilis 2003). Anti- β2GPI binding to the native protein in 
solution provided important evidence against the theory of cryptic epitope 
formation. 
 
In order to understand the pathology of these antibodies, it would be helpful to 
know the association between antibodies to certain epitopes and their contribution 
to thrombosis. A number of studies have been undertaken in order to determine the 
anti-β2GPI antigenic targets on β2GPI (Figure 1.1) (Giles et al., 2003). There is 
now evidence for anti-β2GPI specificity on all five domains of the protein 
(reviewed in Giles et al., 2003). Domain V contains the positively charged lysine 
rich PL binding region and β2GPI binds to human umbilical vein EC (HUVEC) 
through the same PL binding region in Domain V (Del Papa et al., 1998) (Figure 
1.1). The crystal structure of β2GPI shows that domains III and IV are heavily 
glycosylated and partially shielded from protein-protein interactions (Bouma et al., 
1999) (Figure 1.1). They function as links for the N-terminal Domain I exposed to 
the blood and Domain V bound to the PL surface. Extensive work by Iverson and 
colleagues has suggested that Domain I of the molecule contains the major 
epitopes for anti-β2GPI binding (Iverson, Victoria, & Marquis 1998; Iverson et al., 
2002). Domain I is the one most accessible to circulating antibodies and it contains 
a pocket of negative charge which may help to attract clusters of positively 
charged arginine and lysine residues identified in anti-β2GPI complimentarity 
determining regions (Bouma et al., 1999). 
 
β2GPI has a low affinity for PL, but interaction with some anti-β2GPI can increase 
its affinity for PL up to 100 fold (Willems et al., 1996). Experiments with LA 
positive monoclonal anti-β2GPI showed that only bivalent β2GPI /antibody 
complexes were able to bind to PL surfaces and exert LA activity (LAC) (Arnout 
et al., 1998). The addition of a recombinant contruct of dimer-β2GPI to clotting 
assays resulted in polonged clotting times and the same contruct had a much higher 
affinity for EC and activated platelets than the monomeric form (Bas de Laat, 
Derksen, & De Groot 2004a). Dimerization of the protein can occur when both 
Fab’ antigen binding sites of the antibody were engaged with separate protein 
molecules. Anti-β2GPI may cause formation of β2GPI dimers in vivo resulting in 
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clustering of antigen, increased affinity for EC and resultant EC activation (See 
1.17). 
 
 
1.10 The Lupus Anticoagulant 
The term “Lupus Anticoagulant” is universally recognized as a paradox since LA 
prolong blood clotting in the test tube but patients with LA’s have a strong 
predisposition to thrombosis. A systematic review of the literature from 1988 to 
2000 provided strong evidence that LA are a strong risk factor for venous and 
arterial thromboembolic events, odds ratio with 95% confidence interval, 5.7 to 9.4 
(Ginsberg et al., 1995; Galli et al., 2003a). Lupus anticoagulant is the strongest risk 
factor for both venous and arterial thrombosis in patients with SLE. Determination 
of LAC is more specific for APS than aCL (Galli et al., 2003a). Therefore each 
patient with clinical manifestations of APS should undergo testing for LA. 
 
Internationally determined guidelines for the detection and diagnosis of LA have 
been defined. Recommendations for diagnosis of LA include (1): prolongation of a 
PL dependent clotting time (2): evidence of a PL- dependent inhibitor demonstrated 
in mixing studies and (3): phospholipid dependence of the inhibitor effect must be 
confirmed by the addition of excess phospholipid. Tests routinely used for detection 
of LA include a screening test such as the aPTT performed with a LA sensitive 
reagent (if prolonged checked with a 1 to 1 mix of normal plasma to rule out 
clotting factor deficiency), the dilute Russell’s viper venom time (dRVVT), plus 
confirmatory testing with excess PL. Different possible mechanisms of interference 
with the PL-dependent reactions in the coagulation cascade in in vitro testing and 
low specificity mean that more than one assay for LA detection should be 
performed (Greaves et al., 2000). 
 
LA are heterogeneous in terms of antigenic specificity although β2GPI and 
prothrombin (Bevers et al., 1991) bound to the PL surface are the primary targets. 
LA’s were thought, in part, to exert anticoagulant effect by inhibiting 
prothrombinase activity due to binding to the prothrombin activator complex (II, V, 
PL, Ca). But, just as β2GPI was found to be required for the binding of autoimmune 
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aPL to cardiolipin, it was also determined that β2GPI was necessary for some LA’s 
to express their anticoagulant activity in vitro and its depletion resulted in the 
abrogation of LA activity from most LA positive plasmas (Roubay et al., 1992). 
Roubay postulated that autoimmune aPL, indeed anti-β2GPI, amplified the 
interaction of β2GPI with PL surfaces possibly by cross-linking molecules of β2GPI 
on the PL surface resulting in impaired binding and activation of clotting factors. 
Subsequent work by Takeya et al also determined that anti-β2GPI enhance the 
binding of β2GPI to the endothelium and induce the formation of β2GPI complexes 
on the PL surface due to their bivalent property enhancing LA activity via the 
F(ab’)2 fragment and not the Fab’ fragment (Takeya et al., 1997). This suggests that 
the clustering of molecules on the PL surface and the bivalent nature of the anti-
β2GPI may hinder the interaction of clotting factors on the PL surface and exert LA 
activity. The paper stresses the heterogeneous LA activity of aCL. Some anti-β2GPI 
will require β2GPI in order to bind to cardiolipin but will not possess LAC. LA 
activity of anti-β2GPI appears to be epitope dependent (Takeya et al., 1997). Those 
monoclonal antibodies directed against the carboxy terminal of the fourth domain 
and the fifth domain showed no LA like activity while those directed against the 
third and fourth domain inhibited thrombin generation in the dRVVT. The effect 
was blocked in the presence of excess PL confirming the LA activity of the 
antibodies. Increased levels of IgG anti-β2GPI are associated with increased 
incidence of thrombosis in patients positive for LA (Zoghlami-Rintelen et al., 
2005).  
 
Recent studies have resulted in the advent of assay systems more specific for the 
detection of LA positive anti-β2GPI. Bas de Laat et al outline the development of a 
modified aPTT incorporating cardiolipin vesicles that is capable of specifically 
detecting LA caused by anti-β2GPI (Bas de Laat et al., 2004b). The addition of CL 
shortens the clotting time due to anti-β2GPI and prolongs the times due to anti-
prothrombin antibodies. Using the assay, they established that β2GPI dependent LA 
was irrefutably associated with a history of thrombosis (odds ratio 42.3: 95% 
confidence interval 194.3-9.9) while an increase in thrombosis was not associated 
with LA in the absence of anti-β2GPI (odds ratio 1.6). The authors suggested that 
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anti-β2GPI with LA activity are those responsible for thrombosis in APS and their 
assay may be instrumental in identifying patients at risk of thrombosis. 
 
 A subsequent study by the same group divided IgG anti-β2GPI from 52 patients 
with systemic autoimmune diseases into two groups using ELISA. Group A 
antibodies recognized domain I of β2GPI coated onto hydrophobic plates and group 
B showed heterogeneous activity towards all domains. Group A (23 out of 25, 92%) 
antibodies recognized an epitope around Gly40-Arg43, had β2GPI-dependent LAC 
activity and a strong association with thrombosis thereby identifying a subset of 
pathogenic anti-β2GPI specific for domain I of the protein (Bas de Laat et al., 
2004c). 
 
 
1.11 Possible mechanisms of aPL induced thrombosis 
The mechanism by which aPL cause thrombosis is uncertain although a number of 
mechanisms have been proposed. Since aPL bind to negatively charged surfaces, 
it is possible that they interfere with regulatory coagulation proteins that are 
associated with phospholipid on endothelial and platelet surfaces. This could 
result in an imbalance between the pro and anti-coagulant systems and result in 
thrombosis. Antibodies directed against β2GPI and prothrombin are the most 
frequently occurring and best studied of these antibodies. Other candidate proteins 
addressed in the literature which include both activators and inhibitors of clot 
formation are: protein C, protein S, tissue plasminogen activator, 
thrombomodulin, high and low molecular weight kininogens, Annexin V, 
coagulation factor XII, complement component C4, complement factor H and 
coagulation factor VII/VIIa (Pierangeli, Gharavi & Harris, 2000). Protein C 
becomes activated when thrombin binds to thrombomodulin on the EC surface. 
Activated protein C acts as an anticoagulant in conjunction with its cofactor, 
protein S by inactivating factor Va and VIIIa in the cascade (Figure 1.2). 
ProteinC/S interactions occur on phospholipid surfaces. Antibodies to protein C, S 
and thrombomodulin found in some APS patients could interfere with this process 
(Pengo et al., 1996). Impaired fibrinolysis in association with thrombosis and aPL 
has been identified in some patients with SLE. This observation was attributed to 
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increased levels of circulating plasminogen activator inhibitor-1 and tissue 
plasminogen activator in these patients, and possibly the result of antibody 
induced EC perturbation (Jurado et al., 1992).   
  
1.12 Tissue Factor 
 
Tissue factor (TF) is the major physiological initiator of blood coagulation in vivo. 
(Mackman 2006)(Figure 1.2) It is a 47 kDa transmembrane glycoprotein and is 
structurally a member of the class II cytokine receptor family. Cells that are 
normally in contact with blood such as vascular endothelium and monocytes do 
not express TF in its functionally active form. These cells synthesize and express 
TF after being stimulated by lipopolysaccharide (LPS) or other inflammatory 
cytokines (Roubay RAS 2000). TF expression is imperative in order for normal 
endothelium to be converted to a procoagulant surface and increased procoagulant 
activity (PCA) due to TF is associated with thrombosis. Physiological activation 
of the coagulation pathway must be very rapid implying availability of preformed 
molecules. Functionally inactive TF is encrypted within vesicles in the cell 
membrane. Disruption of the membrane exposes PL necessary for the binding of 
coagulation factors and the TF-VIIa complex (Figure1.2) (Price et al., 2004). 
Several transcription factors that control the TF gene are activated by 
inflammatory cytokines such as interleukin1-β (IL-1 β), IL-6, and TNF-α.  
 
In vivo, monocytes adhere to activated EC and become activated in turn, 
expressing TF and subsequent PCA. The possible association between TF and 
APS was first demonstrated in studies using sera from patients with SLE.  
Incubation of normal donor monocytes with patient derived monoclonal aPL, 
resulted in the induction of TF-like PCA (Kornberg et al., 1994). Monocytes from 
a healthy donor incubated with APS plasma expressed more TF antigen and PCA 
than monocytes incubated with control plasma (Amengual et al., 1998). A study 
by Cuadrado et al. (1997) showed that monocytes from PAPS patients with a 
history of thrombosis have increased expression of TF, TF associated PCA, 
cellular and soluble TF. Dobado-Berrios et al. (1999) collected freshly isolated 
monocytes from 14 individuals with PAPS, 9/14 had a history of thrombosis. 
Reverse transcriptase polymerase chain reaction (RT-PCR) was performed on 
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monocyte total RNA in order to evaluate levels of TF gene expression. The 9 
patients with thrombotic history showed increased levels of mRNA for TF gene 
compared to normal controls and patients with no history (Dobado-Berrios et al., 
1999). A study by Williams suggested that monocytes from PAPS patients are 
primed to express more TF-associated PCA in response to a second stimulus such 
as LPS when compared to normal monocytes (Williams et al., 1998).  
 
The complex formed between TF and VIIa initiates coagulation. TF functions as 
the co-factor in order for VIIa to cleave its substrates factor IX and factor X 
(Roubey 2000). Factor VIIa/TF is responsible for the initial induction of Xa 
generation. This initial response will produce enough thrombin to allow local 
aggregation of platelets in addition to factors V and VIII activation. However, 
activated clotting factors will be removed by circulating blood and anticoagulant 
mechanisms involving protease inhibitors and fibrinolysis will be inititated. 
Coagulation must be sustained and amplified on site by the actions of factors IXa, 
VIIIa and XIa stressing the importance of both intrinsic and extrinsic pathways. 
Factor IX and X activation by TF is controlled by tissue factor pathway inhibitor 
(TFPI). TFPI is a Kunitz-type protease inhibitor. The several Kunitz-type domains 
on the TFPI molecule are consistent with the two inhibitory targets, factor Xa and 
factor VIIa/TF. Increased plasma concentrations of TFPI have been identified in 
other diseases and may be considered a marker of EC dysfunction. TFPI regulates 
the beginning of coagulation by factor Xa-dependent feedback inhibition of the 
TF/VIIa complex. TFPI forms a quaternary complex (TFPI, TF, VIIa, Xa) and 
inhibits VIIa and Xa in the presence of calcium ions and negatively charged PL 
(Broze 1995). TFPI may also inhibit factor Xa directly in the absence of 
phospholipid. Three intravascular pools of TFPI exist. 10-50% of TFPI circulates 
in plasma complexed to lipoproteins (50-150 ng/ml), 50 to 90% of TFPI is bound 
to glycosaminoglycans on the vessel wall and can be released into the circulation 
by the introduction of heparin (Kato 2002). A soluble isoform of TF present in 
blood has recently been described called alternatively spliced human tissue factor 
(Szotowski et al., 2005). Endothelial cells incubated with TNF-α or IL-6 released 
asHTF into the supernatant and this soluble TF is thrombogenic in the presence of 
phospholipids.  APS patients have increased levels of both TF and TFPI in their 
plasma (Cuadrado et al., 1997; Amengual et al., 1998). An association between 
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aPL and TF expression on EC and monocytes and upregulation of the TF/TFPI 
pathway in the pathology of thrombosis in APS is strongly implicated based upon 
these observations.  
 
 
1.13 Expression of TF in EC 
When the integrity of the endothelium is breached, EC are stimulated to express 
TF which functions as a high affinity receptor for coagulation factor VII/VIIa. TF 
expression can be induced on EC in response to thrombin, inflammatory 
cytokines, hypoxia, oxidized lipoproteins and LPS (Cines et al., 1998; Vega-
Ostertag et al., 2005). Branch et al. (1993) reported that APS patient sera induced 
PCA on EC (Branch & Rodgers 1993). Vega-Ostertag et al. confirmed the 
upregulation of TF by demonstrating dose-dependent increased expression of TF 
on EC in response to aPL, the effects of which were negated by pre-treating the 
cells with fluvastatin. They were also able to show that aPL increased TF PCA 
(conversion of X to Xa) on EC and up-regulated TF mRNA transcription. aPL 
have been shown to induce increased TF transcription by activating the NF-κB 
pathway incorporating p38 MAPK phosphorylation. Vega-Ostertag et al (2005) 
were able to inhibit aPL induced upregulation of TF in a dose-dependent manner 
by pre-incubating HUVEC with p38 MAPK inhibitor SB203580. Incubation of 
HUVEC with aPL also induced IL-6, IL-8 and iNOS expression (Vega-Ostertag et 
al., 2005).  
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Figure 1.2  The coagulation cascade The extrinsic pathway of coagulation 
is initiated by TF while collagen and activation of Factor XII play a major 
role in the activation of the intrinsic pathway. The cascade organizes the 
sequence of protein interactions in the extrinsic, intrinsic and common 
pathway beginning with the activation of factor X to Xa. These events are 
summarized in Figure 1.1. In the common pathway the prothrombinase 
complex (Xa, II, Va, PL) catalizes the conversion of prothrombin to 
thrombin. Thrombin and Factor XIII act on fibrinogen and in combination 
with platelets, form a fibrin plug. PL surfaces are essential for the 
coagulation mechanism to be carried to completion. Protein C and Protein 
S function as anticoagulants by inactivating VIIIa and Va. 
Thrombomodulin on the EC surface is required for activation of thrombin. 
Plasminogen is cleaved to become plasmin, the enzyme required for 
fibrinolysis of the clot. All proteins contribute to the pro- and anticoagulant 
balance of normal hemostasis. 
www.scielo.br/img/fbpe/bjmbr/v34n6/4133i02.gif 
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1.14 Platelets and APS 
Platelets have a primary role in hemostasis as they provide procoagulant PL 
surfaces for interaction of coagulation factors. Platelet adherence to injured 
endothelium is followed by platelet activation, and platelet granule release. This is 
followed by platelet shape change and exposure of PL in the platelet membrane. 
Platelets circulate in a more activated state in APS have a more prevalent role in 
arterial clots (Greaves 1999). Both polyclonal and monoclonal aPL have been 
shown to activate platelets in vitro (Joseph et al., 2001). Patients with PAPS often 
demonstrate mild thrombocytopenia that is not usually associated with bleeding. 
Platelets sensitized by autoantibodies may be removed from the circulation 
resulting in lower platelet number. In vitro, pre-treatment of platelets with low 
concentrations of another aggregation agonist such as thrombin is required before 
aPL can induce platelet activation. aPL can only bind to activated platelets and the 
binding is β2GPI-dependent (Shi, Chong, & Chesterman 1993). IgG purified from 
patients with APS enhance thrombin induced platelet activation and thromboxane 
B2 (TXB2) formation and complexes of aPL and β2GPI have been shown to 
induce increased platelet TXB2 production (Robbins et al., 1998). TXB2 is a potent 
eicosanoid responsible for vasoconstriction and platelet aggregation.  It is possible 
that β2GPI-anti-β2GPI complexes may prime platelets to be more adherent and 
susceptible to involvement in clot formation. 
 
Parallels have been drawn between heparin induced thrombocytopenia (HIT) and 
APS since both are characterized by autoantibody mediated thrombocytopenia and 
thrombosis in both venous and arterial sites. In both instances the target proteins 
(β2GPI or Platelet factor 4) bind to negatively charged molecules resulting in 
autoantibody formation (Warkentin, Aird, & Rand 2003). Unlike aPL, the 
antibodies in HIT bind to the FcγRII where as antibodies in APS are F(ab)2 
dependent. In HIT PF4/heparin macromolecular molecules form and IgG binds 
only when critical concentrations of heparin and PF4 are reached (Warkentin, 
Aird, & Rand 2003). 
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1.15 Thrombosis in APS  
aPL are associated with thrombosis in APS, indeed thrombosis is the most 
common clinical event manifested in APS (Cervera et al., 2002). Approximately 
70% of events are venous and 30% are arterial (Hughes 1983; Cameron & 
Frampton 1990; Cuadrado et al., 1997; Asherson et al., 1998). Venous thrombosis, 
particularly deep vein thrombosis (DVT) of the legs, is the most common clinical 
manifestation in APS and occurs in 29 to 55% of APS patients. This is 
accompanied by pulmonary emboli in at least half of the patients (Levine, Branch, 
& Rauch 2002). Arterial thromboses are less common, with strokes and transient 
ischemic attacks in the brain being the most common manifestation of arterial 
events (50%). A further 23% of arterial events occur in the coronary vessels while 
the remaining 27% occur in renal, retinal, subclavian and pedal arteries. Cerebral 
events can be caused by emboli from mitral or aortic valve vegetations. 
Thrombosis can occur in vessels of any size. Capillary, arteriole or venule 
involvement can reflect a clinical picture similar to hemolytic-uremic syndrome, 
thrombotic thrombocytopenic purpura or other thrombotic microangiopathies. 
Notably, thrombosis in APS can occur in both the venous and/or arterial 
vasculature whereas thrombotic events occurring in other thrombophilias tend to 
occur in either venous or arterial parts of the circulation but not both (Rosenberg & 
Aird, 1999).  
 
Not all patients with aPL go on to develop APS making it difficult to determine 
the risk of thrombosis associated with these antibodies. The development of 
animal models of APS has helped to confirm that aPL have a direct pathogenic 
role in APS. In vivo experiments by Pierangeli et al. (1995) showed that the 
infusion of APS patient immunoglobulins containing aPL into mice increased the 
size and duration of thrombi formed at the site of an artificially damaged vessel. 
The same group were able to repeat this observation in mice following 
immunization with β2GPI (Pierangeli et al., 1996). Mice and rabbits immunized 
with purified human β2GPI developed aPL and symptoms of APS including fetal 
wastage and readsorption (Blank et al., 1991; Blank et al., 1994). Mice and rabbits 
immunized with purified human β2GPI developed aPL and symptoms of APS. 
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Laboratory measurement of LA and aCL provide clinicians with diagnostic 
markers for APS. Numerous studies have addressed the role of the measurement 
of different aPL and its usefulness when attempting to identify those at risk of 
developing venous and/or arterial thrombosis and subsequent recurrence. LA is 
the strongest risk factor for both venous and arterial thrombosis in patients with 
SLE, and LA positivity is also strongly associated with pregnancy loss in these 
patients (Ginsberg et al., 1995). Importantly, LA is a more specific test for APS 
than aCL. An extensive review of the relevant literature from 1988 to 2000 was 
undertaken by Galli et al., 2003. Comparison of 12 prospective studies in 1608 
patients showed a significant association between LA and thrombosis (Odds ratio, 
OR of 7.3-10.7). Therefore LA are consistently associated with thrombosis, and 
screening for LA is necessary in order to identify patients at risk of developing 
thrombosis as well as aiding their therapeutic management. aCL were not as 
strong risk factors unless present in medium to high titres in the IgG isotype. ACL 
were more strongly associated with arterial events than LA. The review confirmed 
that LA should be included in the laboratory criteria in relation to venous and 
arterial thrombosis while the relevance of anticardiolipin antibodies was slightly 
less certain (Galli et al., 2003a). Retrospective studies are unable to determine 
whether aPL cause thrombosis or are actually a consequence of the 
thromboembolic event.  
 
A prospective Canadian study measured LA and aCL in 256 patients suspected of 
having venous thromboembolism (VTE) or pulmonary embolism (PE). The study 
was undertaken in order to determine the clinical relevance of these antibodies in 
the absence of SLE. A strong association was seen between LA and VTE (OR 
9.4) while no association was seen between aCL and VTE (OR 0.7) although this 
was perceived to be due to the high numbers of positive aCL assays in patients 
without VTE (Ginsberg et al., 1995).    
 
An extensive prospective study of 360 patients with LA and/or elevated IgG aCL 
was undertaken in sixteen institutions included in the Italian Registry of 
Antiphospholipid Antibodies. These patients were investigated for the presence of 
aPL because they had a history of thrombosis, a disease related to the presence of 
aPL, or a coagulation abnormality that was suggestive of LA (Finazzi et al., 
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1996). Patients were followed for a median of 3.9 years and 34 patients developed 
thrombosis. Patients with a previous vascular event showed a 5.4% patients/year 
incidence of recurrent events compared to 0.95% in patients with no symptoms 
thus identifying a previous thrombotic event as the most important clinical risk 
factor for the development of thrombosis. This data was confirmed by another 
European APS study in which 4.5% of patients per year suffered a recurrence 
(Vianna et al., 1994).   
 
Pertinent to and in support of this study, a close association has been found 
between IgG anti-β2GPI and venous thrombosis (VT) (Cabral, Cabiedes & 
Alarcon-Segovia 1995; Martinuzzo, Forastiero & Carreras 1995; Forastiero et al., 
1997; Wahl et al., 1998). Persistently positive anti-β2GPI identifies patients who 
have a higher risk of thromboembolic events (Carreras, Forasterio & Martinuzzo 
2000; Triplett 2002). In a further systematic review and meta-analysis of the 
literature 27 (largely) retrospective studies analysed 60 associations between anti-
β2GPI   and thrombosis  (studies involved patients with SLE, LA or aCL, difficult 
to evaluate these antibodies as independent risk factors for thrombosis.) The odds 
ratio (OR) for anti-β2GPI (95% confidence interval-CI) for thrombosis were 
available for 27 studies in 4,394 patients and 1973 controls. IgG anti-β2GPI were 
significantly associated with thrombosis in 20 of 33 studies(61%), IgM in 7 of 15 
studies (47%) and IgA in 3 out of 3. Overall, IgG anti-β2GPI antibodies were 
associated with venous thrombosis and two multivariate analyses identified them 
as independent risk factors for vascular events. aCL were associated with arterial 
thrombosis (Galli et al., 2003b). It was noted by the author that the majority of 
aCL recognize β2GPI bound to cardiolipin (as well as co-factor independent aPL) 
yet anti-β2GPI and aCL show different associations implying that they are not 
identical. ELISAs for anti-β2GPI are more specific for APS than aCL since only 
antibodies specific for β2GPI are detected. (Martinuzzo et al.,1995). In another 
study, a cohort of 87 patients (55 with a history of thrombosis and 32 without) and 
persistently positive LA were tested for aCL and anti-β2GPI.  Patients with history 
of thrombosis had significantly higher levels of both antibodies compared to those 
without thrombosis. Increased risk of thrombosis was associated with elevated 
IgG anti-β2GPI (OR 4.0, 95% CI 1.2-13.1, OR for VTE was 5.2). Therefore 
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patients with LA who have anti-β2GPI   have a significantly increased risk of risk 
of developing thrombosis. (Zoghlami-Rintelen et al., 2005). 
 
Patients with aPL can be divided into two groups. Those who are asymptomatic 
require observation while those who have had previous thrombosis or miscarriage 
require treatment. Retrospective studies of patients after the initial thrombotic 
event have confirmed that these patients will not have recurrent events if they 
receive high dose oral anticoagulation (warfarin) with an INR (international 
normalized ratio) between 2.5 and 4.0 (Rosove & Brewer, 1992). 
 
 
1.16 Fetal loss in APS  
The classification criteria for APS include recurrent fetal loss as a clinical criterion 
for diagnosis (Wilson et al., 1999) (Table 1.1). Women with APS are most at risk of 
pregnancy loss from the 10th week of gestation (fetal period). The dagnostic criteria 
for the obstetric manifestations of APS state that the patient must have one or more 
unexplained pregnancy losses in the fetal period (up to 34 weeks gestation) or three 
or more losses in the first 9 weeks of gestation in the presence of moderate to high 
titres of aPL. aPL are associated with recurrent miscarriage, fetal death and 
intrauterine growth restriction (IUGR). Pre-eclampsia, premature delivery and 
placental abruption are also associated with APS. (Pre-eclampsia is a common 
condition also associated with intrauterine growth retardation (IUGR) involving 
high blood pressure, kidney malfunction resulting in fluid retention and protein in 
the urine after the sixth month of gestation.)  
 
Several in vivo murine studies have provided evidence for the pathogenic role of 
aPL in recurrent fetal death. An animal model of SLE, MRL/lpr mice with high 
levels of IgG aPL, and thrombocytopenia have intrauterine fetal death with smaller 
litter size compared to NZB/NZW F1 mice (another SLE model) and normal Balb/c 
mice. Branch et al infused pregnant Balb/c mice with IgG aPL fractions from 
women with pregnancy loss and this resulted in intrauterine death and miscarriage 
within 48 hours of injection (Branch, Dudley, & Mitchell 2006). Histopathology 
showed decidual necrosis, intravascular IgG aPL and fibrin deposition while the 
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infusion of IgG from normal pregnant subjects did not result in intrauterine death or 
histological evidence of infarction. High levels of aPL were induced in normal mice 
when they were infused with purified human β2GPI. This resulted in pregnancy loss 
in some strains of mice (Gharavi et al., 1992). 
 
The precise role that aPL play in pregnancy loss remains uncertain. The binding of 
affinity purified aPL to placental antigens suggests that they may cause placental 
damage. β2GPI has been demonstrated on the surface of trophoblasts by in vivo 
histochemical staining and is present in higher concentration on trophoblastic villi 
of women with APS and fetal loss when compared to controls (LaRosa et al., 1994). 
It has been demonstrated that phosphatidylserine is exposed on the external cell 
surface during intertrophoblastic fusion (syncytium formation) and this would 
provide a negatively charged surface for the binding of β2GPI. Human monoclonal 
and polyclonal anti-β2GPI are able to bind to trophoblasts in vitro directly through 
exposed anionic PL (co-factor independent) or adherent β2GPI. Binding altered in 
vitro trophoblast function by reducing the release of human chorionic 
gonadotrophin (hCG) and reducing matrigel invasiveness suggesting that aPL may 
alter trophoblast development and placentation (Di Simone et al., 2005). The same 
group demonstrated binding of β2GPI to the trophoblast surface by the PL binding 
site in the fifth domain of the protein as in EC (Di Simone et al., 1999). This 
suggests that aPL may bind to adherent β2GPI on trophoblasts in vivo. Incubation of 
polyclonal IgG containing anti-β2GPI impaired fusion of cytoptrophoblasts. The 
authors postulated that binding of antibody to adherent β2GPI may reduce hCG 
secretion and prevent normal syncytiotrophoblast formation resulting in the 
defective placentation seen in APS (Di Simone et al., 2005).  
 
In APS, fetal death is preceded by intrauterine growth retardation, oligohydramnios, 
and abnormalities of heart rate all triggered by impaired fetal blood supply and 
hypoxia. These effects are thought in part to be a consequence of inadequate utero-
placental blood flow (Branch 1994). Infarction is described as an area of ischaemic 
villous necrosis, aggregation of the villi and destruction of the intervillous space. 
Isolated case reports have attributed uteroplacental insufficiency to abnormality in 
the terminal branches of the spiral arteries that provide maternal blood to the 
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intervillous space in the placenta. In 1982, De Wolf et al. (1982) identified the 
absence of these normally occurring changes in the spiral arteries in the placenta 
from a woman with APS, LA and fetal death in the third trimester. The vessels were 
smaller and showed intimal thickening, fibroblastic proliferation, intraluminal 
thrombosis and infarction of greater than fifty percent of the placenta. The 
vasculopathy revealed accumulation of lipid laden macrophages similar to that seen 
in atherosclerotic lesions. In normal pregnancy fetal trophoblasts 
(cytoptrophoblasts) invade the wall of the spiral arteries replacing some of the 
endothelium. Muscular tissue is replaced by fibrous material and as a consequence, 
the arterioles lose their elasticity. This allows maternal blood to freely enter the 
intervillous space where nutrients and oxygen are absorbed by fetal blood (Branch 
1994). Defective trophoblast invasion has been implicated in some SLE, pre-
eclampsia and APS pregnancies with IUGR.  
 
A previous study of 47 women experiencing fetal death (16 had aPL) concluded that 
women with APS showed no distinct placental pathology but most showed signs of 
infarction, thrombosis, fibrosis and hypovascular villi (Out et al., 1991). This is in 
agreement with a recent prospective study of placental biopsies from 12 women 
with PAPS. The results did not show absence of remodelling in spiral arteries 
compared to controls, however third trimester APS placental bed biopsies with 
adverse pregnancy outcome showed evidence of failed endovascular trophoblast 
invasion, more prominent synctial knot formation than controls, and more 
parenchymal infarction or thrombosis (Stone et al., 2006). Of note, a significant 
increase in the concentration of inflammatory cells, particularily macrophages, 
clustered around the blood vessels in APS biopsies was observed. The authors 
postulated that these inflammatory cells could be contributing to pregnancy 
complications (Stone et al., 2006). In conclusion, there does not appear to be a 
distinct histological lesion for APS in the placenta. Histologic findings in pre-
eclampsia and SLE with secondary APS are difficult to distinguish from those of 
APS in pregnancies with poor outcome. 
 
Thrombotic manifestations are a major contributing factor in aPL mediated 
pregnancy loss (Holers et al., 2002). Annexin V is a PL binding protein with 
anticoagulant properties (displaces other coagulation proteins from PL surface) 
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Rand et al. (1997) reported that annexin V expression (placental anticoagulant 
protein I) was markedly reduced on placental villi of patients with APS. A 
subsequent study by the same group showed that incubation of trophoblasts and 
endothelial cells with IgG aPL resulted in reduced expression of annexin V on the 
surface of both cell types resulting in a procoagulant phenotype in vitro (Rand et al., 
1997). 
 
aPL have been shown to induce fetal loss in vivo. Recent studies have shown a 
direct association between complement activation in the placenta, tissue damage, 
and fetal loss in aPL treated mice. In vivo blocking of the complement cascade 
with C3 convertase inhibitor complement receptor-1 elated gene/protein y (Crry) 
blocked fetal growth retardation and fetal loss (Holers et al., 2002). The major 
complement components involved are C3 and C5, mice deficient in these were 
resistant to enhanced white cell adhesion and thrombus formation induced by aPL 
(Pierangeli et al., 2005). Products of complement activation such as C5a and C3a 
can trigger the release of TF, recruitment and activation of neutrophils as well as 
other inflammatory cells such as monocytes (Girardi et al., 2003). Girardi 
proposed that treatment with heparin prevents obstetric complications by blocking 
activation of complement rather than preventing thrombosis (Girardi, Redecha & 
Salmon, 2004). This observation further lends support to the finding that placenta 
of APS patients demonstrate infiltration with large numbers of macrophages 
indicating that the aPL-mediated mechanism of fetal loss may in fact be mediated 
primarily by inflammation (Stone et al., 2006). 
  
 
1.17 aPL mediated activation of EC 
EC activation was defined as “altered synthesis of proteins that mediate functional 
characteristics of cells in response to stimulation with cytokines.”(Cines et al., 
1998). Upon EC activation, production of mRNA generally results in protein 
synthesis and change in the phenotype of the cell, this is called endothelial type II 
activation (Kaplanski et al., 1997). However, EC activation can include 
alterations in cell function that do not require transcription and translation. 
Therefore, EC activation is better defined more generally as a change in cell 
phenotype or function in response to external stimuli (Zimmerman et al., 1999).  
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It is well documented that aPL cause EC activation. Initial experiments assessed 
the effect of APS patient IgG on endothelial cell activation. The ability of affinity 
purified IgG aPL to bind to EC and upregulate adhesion molecule expression was 
first demonstrated by Del Papa et al. (Del Papa et al., 1995). This effect was 
shown to be due to the binding of the antibodies and autocrine expression of IL-
1α. Activation resulted in expression of IL-6 and IL-1β which upregulate 
adhesion molecule expression in turn. Upregulation of adhesion molecules 
(ICAM-1, VCAM-1, E-selectin) in the presence of anti-β2GPI was confirmed by 
Simantov et al. who were able to further support their findings by showing 
increased adhesion of monocytes to the EC (Simantov et al., 1995). Incubation of 
EC with β2GPI and rabbit anti-β2GPI resulted in significant increases in a 
monocyte cell line (MM6) cell adhesion and EC surface E-selectin expression. 
Cells were only activated in the presence of both β2GPI and anti-β2GPI 
confirming co-factor requirement for EC activation. Subsequent experiments 
demonstrated   a dose-dependent increase in the expression of ICAM-1, VCAM-1 
E-selectin, IL-6 and 6-keto prostaglandin F1α in response to affinity purified IgG 
anti-β2GPI and monoclonal anti-β2GPI -derived from an APS patient (Del Papa et 
al., 1997). 
 
 Experiments by Pierangeli et al. (1995) provided the first in vivo evidence that 
immunoglobulins from patients with APS increased adhesion of white cells to 
endothelium. They developed a mouse model of the microcirculation that enabled 
measurement of changes in adhesiveness of leukocytes to the postcapillary 
venules of the cremaster muscle in mice. After 72 hours, mice infused twice with 
aPL showed an increase in the number of adherent white cells when compared to 
mice infused with normal control IgG (Pierangeli et al., 1995). Subsequent 
experiments in mice immunized with β2GPI or human IgG aPL antibodies 
showed dose-dependent formation of significantly larger thrombi in vivo at the 
site of vascular injury when compared to normal control IgG infusion (Pierangeli 
et al., 1996). Thrombi also took longer to lyse. Similar results were noted in 
response to IgM and IgA APS immunoglobulin (Pierangeli et al., 1995). 
Importantly, these experiments demonstrated the association between aPL 
induced EC activation and thrombus formation in vivo.   
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It has been proposed that several pathways may be involved in anti-β2GPI induced 
EC activation. One pathway through which aPL activate endothelial cells is the 
transcription factor NF-κB. NF-κB is linked to its inhibitor IκB in the cytoplasm. 
When EC are activated by inflammatory cytokines, IκB becomes phosphorylated 
and degraded by IκB kinases. NF-κB is then free to move to the nucleus where it 
induces transcription in a large number of genes that possess the corresponding 
promoter (Tak & Firestein 2001). Inflammatory mediators such as TNF or IL-1 
activate EC via NF-κB resulting in increased transcription of TF and leukocyte 
adhesion molecules. Incubation of EC with anti-β2GPI results in the movement of 
NF-κB from the cytoplasm into the nucleus (Dunoyer-Geindre et al., 2002). 
Preincubation of the cells with the nuclear translocation inhibitor BAY11-7085 
prevented the increase in adhesion molecule expression normally seen in response 
to these antibodies. Dunoyer-Geindre et al. concluded from these observations that 
NF-κB is key to at least part of the inflammatory response triggered by anti-β2GPI. 
(Dunoyer-Geindre et al., 2002). Incubation of EC with anti-β2GPI resulted in a 
partial translocation of NF-κB to the nucleus after several hours although this delay 
could be due to suboptimal concentrations of antibody used in the experiments. 
TNF triggers complete translocation that occurs within 30 minutes. This suggests 
that there may be differences as well as similarities between signal transduction 
pathways activated by anti-β2GPI and other inflammatory cytokines. Fluvistatin 
was shown to inhibit upregulation of adhesion molecules in HUVEC in the 
presence of aPL by impairing the migration of NF-κB transcription factor to the 
nucleus and its subsequent binding to pro-inflammatory genes (Meroni et al., 2001). 
Activation of EC by anti-β2GPI results in activation similar to that induced by 
cytokines (IL-1β or TNF-α or LPS) (Meroni et al., 2001). Anti-β2GPI and LPS 
activate EC via IL-1 receptor-activated kinase (IRAK) phosphorylation and the 
MYD88 pathway, suggesting the involvement of the toll-like receptor family 
(Raschi et al., 2003a).   
 
Endothelial activation by aPL is not mediated by Fc receptor binding. Thrombus 
formation and EC activation were studied in mice deficient in the FcR γ (-/-) in the 
presence of aPL IgG and IgG-NHS. FcR γ (-/-) mice injected with aPL IgG had 
significantly larger thrombi than those injected with normal IgG. These mice also 
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showed increased white cell adhesion compared to controls (Pierangeli, Gharavi, & 
Harris 2000). 
 
 
1.18 Origin of anti-β2GPI antibodies- An autoimmune response mediated 
by molecular mimicry? 
 
In general, autoimmune diseases are thought to be caused by a combination of 
genetic and environmental factors. Autoimmunity can be defined as the breakdown 
of mechanisms responsible for self tolerance. As a consequence, immune cells 
launch an immune response against self-antigens. All individuals have small 
numbers of autoreactive T cells that recognize self antigens with low avidity. Some 
autoreactive T cells may have a beneficial role such as elimination of malignant 
cells. When normal regulatory mechanisms fail, loss of tolerance to self antigens 
can lead to the production of organ specific and/or systemic autoreactive 
antibodies.  
 
The healthy immune system is exposed to a variety of bacterial, viral and parasitic 
antigens, and many are representative of highly conserved protein families. 
Molecular mimicry occurs when similar tertiary protein conformation or 
similarities in amino acid sequences occur between self and foreign proteins. This 
can result in cross-reactivity between B and T cells and subsequent autoimmune 
disease. B or T cells initially reactive against an infectious agent can cross-react 
with self tissues or proteins leading to tissue damage and chronic autoimmune 
disease (Baum et al, 1996). Molecular mimicry will only lead to autoimmunity 
when the host and infectious agent are similar enough to cross-react but different 
enough to break immunological tolerance (Oldstone et al., 1987). 
 
Molecular mimicry has been proposed as the primary cause of a number of 
autoimmune disorders such as rheumatoid arthritis, diabetes, inflammatory bowel 
disease as well as multiple sclerosis (Kohm, Fuller, & Miller 2003). Infection is 
now considered to be the major trigger for the development of anti-β2GPI 
antibodies.  It has been suggested that molecular mimicry between pathogens and 
the β2GPI molecule may result in APS. Protein data bases have revealed strong 
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sequence homology between target epitopes for anti-β2GPI antibodies and a 
number of common pathogens (Shoenfeld et al., 2006). A number of bacterial and 
viral infections result in elevated titres of aCL and anti-β2GPI resulting in the 
clinical manifestations of APS (Blank et al., 2004a; Blank et al., 2004b). Examples 
include Hepatitis C, EBV, CMV, HIV, S.aureus, Streptococcus, Salmonella and E. 
coli. Molecular mimicry following infection has been implicated as a major 
mechanism responsible for development of Catastrophic APS (Blank et al., 2002).  
 
Molecular mimicry at the PL binding site on β2GPI may result in loss of self 
tolerance and the development of anti-β2GPI. Initial experiments involving 
infusion of three synthetic peptide sequences complementary to antigens 
recognized by patient derived monoclonal anti-β2GP, showed inhibition of EC 
activation in vitro and inhibition of induction of experimental APS in naïve mice 
in the presence of anti-β2GPI. (Peptide A 58LKTPRV63 corresponds to the first and 
second domain of the ß2-GPI molecule, peptide B 208KDKATF213 the fourth 
domain, and peptide C 133TLRVYK138 the third domain) (Blank et al., 1999).  
Subsequent experiments by Gharavi et al. (1999, 2003) showed induction of anti-
β2GPI production in naïve mice immunized with synthetic peptides with sequence 
homology to 72 kDa human adenovirus type 2 DNA-binding protein, CMV, 
HCMVA and Bacillus subtillis (Gharavi et al., 1999; Gharavi, Pierangeli & Harris 
2003). Immunization of mice with GDKV, a 15 AA synthetic peptide with 
sequence homology to Gly274 –Cys288 representing a major PL binding region of 
β2GPI induced aPL production in vivo. These antibodies induced thrombus 
formation. The same group of investigators were able to induce aPL in mice using 
synthetic peptides of bacterial and viral origin with AA sequence similar to 
GDKV (Gharavi et al., 1999).  
 
Several studies have demonstrated that bacteria and viruses with sequence 
homology similar to β2GPI induce production of pathogenic anti-β2GPI and 
manifestations of APS in vivo (Gharavi et al., 1999; Blank et al., 2002; Gharavi, 
Pierangeli & Harris 2003). Anti-β2GPI production was induced in naïve mice 
immunized with microbial pathogens sharing sequence homology with peptide C 
133TLRVYK138 from the third domain of β2GPI identified by phage display. The 
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highest levels of anti-β2GPI resulted in animals immunized with Haemophilus 
influenzae, Neisseria gonorrhoeae or tetanus toxoid. Resultant anti-TLRVYK 
antibodies were affinity purified and infused into naïve pregnant mice.  Recipient 
mice developed significant thrombocytopenia, prolonged aPTT and increased 
percentage of fetal loss. This study demonstrated that bacteria with structural 
homology to β2GPI could induce production of pathogenic anti-β2GPI (Blank et 
al., 2002). 
 
The development of pathogenic aPL involves the production of autoantibodies by 
autoreactive B cells and T cell help. CD4+ HLA class II restricted T cells are 
responsible for antibody production from B cells (Hattori et al., 2000). T cell 
clones from APS patients preferentially recognise the antigenic peptide containing 
the major PL binding site and stimulate B cells to produce anti-β2GPI through IL-6 
dependent helper activity and CD40-CD40 ligand engagement (Arai et al., 2001; 
Kuwana 2002). Subsequent studies have confirmed that TCRß chain expression is 
highly restricted in ß2-GPI reactive T cells from APS patients and suggest that 
targeting the Vß7+TCR region may be a possible therapeutic strategy to prevent 
the production of anti-β2GPI (Yoshida et al., 2002). It was postulated that since 
toll-like receptors (TLR) are the ligands for microbial structures, the protein may 
interact with TLR and anti-β2GPI may cross-link the receptors resulting in 
activation of EC.  
 
 
1.19 Heredity of PAPS 
 
Molecular mimicry may be one of the mechanisms responsible for development of 
autoimmune disease in response to a virus or bacteria. However, it is clear that not 
all individuals exposed to a pathogen go on to develop APS. It has been suggested 
that the disease occurs through a two hit mechanism (Pierangeli, Chen, &. 
Gonzalez 2006). Although PAPS is considered to be an acquired disease, this 
implies that genetic predisposition may also be a contributing factor. Certain HLA 
haplotypes are associated with SLE (DR4, DR5, or DR7) and other autoimmune 
diseases (Arnett, Olsen, Anderson & Reveille 1991). Cantalapiedra et al. described 
a father and daughter with PAPS who both suffered episodes of venous thrombosis 
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and thrombocytopenia (Cantalapiedra et al., 1999). Another study described 12 
families with inherited PAPS (Durrani, Gordon, & Murray 2002). Older family 
members of PAPS patients show a higher incidence of autoimmune diseases 
including SLE and RA and patients initially presenting with PAPS can go on to 
develop features of SLE. This suggests expression of familial autoimmunity 
(Andrews, Frampton, & Cameron 1993).  
 
 
1.20 Microarray Background 
The completion of the Human Genome project has provided scientists with 
limitless potential in their quest for insight into the interactions of genes and their 
functions within cells and biological systems (Venter et al., 2001). In the context of 
human health and disease, this invaluable knowledge can be utilized in order to 
determine the mechanisms of disease, how drugs interact with cells and also aid in 
the identification of genes that may themselves be therapeutic targets. New 
methods of statistical analysis are enabling the comparison of genomic and 
proteomic data leading to a better understanding of biological processes. As a 
consequence of this, the drug discovery industry will benefit from the technology. 
Microarray can be used to identify mutations/polymorphisms within genomic 
DNA. It is also one of a number of methods that measure gene expression. The 
methodology is exceptional in that it enables the analysis of the expression of 
thousands of genes in a cell type or tissue type simultaneously rather than one gene 
at a time.  
 
It is now possible to determine and compare differential gene expression between 
diseased and healthy cells or tissue, perhaps at different time points, in response to 
drug treatment or under variable conditions. A number of large studies have used 
microarray methods to gain insight into tissue specific regulatory genes potentially 
involved in the development of cancer. This endeavour has been facilitated by the 
availability of homogeneous cell samples in biopsy material. One such study has 
lead to the identification of markers of gene expression (mRNA) capable of 
distinguishing between different types of B cell lymphoma. In addition, these 
diagnostic markers were predictive of likely prognosis in the corresponding 
patients and therefore helpful for therapeutic strategy (Alizadeh et al., 2000). The 
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results of this study were particularly powerful in that large numbers of samples 
were tested on homogeneous cell populations. In another example, microarray 
technology was used for compiling a list of genes associated with and specific to 
the 6 major subclasses of acute lymphoblastic leukaemia (ALL) and their 
prognostic indices (Mitchell et al., 2004). 
  
Several studies have used microarray to investigate gene expression in SLE and 
identified prominent up-regulated expression in a number of interferon-regulated 
genes. These studies looked at gene expression in heterogeneous cell populations, 
peripheral blood mononuclear cells (PBMC). Even though proportions of different 
cell populations varied between individuals in these studies, a strong interferon 
regulated gene signature was observed in each (Baechler et al., 2003; Bennett et 
al., 2003; Crow, Kirou, & Wohlgemuth 2003; Han et al., 2003). Relevant to this 
study, a recent paper by Potti et al., (2006) presented the results of oligonucleotide 
array used to assess global genes expression in subsets of patients with APS and/or 
VTE in the presence or absence of aPL. Such information could possibly identify 
those patients at greater risk of developing thrombosis, enabling better clinical 
management and reducing the need for long-term anticoagulation with its inherent 
risk of bleeding. Using RNA from PBMC, the authors were able to detect subtle 
differences in gene expression potentially valuable in discerning those APS 
patients with thrombosis and patients with VTE and no APS (Potti et al., 2006). 
Although promising, these results were not totally definitive since evaluation of 
differential gene expression in monocytes and lymphocyte subsets may have been 
more informative. In addition, differences in gene expression related to previous 
thrombosis only could not be ruled out. 
 
A number of studies have examined the effect of inflammatory stimuli on global 
gene expression in HUVEC. Septic shock is caused by the liberation of large 
amounts of bacterial endotoxin (LPS) into the circulation and is a leading cause of 
death. cDNA microarrays were used to determine the effect of LPS exposure on 
gene expression in HUVEC at a number of time points (1-24 hours) (Zhao et al., 
2001). Results showed induction of a number of pro-inflammatory genes regulated 
primarily through the NF-κB transcription factor. Another study assessed the effect 
of interleukin 1 (IL-1) on gene expression in HUVEC at time points from ½ to 6 
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hours using Affymetrix 133A arrays (Mayer et al., 2004). This study provided 
evidence for both positive and negative IL-1 mediated feedback mechanisms that 
may have implications for treatment of chronic inflammatory conditions. 
Collectively, these studies revealed a number of genes and activation pathways 
potentially common to mediators of inflammation.  
 
Selective nucleotide base pairing (hybridization) is the underlying principle behind 
microarray technology (Lennon & Lehrach 1991). Micorarray chips are prepared 
by attaching DNA of known sequence (probe) to a solid surface glass slide 
(microarray chip) at precise co-ordinates. The array is exposed to labelled 
(radioactive or fluorescent tag) sample (target) DNA or RNA in solution. The 
target DNA binds to complementary sequences on the array and the identity and 
abundance of the target sequences are determined. The two basic types of 
microarray technology are: (1) the two dye cDNA microarray using double-
stranded cDNA fragments as probes and (2) the single dye oligonucleotide probe 
method (Lockhart & Winzeler 2000). This project used commercially prepared 
oligonucleotide labelled GeneChips (Affymetrix, Santa Clara. CA). The starting 
material for analysis was HUVEC derived messenger ribonucleic acid (mRNA). 
mRNA provides the expression profile of a cell in that it is a quantitative 
representation of  those genes that have undergone transcription. The Affymetrix 
protocol amplifies and converts cellular mRNA into cRNA that is then hybridized 
to the GeneChips. Stringent adherence to protocol and quality control ensure that 
the amount of target cRNA is representative of the relative amounts of each 
mRNA molecule in the original sample. 
 
In both methods, probe sequences are spotted onto glass slides at precise 
coordinates. Probes on Affymetrix oligonucleotide arrays are synthesized in situ 
one nucleotide at a time by a process called photolithography. This technology was 
pioneered by Affymetrix Company. Microarray technology has been refined to the 
extent that an Affymetrix GeneChip can scan for approximately 15,000 known 
genes within the human genome. One GeneChip contains 400,000 features or 
oligonucleotide binding sites in an area of 1 square centimetre. Evolving 
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technology will ultimately enable the entire human genome to be downloaded onto 
a single chip. 
 
Numerous experiments in a large variety of disciplines have lead to the 
accumulation of vast amounts of gene expression data. As the use of the 
technology becomes more widespread, increasing attention is being paid to details 
of experimental design and methods of data analysis in the interests of optimal use 
of information and the benefit of the scientific community at large. The minimum 
information about a microarray experiment (MIAME) has been compiled as the 
result of an international initiative to enforce standards for microarray data 
(Brazma et al., 2001). The greatest challenge posed by microarray technology lies 
in the ability to consolidate and share new knowledge in a mutually beneficial way 
within the scientific and medical communities. 
 
 
1.21 Aims of the study 
 
Patients with APS are prone to thrombosis and recurrent miscarriage and these 
manifestations are thought at least in part, to be due to interaction of aPL and the 
endothelium throughout the vasculature. APL, and more specifically anti-β2GPI 
activate EC in vitro. To date, investigation into the mechanisms by which such 
activation occurs, have been limited to measurement of levels of individual 
genes/proteins in EC and phenotypic changes in the cells themselves. An increase 
in leukocyte adhesion molecules on vascular EC and stimulation of pro-
inflammatory cytokines in response to anti-β2GPI has been well-documented in a 
number of in vitro studies. Preliminary experiments to investigate the possible 
activation pathways triggered by anti-β2GPI have provided some interesting 
insights.  
 
To date, there have been no studies to formally investigate the extent and diversity 
of gene regulation in response to anti-β2GPI. This is the first study to look at global 
gene expression in HUVEC in response to anti-β2GPI using microarray 
technology. Briefly, the aims of the study were: 
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1. To collect sera from PAPS patients with history of thrombosis and high 
titre β2GPI-dependent aPL. To affinity purifiy anti-β2GPI and characterize 
the antibody preparations. 
2. To design and carry out microarray experiments to assess global gene 
expression in HUVEC after incubation with patient polyclonal anti-β2GPI 
preparations. Particular reference will be made to inter and intra-
experiment technical reproducibility and meticulous care in following 
Affymetrix protocol.  
3. To perform appropriate analysis and statistical analysis on the microarray 
data using available software in order to identify those genes differentially 
expressed in response to polyclonal anti-β2GPI when compared to HUVEC 
incubated with normal control IgG. 
4.  To confirm results of microarray analysis with another method appropriate 
for assessment of changes in gene expression. 
5. To look for possible associations between those genes differentially 
expressed and consider their potential contribution to the pathology of 
APS. 
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Chapter 2 
Materials and Methods 
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2.1 Patients 
 
Sera were collected from patients in the Louise Coote Lupus Clinic at St. Thomas’ 
Hospital in London. Samples were taken and saved with written patient consent 
and formal hospital ethical approval. Patients had APS with SLE or PAPS and 
were diagnosed using the Sopporo classification criteria (Wilson et al., 1999).  5 
ml of sera were collected from 13 APS patients for initial HUVEC activation 
studies. Diagnostic criteria are given in Table 2.1. This serum was used for the 
development of antibody purification techniques and antibody classification. IgG 
purification followed by affinity purification of anti-β2GPI were performed 
according to the method of Tincani et al., (1996).  
 
Table 2.1  APS diagnostic criteria for patients whose sera were used for IgG 
purification and HUVEC activation studies. 
Sample Clinical History 
1 PAPS, 3 recurrent miscarriages, PE 
2 
PAPS, DVT, 2 stillbirths,PE, cerebral vascular disease, 
catastrophic APS 
3 PAPS, 3 fetal losses, MI, microinfarct CNS, aortic stenosis 
4 PAPS, 3 recurrent miscarriages, PE 
5 APS, cerebral SLE 
 6 SLE, recurrent miscarriages 
7 PAPS, DVT 
8 PAPS, retinal arterial thrombosis, cerebral thrombosis 
9 APS, SLE, arterial thrombosis, lupus nephritis 
10 PAPS, DVT 
11 PAPS, PE, microangiopathy 
12 PAPS, 2 recurrent miscarriages 
13 APS/ SLE 
 
 
APS= antiphospholipid syndrome, DVT= deep vein thrombosis, PAPS= primary 
antiphospholipid syndrome, PE=pulmonary embolism, SLE=systemic lupus 
erythematosus 
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Sera from 5 additional PAPS patients were collected (diagnostic criteria are listed 
in Table 2.2). Approximately 25ml of serum was collected from each of these 
patients and IgG and anti-β2GPI were purified from the total volume of sera for 
each. The larger volume of serum was required in order to obtain adequate 
amounts of anti-β2GPI for characterization and subsequent microarray 
experiments. Samples were collected into red top vacutainer tubes, allowed to clot 
at room temperature (RT) and spun for 15min at 2000g. Serum was removed and 
frozen at -70°C until use. 
 
 
2.2 ELISA for the detection of anticardiolipin antibodies (aCL) 
Microtitre plates (Immulon B, Fisher Scientific, UK) were coated with bovine 
cardiolipin (Sigma Chemical Company, Poole UK) (30µl of 52µg/ml cardiolipin in 
absolute ethanol per well) and incubated overnight at 4°C uncovered in order to 
allow the ethanol to evaporate. Plates were washed 3X with PBS and blocked with 
PBS containing 10% adult bovine serum (Sigma) for one hour at RT. Plates were 
washed 3X with PBS. Patient serum samples were diluted 1/50 in PBS containing 
10% adult bovine serum and 50µl of each sample was placed on a 96 well 
microtitre plate in duplicate. Dilutions of IgG aCL standard (1/50 – 1/6400 
corresponding to serial dilutions, 261- 0.1 GPL U/ml, the aCL standard is a patient 
serum with high titre IgG aCL which has been calibrated using the Harris 
standards (Harris et al., 1987) were applied to the plate in duplicate and incubated 
for 3 hours at RT. Plates were washed 3X with PBS. Wells were washed and 
incubated with 50µl alkaline phosphatase conjugated goat anti-human IgG (Sigma) 
diluted 1/8000 in PBS/10% ABS for 1.5 hours at RT. Plates were washed 3X with 
PBS and incubated with 50µl P-nitrophenyl phosphate substrate per well (1 mg 
/ml, Sigma) until the OD of the 1/50 dilution of standard was greater than 1.0. 
Plate ODs were read at 405 nm using a microtitre plate reader (Titertek Multiscan 
PLUS MKII, ICN Flow). Patient values were determined from the standard curve. 
The cut-off for normal was <2 GPLu/ml, moderate titre 20-80 GPL and high titre 
>80.0 GPL. 
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A modified aCL assay (George et al., 1998) was used to test β2GPI (co-factor) 
dependence. Microtitre plates were coated with bovine cardiolipin as in the 
standard aCL assay. Samples were diluted and microtitre wells were blocked in 
PBS/10% adult bovine serum. In parallel, on the same plate, the same samples 
were also diluted in and microtitre wells were blocked in PBS/0.6% gelatin 
(Sigma) for comparison. The IgG aCL standards were not run in the absence of 
cofactor (10% adult bovine serum). The assay was taken through to completion as 
for the standard aCL assay (See Appendix 1.1 for buffers). Sample OD’s with and 
without co-factor were compared. 
 
 
2.3 HUVEC tissue Culture 
Human umbilical cords were obtained from the labour ward at St. Thomas’ 
Hospital London, following Hospital ethical approval and written patient consent. 
HUVEC were isolated from normal full term umbilical cord vein using collagenase 
enzyme (Sigma, Poole,UK.) and cultured as previously described at 37°C in 5% 
CO2 in a humidified incubator (Jaffe et al., 1973). (See Appendix 2 for materials 
and reagents required.) 
 
2.3.1 Method 
Cords were collected by the mid-wives and stored in storage solution at 4°C. (See 
Appendix 1.3) Cords were used within 24 hours of collection. The cord was rinsed 
in Hank’s Balanced Salt Solution (HBSS)(Sigma) and a sterile bone marrow 
needle was inserted into the vein at one end and secured with string. Using a sterile 
20ml syringe, the vein was thoroughly rinsed with DMEM, (Dulbecco’s Eagle’s 
Medium, Gibco Life Technology Ltd., Paisley, UK) to remove as much blood as 
possible. A second bone marrow needle was secured in the vein at the other end of 
the cord and a 20 ml syringe was placed into the needle. 50µl of collagenase 
enzyme 100 mg/ml (Sigma) was added to 50ml of DMEM. This solution was 
filtered with a syringe driven 0.22µm filter (Millipore) and the vein was filled with 
approximately 25ml of the collagenase solution. The cord was left for 10min at RT 
with occasional gentle massaging of the vein to loosen the cells. The second 
syringe was used to remove the cells and the vein was rinsed with DMEM 
containing 10% FCS in order to inactivate the collagenase. The media containing 
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cells was divided between two sterile universal tubes. The cord was flushed with 
DMEM + 10% FCS to remove remaining cells. The tubes were spun at RT for 
5min at 800g. The supernatant was carefully decanted and the cell pellets were 
gently resuspended. The bottom of a small tissue culture flask (25 cm2) was 
thoroughly coated with 3ml of 0.1% gelatin (w/v)(Sigma) and excess was 
removed. The cells were resuspended in 5 ml of M199 (Gibco) supplemented with 
10% FCS (Biowest, East Sussex, UK), Penicillin/Streptomycin (100µg/ml, Sigma), 
Fungizone (l2.5µg/ml, Gibco) and 2mM/l glutamine (Sigma) – further referred to 
as complete media. The flasks were labeled with the date, cord number and 
passage zero. The flask was placed in a 37°C incubator with 5% CO2. The flask lid 
was loosened if not vented. 
 
2.3.2 Splitting the cells:  Passage 1 
Passage zero HUVEC were checked for confluence after 48 hours incubation. 
using a phase contrast microscope. Confluent cells were split and placed in a larger 
tissue culture flask (75 cm2) as follows. Media was removed and cells were gently 
washed with HBSS. 3 ml of 0.5% Trypsin EDTA (Sigma) was warmed to 37°C 
and placed on the cells. The cells were exposed to the trypsin for no longer than 
20-30 sec, the cells should round up and lift off of the flask surface and this was 
checked under the microscope. The flask was tapped on the bench to loosen those 
cells still adherent. 5 ml DMEM + 10% FCS was added to the trypsinized cells in 
order to inactivate the trypsin. Cells were resuspended and divided between two 
sterile universals. The tubes were spun for 5min at 800g at RT. The supernatant 
was decanted and cells resuspended in complete media. The bottom of a large 
tissue culture flask was coated with 0.1% gelatin and the cells were transferred to 
the labeled flask. The cells were incubated at 37°C with 5% CO2 until reaching 
confluence. The large confluent flask was spit into two 75cm2 flasks following the 
same protocol and labeled passage 2. HUVEC in passage 3 were used in both 
HUVEC activation assays and microarray experiments. 
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2.4 Method for determination of HUVEC (EC) activation as assessed by E-
selectin and ICAM-1 ELISA 
HUVEC from passage 2 were seeded onto 96 well plates (1 X 104 cells per well) 
and grown to confluence (therefore used in passage 3) in complete media. Cell 
numbers were determined using a haemocytometer. EC were washed gently 2X 
with sterile PBS and incubated with either purified IgG (500µg/ml) or affinity 
purified (AP) anti-β2GPI (various concentrations) for 4 hours at 37°C in 5% CO2.  
Supernatants were removed and cells were washed carefully 2X with PBS. EC 
were checked under the microscope for structural integrity and fixed in 1% w/v 
glutaraldehyde (Sigma) for 5min at RT. EC were washed 3X with PBS. 
Monoclonal antibodies to E-Selectin and/or ICAM-1 (R&D Systems, Abingdon, 
Oxford, UK) were diluted to a working concentration of 1µg/ml in PBS and 200µl 
was incubated individually with the EC for 1½hours (37°C in 5% CO2). EC were 
washed 3X with PBS. HRP conjugated goat anti-mouse IgG (Sigma) was diluted 
1/500 in PBS. 200µl of conjugate was added to each well and incubated at 37°C 
for 1hour. EC were washed 3X with PBS. 100µl of ABTS chromogenic substrate 
(Sigma) was added to each well and optical density (OD) was read at 410 nm. 
Unstimulated EC served as a negative control and positive control was rTNF 
(R&D Systems) at a working concentration of 10ng/ml (Carvalho et al., 1996). 
Calculation: 
The average of the ODs of negative control non-stimulated cells was taken and 
used as a blank value. The OD for the blank was subtracted from the sample OD 
and the normal control OD. The ratio of sample OD to Normal control OD was 
calculated. A ratio of 1.0 represented 0% EC activation. 
 
 
2.5 Detection of anti-β2GPI antibodies 
Anti-β2GPI titres on the first 13 APS patients collected were determined using the 
Genesis Beta2 Glycoprotein I IgG ELISA kit for the determination of anti-β2GPI 
(Genesis Diagnostics, Ely, Cambridgeshire, UK). Results in the assay greater than 
10 u/ml were considered positive. Because of the cost of the ELISA kit, further 
patient serum samples were screened for the presence of anti-β2GPI antibodies 
using an in house ELISA. Immunlon B microtitre plates were incubated overnight 
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at 4°C with 100µl per well β2GPI (10µg/ml) (SCIPAC Ltd., Sittingborne, Kent, 
UK) diluted in coating buffer (0.05M carbonate buffer, pH 9.6). Plates were 
washed 3X with wash buffer PBS/ 0.05% Tween (Sigma) and blocked at RT with 
100µl of blocking buffer PBS/ 1%BSA(Sigma) for 1hour. Samples were diluted 
1/50 in dilution/wash buffer and filtered through a 0.22micron filter (Millipore). 
Samples were applied to the microtitre plate (100µl) in duplicate and incubated at 
RT for 2hours. Plates were washed three times with 150µl of wash buffer. 100µl of 
phosphatase-conjugated anti- IgG (1/2000 in dilution buffer) was incubated 1½ 
hours at RT and washed 3X with wash buffer. Chromogenic substrate (PNPP, 
Sigma) was diluted (1 mg/ml) in substrate buffer (0.05M Mg Carbonate buffer pH 
9.8) and 100µl per well was added. Plates were incubated at 37°C until the positive 
control had an OD of 1.0 at 405nm. A reagent blank and normal control serum 
were included in each assay. Results were reported as OD. (See Appendix 1.2) 
 
2.6 Purification of normal control IgG and anti-β2GPI antibodies from 
sera 
 
IgG from patients or normal control age and sex-matched subjects were purified 
using 1ml or 5ml HiTrap Protein G HP affinity columns (GE Healthcare, 
Buckinghamshire, UK) as per the manufacturer’s instructions. Purified human 
β2GPI protein was purchased from SCIPAC Ltd. (Sittingborne, Kent, UK.) The 
protein was coupled to a HiTrap NHS-activated HP column as recommended by 
the manufacturer (GE Healthcare). (See Appendix 1.4) 
 
2.6.1 Manual IgG purification using HiTrap Protein G sepharose columns 
IgG from patients or normal subjects were purified using 1 ml or 5 ml HiTrap 
Protein G HP affinity columns (GE Healthcare) as per manufacturer’s instructions.  
The column was equilibrated with 5-10 ml of binding buffer (20mM NaP04 pH 
7.0). 1ml of serum was diluted with 7ml of binding buffer (1/8 diln). The diluted 
sample was filtered using a 0.22µm filter (Millipore) and applied to the column at 
a rate of approximately 1 ml per min. Applying the sample too quickly resulted in 
compression of the column. 3 to 5ml of elution buffer (0.1 M Glycine-HCl pH 2.7) 
was applied to the column and the eluate was collected 0.5 ml at a time into 1.5ml 
eppendorf tubes containing 60µl neutralizing buffer (1M Tris-HCl, pH 9.0). 
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Fractions containing the IgG were identified using the Bicinchoninic Protein assay 
(Sigma). IgG fractions were pooled and dialyzed overnight against PBS pH 7.0 at 
4°C followed by a further protein assay to determine final protein concentration. 
The column was equilibrated with 5-10ml of binding buffer and filled with 20% 
ethanol in sterile endotoxin free water (Sigma) for storage at 4°C. 
2.6.2 Preparation of β2-GPI affinity columns 
Purified human β2GPI protein was purchased from and coupled to a N-
hydroxysuccinimide (NHS) activated sepharose column following manufacturer’s 
instructions (GE Healthcare) (Del Papa et al., 1997). (See Appendix 1.5) NHS 
activated agarose beads allow covalent coupling of the protein ligand containing 
primary amino groups. 1mg of β2GPI was dissolved in 5ml of coupling buffer (1 
mg/ml). 1 drop of ice-cold 1mM HCl was added to the top of the column. Using a 
5ml sterile plastic syringe 6 column volumes of 1mM HCl were added to the 
column to remove isopropanol used for column storage (1 drop per 2 sec). β2GPI 
was drawn into a syringe and passed through column at the same rate and was 
collected in another 5 ml syringe attached to the bottom of the column. The protein 
was passed through the column 3X over a 30 min period. The column was washed 
and free binding sites were inactivated with ethanolamine (buffer A) and acetic 
acid (buffer B) as follows: column was washed with 6 column volumes (6ml) of 
buffer A, column was washed with 6ml of Buffer B, column was washed with 6 ml 
of buffer A, and left at RT for 30min. Column was washed with 6ml buffer B, 
column was washed with 6 ml of buffer A, column was washed with 6ml buffer B. 
Column was washed with 5ml of storage buffer and stored at 4°C(See Appendix 
1.5 for contents of buffers A and B). 
 
2.6.3 Affinity Purification of anti-β2GPI 
The β2GPI column was equilibrated with 3 volumes of start buffer and three 
volumes of elution buffer. Ten ml of binding buffer were applied to the column at 
a flow rate of 0.2-1.0ml per minute. Protein concentration of purified IgG was 
determined and the sample was diluted to 1mg/ml in binding buffer (pH 7.0). 
Diluted IgG was filtered with a 0.22µm filter (Millipore). The sample was applied 
to the column manually with a 3ml sterile plastic syringe, affinity-purified anti-
β2GPI was eluted with 3ml of elution buffer (0.1M glycine-HCL, pH 2.7). Sample 
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fractions were collected in 1.5ml eppendorf tubes containing 100µl of neutralizing 
buffer (1M Tris-HCL pH 9.0).  
 
Subsequent to obtaining an AKTAprime 3 protein purification system (GE 
Healthcare) the protocols for IgG and antibody purification were programmed on 
the machine. For purification protocols on the AKTAprime 3, serum samples were 
diluted 1/8 in start buffer for purification of IgG and further diluted to a 
concentration of 1 mg/ml for affinity purification of anti-β2GPI as in manual 
protocols. Protein fractions were collected into neutralizing buffer on a fraction 
collector. The AKTAprime incorporates a UV flow cell and a recorder so that 
fractions containing the protein could be visually identified. (See Appendix Figure 
1A and 1B for examples of tracings) 
 
The IgG and anti-β2GPI were purified and buffer exchange was achieved by 
dialysis overnight at 4°C against 20mM phosphate buffer, pH 7.0. Occasionally the 
IgG or anti-β2GPI would precipitate and we had difficulty re-dissolving the 
precipitate.  
 
The IgG and antibody preparations were subsequently buffer exchanged with start 
buffer and concentrated using an Amicon Ultra-15 Centrifugal Filter device MW 
30,000 (Millipore). Samples were spun 4 or 5 times at 800g at RT, adding 20mM 
phosphate buffer between spins. Samples were concentrated to a final volume of 
approximately 200µl. Concentration resulted in a total volume of approximately 
250 to 300µl of antibody from 25ml of serum. When antibody purification was 
completed on a patient IgG preparation, fractions were pooled, the protein 
concentration was determined, and aliquots were frozen in sterile start buffer 
at -70°C until use.  
 
 
2.7 Bicinchoninic protein assay 
The principle of the Bicinchoninic acid protein assay (Sigma) relies on the 
formation of Cu2+-protein complex under alkaline conditions. Cysteine, cystine, 
tryptophan, tyrosin and the peptide bonds are able to reduce Cu2+ to Cu1+ resulting 
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in a purple-blue colour with intensity proportional to the protein concentration. The 
Protein Standard (BSA 1mg/ml, Sigma) was diluted in HBSS buffered salt solution 
(Sigma) to give protein concentrations of 200, 400, 600, 800 and 1000µg/ml for a 
standard curve. Samples were run undiluted, and at 1/5 and 1/10 dilutions. 25µl of 
standards and samples were placed on a 96 well plate. 175µl of a 1/50 dilution of 
Copper (II) Sulfate Pentahydrate in Bicinchoninic acid was added to each sample. 
The plate was incubated at 37°C for 30min. The absorbencies were read at 490 nm 
using a microtitre plate reader (Dynex MRX II) and sample values were read from 
the standard curve. In order to determine the protein concentration in the affinity 
purified antibodies (µg/ml), the protein standard was diluted 1/10 in HBSS to give 
a concentration of 100µg/ml and dilutions of 20, 40, 60, 80 and 100µg/ml were 
made and run as a standard curve. 
 
2.8   ELISA method for the measurement of IL-8  
 
The concentration of IL-8 in cell supernatants was determined according to 
manufacturer’s instructions (BD Biosciences). Microtitre plates (Immulon B,  
Fisher Scientific, UK) were coated with 100µl of capture antibody diluted 1/250 
(dilution specified for each lot number) in coating buffer (0.1 M Sodium 
Carbonate, pH 9.5). Plates were incubated with capture antibody overnight at 4ºC. 
Plates were washed 3X with wash buffer (PBS pH 7.0 with 0.05% Tween). Plates 
were blocked for 1hour at RT with 200µl assay diluent (PBS pH 7.0 with 10% 
FCS). Plates were washed 3X with wash buffer. The concentration of the IL-8 
standard in the kit was provided and the standard was reconstituted in 1.0ml 
deionized water. The standard was further diluted in assay diluent to a 
concentration of 200ng/ml. Serial dilutions of the standard (200ng/ml) were made 
to a final dilution with an IL-8 concentration of 3.1pg/ml. Several dilutions of each 
sample were made in assay diluent to ensure that a value could be read from the 
standard curve. 100µl of each dilution of standard, sample and control were added 
to appropriate wells and the plates were incubated at RT for 2hour at RT. Plates 
were washed 5X with wash buffer. 100µl (1/250 dilution of detection antibody 
biotinylated anti-human IL-8 antibody in assay diluent) was added to each well and 
incubated for 1hour at RT. Wells were washed 7X with wash buffer allowing 
buffer to soak wells for 1min after each wash. 100µl of substrate solution (1/250 
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dilution of streptavidin-horseradish peroxidase conjugate in assay diluent) was 
added to each well and incubated for 30min at RT in the dark. 50µl of stop solution 
(2N H2S04) was added to each well. OD was read at 450 nm using a microtitre 
plate reader (Titertek Multiscan PLUS MKII, ICN flow) within 30min of stopping 
the reaction. The concentrations of IL-8 in cell supernatants were determined from 
the standard curve. Sample diluent was included in each assay as a negative 
control. TNF-α (R&D Systems) was included in each assay as a positive control 
(10ng/ml in assay diluent). 
 
2.9 Precautions taken to prevent endotoxin contamination of IgG and anti-
β2GPI preparations 
 
As a precaution, buffers were prepared with endotoxin free water (Sigma W3500) 
and filtered using vacuum system 0.22µm stericup filters (Millipore). Diluted 
serum samples were also filtered before putting them through columns. Amicon 
ultra centrifuge tubes used for concentrating and buffer exchange were sterile, 
collection tubes containing neutralization buffer were sterile. Polymixin B (Sigma) 
(5µg/ml) was added to the anti-β2GPI/HUVEC incubation step before RNA 
extraction for microarray analysis to minimize the possibility of endotoxin effects 
as previously described (Raschi et al., 2003a). 
 
2.10 Measurement of Endotoxin- Limulus Amebocyte Lysate Assay 
 
Endotoxin in antibody preparations was measured using the Pyrochrome® 
Chromogenic Test Kit incorporating limulus amebocyte lysate (LAL) (Associates 
of Cape Cod Inc., Falmouth MA). In the presence of endotoxin, LAL activates a 
proteolytic cascade that results in the cleavage of a colourless peptide substrate 
present in Pyrochrome LAL. Cleavage of the substrate liberates P-nitroaniline 
which is yellow in colour. The intensity of colour is proportional to the endotoxin 
concentration in the sample and the absorbance is read at 405 nm. The kit 
contained pyrochrome LAL reagent, pyrochrome reconstitution buffer, LAL 
reagent water and a 2.0 Endotoxin Unit (EU) vial of control standard endotoxin. 
The standard was reconstituted with 0.5ml LAL reagent water (4.0 EU/ml). The 
pH of antibody preparations to be tested was checked using universal indication 
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paper. Values were acceptable for inclusion in the LAL assay (pH ranged from 6.0 
to 8.0). 100µl of antibody and standards were applied to an endotoxin free 96 well 
microtitre plate.  
Antibody samples were diluted 1/5 and 1/50 in LAL water on the plate. Serial 
dilutions of endotoxin standard (4 EU-0.0625 EU) were prepared in LAL reagent 
water in lidded FACS tubes and applied to the plate. All samples and standards 
were tested in duplicate. 100µl of pyrochrome LAL reagent was added to the 
sample in each well and the plate was incubated at 37ºC for 30min. The colour 
reaction was stopped with 50µl of 50% acetic acid. The absorbance was read at 
405nm. Endotoxin concentrations in the antibody samples were calculated from 
the standard curve. LAL reagent water was included as a negative control and gave 
an OD lower than the lowest concentration of the standard curve. 
 
2.11   Anti-β2GPI antibodies and normal control IgG incubation with 
HUVEC-preparation  for microarray analysis 
 
Experiment 1 
HUVEC were grown to confluence at passage 3 in six well tissue culture plates 
incubated with complete media (see 2.3.1) containing 10% FCS. A single well of a 
six well tissue culture plate contained approximately 1 X 106 cells (counted with 
hemocytometer). A single well of confluent HUVEC at passage 3 was incubated 
with anti-β2GPI antibody preparation from P5 (Table 2.2) or normal control IgG 
(both at 50µg/ml) for four hours at 37°C in a humidified incubator with 5% CO2. 
The experiment was repeated three times on different HUVEC donors on three 
separate occasions. Total HUVEC RNA was then extracted using the RNeasy Kit 
Section 2.12) (Qiagen, Crawley, West Sussex, UK). The quality of the RNA was 
checked using a 1% agarose gel after each experiment.  
Experiment 2 
Confluent HUVEC at passage 3 were incubated with four independent PAPS-
derived anti-β2GPI antibody preparations (P1, P2, P3, P4, 50µg/ml) or four normal 
control IgG (N1, N2, N3, N4, 50µg/ml) for four hours at 37oC in a humidified 
incubator with 5% CO2. Three independent experiments using HUVEC from three 
different donors were carried out on different occasions and samples were 
processed as above. 
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2.12 RNeasy Mini protocol for the isolation of total RNA from HUVEC 
RNA was extracted from HUVEC using an RNeasy Mini kit (Qiagen, Crawley, 
UK). (See Appendix 3.0 for kit contents) After the 4hour incubation time (see 
2.11), all supernatant was carefully removed from the cells and cells were gently 
washed once with HBSS. The cells were trypsinized with 0.5ml 0.25% 
Trypsin/EDTA in PBS for 30sec and 0.5ml M199 + 10% FCS was added to 
neutralize the trypsin. Cells were transferred to a sterile 1.5ml eppendorf tube and 
pelleted by centrifugation (2200g for 2min). β-mercaptoethanol (β–ME) was added 
to RLT Buffer in the fumehood before use (10µl per 1.0ml Buffer RLT). 350µl of 
buffer RLT/β–ME was added to the cells and mixed in order to lyse the cells. (The 
buffer contains denaturing guanidine isothiocyanate and inactivates RNases.) The 
cells were homogenized by passing the lysate through a 20-gauge needle fitted to a 
1 ml RNase-free syringe five times. An equal volume of 70% ethanol was added to 
the sample and mixed by pipetting. The sample was applied to an RNeasy mini-
column, placed in a collection tube and centrifuged for 15sec at 2200g. Flow-
through was discarded. The column was washed with 700µl of RW1 wash buffer, 
centrifuged again at 2200g for 15sec, and the flow-through was discarded. The 
RNeasy column was transferred to a new collection tube, 500µl of RPE buffer was 
added to column and the column was centrifuged for 15sec at 2200g, flow-through 
was then discarded. The last step was repeated but the column was centrifuged for 
2min at 2200g. The column was transferred to a new 1.5ml collection tube and 
30µl of RNase-free water was carefully applied to the column membrane. RNA 
was eluted from the column by centrifuging for 1 min at 2200g. RNA was frozen 
at -70°C until use. 
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2.13 Preparation of RNA Sample for Affymetrix Microarray 
 
 
 
HUVEC incubated with affinity purified anti-β2GPI or control IgG 
 
 
Total RNA Extracted using Qiagen RNeasy mini kit 
 
 
 
First strand cDNA synthesis from RNA, followed by second strand cDNA 
synthesis and cleanup 
  
 
Synthesis of Biotin-labelled cRNA, cRNA cleanup and quantification. 
 
 
 
cRNA fragmentation 
 
 
 
Hybridization of fragmented cRNA to Affymetrix chip 
 
 
 
 
 
 
Figure 2.1    Method scheme for Affymetrix microarray sample 
preparation 
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Figure 2.2: Scheme for preparation of labeled cRNA for Genechip 
microarray cRNA samples for microarray hybridization were 
prepared following manufacturer’s instructions (Gene Chip® 
Expression Analysis: Data Analysis Fundamentals, 2004. 
Affymetrix, Santa Clara CA). The overall scheme is outlined in 
Figures 2.1 and 2.2. 
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In summary: Total RNA quality and concentration were determined using the 
Nanaodrop spectrophotometer and further assessed on RNA 6000 Nano Assay 
micro-capillary gel (Agilent Technologies, Santa Clara, CA) (See Appendix Figure 
3). This was followed by cDNA synthesis using RT oligo-dT primer T7-(dT)24   
(Genset Corporation, LaJolla, CA) and an in vitro transcription reaction for cRNA 
synthesis incorporating biotinylated ribonucleotides. Full-length cRNA was then 
fragmented to 35 to 200 base fragments by metal-induced hydrolysis. The quality 
of cRNA was then assessed along with the fragmented RNA on a micro-capillary 
gel (See Appendix Figures 4, 5 and 6). Fragmented cRNA was hybridized 
overnight to gene chip arrays at 45°C for 18 hours. Control cRNAs were then 
added to the hybridization mix. Human Genome 133A (HGU133A) arrays were 
used in Experiment 1 and HGU133-2.0 arrays were used for Experiment 2. Both 
types of chips screen for 18,400 human transcripts, but HGU133-2.0 are a slightly 
smaller format and require slightly less RNA sample. Experiment 1 incorporated 6 
chips in total. In one of the 3 independent experiments from Experiment 2, one 
anti-β2GPI antibody (P2) treated sample and one control IgG treated (N2) sample 
were not processed beyond initial RNA quantitation due to low RNA yield. 
Therefore, a total of 22 chips were hybridized and scanned in Experiment 2. Gene 
chips were washed and stained on the GeneChip Fluidics Station 400 (Affymetrix). 
Fluorescent signals were detected using the HPG2500A Gene Array Scanner (see 
Figure 2.2).  
 
The quality of the total RNA must pass the minimum requirements for the standard 
Affymetrix labeling protocol; minimum concentration = 0.5µg/µl, minimum total 
amount per sample = 5µg (slightly less for the HG133A_2 chip) The RNA must be 
clean, pure and undegraded. The approximate number of confluent HUVEC that 
would yield sufficient RNA for an Affymetrix chip was calculated (See Appendix 
Table 2 and Figure 2) 
 
Before proceeding to cDNA synthesis, the concentration and purity of each total 
RNA sample was assessed using the Nanodrop Spectrophotometer (Agilent 
Technologies, Santa Clara, CA ). It was imperative that precisely the same amount 
of RNA from each sample for comparison was incorporated into the cDNA 
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synthesis step. The Nanodrop measured the RNA OD at A260, provided the OD 
ratio of 260/230, 260/280 and calculated the concentration in ng/µl. 
  
2.13.1 First strand cDNA synthesis 
The total amount of RNA in each sample was calculated (30µl of RNA from 
extraction protocol X concentration in ng/µl) eg; experiment carried out on 20.9.05 
, 29 X 90.5 = 2.6µg total RNA. Therefore 2.6µg of RNA would be used for 
analysis for all samples, the identical amount. Of this, approximately 5% was 
mRNA. (Samples with low concentration were concentrated using the speed vac) 
All reactions were carried out in 0.2ml PCR tubes.  
 
The T7 oligo sequence for reverse transcription: 5’- GGC CAG TGA ATT GTA 
ATA CGA CTC ACT ATA GGG AGG CGG (T)24- 3’ 
 
The appropriate volume of total RNA (and molecular biology grade RNase-free 
water if required to make up to the maximum allowable volume) and 1µl of T7 
primer (200ng/µl) were mixed (Table 2.3). Samples were incubated at 70°C for 
5min in a PCR block (with heated lid), then put on ice for 5min and pulsed down 
(2200g for 10sec).  
 
Table 2.3  Reagents for first strand synthesis (FSS) 
Amount of 
RNA 
Maximum 
volume of 
RNA 
Total volume 
of RT 
reaction 
Total amount 
of T7 oligo  
Volume of 
RT premix 
(µl) 
3-10 µg 11µl 20µl 200ng (1µl) 8 
 
Samples were placed on ice until ready to add premix. RT premix was prepared 
(Table 2.4). A larger volume was prepared, ½-1 reactions extra to compensate for 
pipetting inaccuracies. 8µl of premix was added to each reaction tube to make a 
total of 20µl. Samples were pipette- mixed, pulsed down, and incubated at 42°C 
for 1hour in a PCR machine (with heated lid).  
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Table 2.4   RT premix constituents 
Component Volume for 8µl 
 RT premix (µl) 
5X First strand buffer 4 
0.1 MDTT 2 
10 mM dNTPs 1 
Superscript II reverse transcriptase 
(200U/ml) 
1 
 
2.13.2 Second strand synthesis (SSS) 
First strand synthesis reactions were incubated on ice for 5min immediately after 
42°C incubation. Second strand premix was prepared 5-10 min before the end of 
the first strand incubation (Table 2.5). 130µl of SSS premix was added to each 
20µl 1st strand synthesis reaction. Samples were pipette mixed well and pulsed 
down. Samples were incubated at 16°C for 2 hours in a PCR machine (with lid 
open). 12µl of 0.5M EDTA was added to each tube and mixed well to stop the 
reaction. The cDNA was now in a total volume of 162µl. The cDNA synthesis 
reactions were placed in the -20°C freezer or processing was continued. 
 
Table 2.5  SSS premix constituents 
Component Volume for 130µl  
SSS preparation (µl) 
RNase-free water 91 
5X 2nd strand buffer 30 
10 mM dNTP mix 3 
DNA ligase (10U/µl) 1 
DNA Polymerase (10U/µl) 4 
RNase H (2U/µl) 1 
 
2.13.3 cDNA extraction and clean-up 
The cDNA products were transferred from 0.2ml tubes into 1.5ml tubes. The 
Affymetrix sample clean-up kit was used for the next step. The kit contained 
cDNA binding buffer, cDNA wash buffer (with ethanol added), cDNA elution 
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buffer, cDNA spin columns in 2ml collection tubes, extra 2ml collection tubes, 
extra 1.5ml elution tubes.  
 
600µl of cDNA binding buffer was added to the 162µl of cDNA. The sample was 
vortexed for three sec. 500µl of sample was applied to a cDNA spin column. 
Sample was spun for 1min at 8000g in a microcentrigfuge, flow-through was 
disgarded. The remainder of the sample (262µl) was applied to the column and the 
spin was repeated. The flow-through and collection tube were discarded. The 
column was placed in a new 2 ml collection tube, 750µl of cDNA wash buffer was 
added and the column was spun for 1min at 8000g. Flow-through was discarded. 
The columns and tubes were placed back in the centrifuge with open caps. The 
columns were spun at full speed 16000g for 5min. Collection tubes were discarded. 
Columns were placed in fresh 1.5ml eppendorf tubes. 14µl of cDNA elution buffer 
was carefully applied to the column membrane and incubated for 1min. The 
column was spun for 1min at full speed to elute the cDNA. The samples were 
stored at -20°C or we proceeded with the IVT (in-vitro transcription) reaction. 
 
2.13.4 In vitro transcription reaction (IVT) 
The Affymetrix IVT kit was used for this step. All solutions except the IVT 
enzyme mix were brought to RT, including the cDNA. The tubes containing IVT 
buffer and dNTPmix were fully vortexed to eliminate precipitates. The volume of 
eluted cDNA was measured. We routinely began with less than 5µg of total RNA 
so all of the cDNA was transferred to a 1.5ml screw-cap microcentrifuge tube for 
the IVT reaction. The total volume of cDNA was brought up to 20µl using the 
water from the IVT kit. The IVT reagent mastermix was prepared (Table 2.6).  
 
Table 2.6   IVT reagent mastermix 
Volume per sample Reagent 
4µl 10X IVT Labelling Buffer 
12µl IVT Labelling NTP Mix 
4µl IVT Labelling Enzyme Mix 
20µl TOTAL VOLUME 
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2.13.5 Clean-up of biotin cRNA 
The Affymetrix/Qiagen kit was used for this step. The kit incorporated cRNA 
binding buffer, molecular biology grade ethanol (100%), cRNA wash buffer, 80% 
ethanol (made up with molecular biology grade ethanol and water), cRNA spin 
columns in 2ml collection tubes and extra 2ml collection tubes and 1.5ml elution 
tubes. 
 
The 20µl IVT reaction was made up to 100µl with RNase-free water. 350µl of 
cRNA binding buffer was added and contents of tube mixed on vortex for 3sec. 
250µl of absolute ethanol was added and vortex mixed. Each whole sample 
(700µl) was applied to a cRNA spin column and spun for 15sec at 8000g. The flow 
through and collection tubes were discarded. Columns were placed in new 
collection tubes and 500µl of cRNA wash buffer was added to the columns. 
Columns were spun for 15sec at 8000g and flow-through was discarded. 500µl of 
80% ethanol as added to the columns, spun for 15sec at 8000g and flow-through 
was discarded. The caps on the columns were opened and columns were spun dry 
by spinning at full speed (16000g) for 5min. Flow through and collection tubes 
were discarded. Columns were placed in fresh 1.5ml elution tubes and 11µl of 
RNase-free water was piptetted onto the column membrane and spun at 16000g for 
1min to elute the cRNA. Another 10µl of RNase-free water was placed onto the 
membrane and spin was repeated. Purified biotin-cRNA (20µl) was stored at -80°C 
until use or used straight away in the hybridization protocol. 
 
2.13.6 cRNA quantification and fragmentation 
The concentration of the cRNA samples was determined at an absorbance of 
260nm on the Nanadrop spectrophotometer. The IVT reaction should yield at least 
15µg of biotin-cRNA in the 20µl at a concentration of ~2.5µg/µl. If the IVT 
reaction yielded sufficient cRNA for hybridization, cRNA fragmentation was the 
next step.  
 
At least 15µg of fragmented cRNA from each sample was required for preparation 
of the hybridization cocktail. It was necessary to prepare enough fragmented 
cRNA in order that 100-250ng (0.1-.25µg) were available for quality control on a 
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NanoLab gel electrophoresis chip. The maximum final volume of the 
fragmentation reaction was 31µl. Based on the cRNA concentration, the volume 
required for 15.5µg cRNA was calculated for each sample, 6.2µl of 5X 
fragmentation buffer (31/5) was added and RNase-free water was added top make 
up a total volume of 31µl. Samples were incubated at 94°C for 35min in a PCR 
machine with heated lid. 
 
The biotinylated cRNA and the fragmented biotinylated cRNA were analyzed on a 
gel chip using the Agilent bioanalyser. cRNA should show a symmetrical smear of 
average length 1000-2000 nuceotides (Appendix Figure 5) 
(http://www.affymetrix.com/support/technical/manual/expression_manual.affx., 
http://microarrays.berkeley.edu/affy_services.php). Fragmented cRNA should 
show a single RNA peak of around 100 nuceotides in length (Appendix Figures 4 
and 6). 
 
2.13.7 Preparation of the hybridization cocktail 
When the acceptable quality of the cRNA and fragmented cRNA were confirmed 
on the gel chip, the hybridization cocktail was prepared for hybridization to the 
GeneChips. The 20X Genechip Eukaryotic control and B2 Oligos were heated at 
65°C for 5min to ensure that the cRNA was completed resuspended after being 
frozen. The appropriate number of gene chips were removed from the storage bags 
and left to warm to RT. The fragmented cRNA was transferred to an RNase-free 
screw-cap 1.5ml tube. The hybridization cocktail mastermix was prepared 
including volume for an extra reaction (Table 2.7). 
 80
 
Table 2.7   Hybridization cocktail mastermix 
Component Volume (µl) 
Control Oligo B2 5 
20X Eukaryotic Hybridization Controls 15 
Herring Sperm DNA (10mg/ml) 3 
Acetylated BSA (50mg/ml) 3 
2X Hybridization Buffer 150 
DMSO 30 
RNase-free water 64 
Total volume 270 
 
270µl of hybridization cocktail mastermix was added to the fragmented cRNA in a 
fresh 1.5ml screw-cap tube and mixed. The completed hybridization cocktail was 
heat-denatured at 99°C for 5min in a heat block, followed by 45°C for 5min in the 
pre-heated hybridization oven. 
  
2.13.8 Preparation of Genechips and sample hybridization 
While the hybridization cocktail was denaturing, the chips were prepared. 1X 
hybridization buffer was made up from stock. The chips (1 per sample) were filled 
with 1X hybridization buffer and pre-hybridized in the Affymetrix rotisserie oven 
for 10min at 45°C rotating at 60 rpm. The tubes containing the hybridization 
cocktail were spun at max speed in a microcentrifuge for 5min to remove any 
insoluble or precipitated material from the hybridization mixture, being careful not 
to disturb any pellet that may have formed. The pre-heated chips were removed 
from the oven and the pre-hybridization solution was removed and replaced with 
200µl of the hybridization cocktail containing fragmented cRNA. Hybridization 
takes place in the rotisserie oven for ≥16 hours at 45°C rotating at 60 rpm. 
 
2.13.9 Washing, staining and scanning chips 
Buffers A and B (commercially prepared by Affymetrix) for the fluidics station 
must be filtered before use. Scanner, computer and Fluidics station were switched 
on in that order and allowed to warm up for 15min before use. Individual files for 
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the chips were set up in Microarray suite. The Fluidics station was primed with 
buffers A and B, using the prime protocol. The chips were removed from the 
rotisserie oven and the hybridization cocktail was removed from the chips and 
saved at -20°C. The chips were filled with 250µl wash buffer A and placed in the 
Fluidics station. 2400µl of stain 1 and 1200µl of stain 2 were prepared for each 
chip. After preparation, the stain was aliquoted into 1.5ml eppendorf tubes each 
containing 600µl and placed on the fluidics station. Staining protocol was 1 
application of Stain 1, 1 application of stain 2, followed by a second application of 
Stain 1. 
 
Table 2.8   Stain 1  
600µl 2X stain buffer 
540µl Water 
48µl Acetylated BSA(5mg/ml) 
12µl 
Streptavidin-phycoerythrin (SAPE)      
(1mg/ml) 
 
Make up 600µl of antibody solution for each chip. 
 
Table 2.9  Stain 2  
300µl 2X stain buffer 
266.4µl Water 
24µl Acetylated BSA (50mg/ml) 
6µl Normal Goat IgG (10mg/ml) 
3.6µl 
Biotinylated  anti-streptavidin antibody 
(0.5mg/ml) 
 
The appropriate stain protocol was run for each chip on the Gene Chip Fluidics 
Station 400 (Affymetrix), four chips at a time. The chips were removed from the 
machine and checked for air bubbles. When chips were bubble free, they were 
scanned.  
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2.14 Statistical analysis of microarray data 
After scanning the gene chips, images were analyzed using the Affymetrix 
microarraysuite (MAS) 5.0 to generate raw data in the form of ‘.cel’ files. Further 
analysis was carried out using a combination of the MAS 5.0 and GeneSpring 
(Agilent) software programmes. The detection of a particular gene as ‘present, 
absent or marginal’ was carried out using the MAS 5.0 software. The .cel files 
were imported into GeneSpring and normalized by GC-Robust Multichip Average 
(GCRMA), an algorithm that normalizes the data by quantile normalization, in 
order to minimize the biological variation between samples. Further analysis was 
carried out on genes identified as present or marginal. Genes with statistically 
different expression between the control IgG and the anti-β2GPI antibody treated 
cells (p<0.05) were identified by the Kruskal Wallis test (non-parametric one way 
analysis of variance (ANOVA) with the Benjamin and Hochberg multiple testing 
correction. Filtering the gene list on the criteria of a two-fold or more increase or 
decrease in expression identified a panel of genes that were significantly changed 
in HUVEC by anti-β2GPI antibody treatment compared to normal control IgG 
treatment. Average-linkage hierarchical clustering (using the Pearson Correlation) 
was carried out separately on the genes and the samples generating a genetree and 
condition tree, respectively, to highlight any distinct patterns in gene expression 
and the relationships between the samples (Eisen et al., 1998). 
 
 
2.15 Agarose gel electrophoresis  
Extracted RNA and PCR reactions were run on agarose gels to ensure that the 
RNA was of good quality and that the PCR reactions had been successful. % gels 
were prepared by dissolving 1g of agarose (Invitrogen, Paisley, UK) in 50ml 
.045M TBE by heating the solution in a microwave. The melted agarose was 
cooled to approximately 50°C and 20µl (10mg/ml) of ethidium bromide (EtBr) 
was added before pouring the gel. 3µl of sample was mixed with 6µl loading dye 
(Promega) and each sample was applied to a well on a gel and electrophoresed in 
parallel with 100bp ladder (Promega). Gels were electrophoresed for 
approximately 30min at 100V.  
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2.16 Quantitative real-time RT-PCR analysis of gene expression 
Quantitative real time PCR was used to confirm the microarray results for the 
expression levels of selected genes. Primers were purchased from MWG-Biotech 
AG(98% pure). The primer pairs used for the following genes were: CSF3 (75nt), 
forward 5'- CGCTCCAGGAGAAGCTGT-3', and reverse 5'- 
CCAGAGAGTGTCCGAGCAG-3',  
CX3CL1 (76nt), forward 5'-ATCTCTGTCGTGGCTGCTC-3', and reverse 5'- 
TCACACCGTGGTGCTGTC-3', 
 E-selectin (91nt), forward 5’-TGAAGCTCCCACTGAGTCCAA-3’, and reverse 
5’-GGTGCTAATGTCAGGAGGGAGA-3’, 
FGF18 (113nt), forward 5'-CTCTACAGCCGGACCAGTG-3' and reverse 5'- 
CCGAAGGTGTCTGTCTCCAC-3', 
ID2 (100nt), forward 5'-CAGCATCCTGTCCTTGCAG-3', and reverse 5'- 
AAAGAAATCATGAACACCGCTTA-3', 
SOD2 (85nt), forward 5'-CAAATTGCTGCTTGTCCAAA-3', and reverse 5'- 
CGTGCTCCCACACATCAAT-3', 
Tenascin C (108nt), forward 5'- GCTCAAAGCAGCCACTCATT-3', and reverse, 
5'-CCCATATCTGGAACCTCCTCT-3',  
β-actin (100nt), forward 5’-CCAACCGCGAGAAGATGA-3’, and reverse 5’- 
CCAGAGGCGTACAGGGATAG-3’. 
 
β-actin was used as an internal control as no changes were found in levels of 
expression of this housekeeping gene when cells were treated with antibodies in 
microarray experiments. Primers for the genes were designed using the Roche 
universal probe library (MWG Biotech, UK). Primers were reconstituted with 
sterile endotoxin free H2O (Sigma) to a concentration of 100µM, and frozen in 
aliquots at -20°C. Primers were further diluted to 10µM concentration in sterile 
endotoxin free H2O for PCR.  
 
Concentration and quality of the total RNA was determined on the Nanodrop 
spectrophotometer. 1 µg of total RNA from HUVEC incubated for four hours in 
complete media alone (blank), or with 2 normal control IgG preparations (N3, N4) 
or 4 anti-β2-GPI antibody preparation (P1, P2, P3, P5), or with TNF-α were reverse 
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transcribed into cDNA with the Quantitect reverse transcription kit (Qiagen) using 
oligo-dT primers. DNA wipeout buffer (2µl) (for removal of any contaminating 
genomic DNA) was combined with 1µg RNA and made up to a total volume of 14 
µl with RNase-free water. The reaction was incubated at 42°C for 2min, and placed 
on ice.  
 
Next, each reverse transcription reaction included 1µl of reverse-transcriptase, 4µl 
of RT buffer, 1µl RT primer mix and 14µl template RNA from previous incubation 
(Table 2.10). These were combined and incubated at 42°C for 15min. The 
reactions were then incubated for 3min at 95°C to inactivate the reverse 
transcriptase. A PCR using primers for β-actin was performed on each cDNA 
sample and run on a 2% agarose gel to ensure that the cDNA synthesis was 
successful. 
 
Table 2.10   Reverse-transcription reaction components 
Component Volume 
per 
reaction 
Reverse-transcription master mix- 
Quantiscript Reverse Transcriptase 
 
1µl 
Quantiscript RT Buffer 5X- includes Mg2++ 4µl 
RT Primer Mix 1µl 
Template RNA 
Entire genomic DNA elimination reaction 
 
14µl 
Total Volume 20µl 
 
 
2.16.1 Preparation and purification of cDNA standards 
HUVEC were incubated with TNF-α (10ng/ml) (R&D Systems, Abingdon, 
Oxford, UK.) for four hours, RNA was extracted and cDNA was prepared as 
previously described. cDNA was used for PCR in order to produce enough of each 
gene specific target to make DNA standards for absolute real time PCR. Forward 
and reverse primer pairs for selected genes were initially tested with DNA in a 
   1    2     3    4    5    6    7    8     9   10   11 
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25µl PCR reaction and checked on a 2% agarose gel to ensure that amplification of 
PCR product was successful. A 100µl reaction mixture was used to obtain enough 
gene specific product for standard preparation. PCR master mix contained Taq 
DNA polymerase 50units/ml, 400µM dNTPs, 3mM MgCl2 and reaction buffer 
(Promega). A 100µl reaction mixture contained 2X PCR master mix, upstream 
primer, downstream primer, (primer concentrations 0.3µM), template DNA and 
nuclease-free water. A blank control including water rather than cDNA was run in 
parallel to each PCR reaction to check for DNA contamination in the reagents. 
PCR was performed in a DNA thermocycler (Biometra UNOII- ThermoblockNR 
9611222, Whatman Biometra GMbH, Niedersachen, Germany) with 1 cycle of 
2min at 95°C; 30 cycles of 30sec at 94°C, 30sec at 58°C (57°C or 61°C  depending 
on the melting temperature) and 30sec at 72°C; and a final extension of 5min at  
72°C. 3µl of PCR products and blanks were run on a 2% agarose gel to verify 
success of reaction. cDNA was checked on gel and the remainder was purified by 
electrophoresis and ethanol preciptitation based on methods described respectively 
in Chapter 5 and Appendix 8.14 of Molecular Cloning- A Laboratory Manual, J. 
Sambrook and D. W. Russell (eds.), CSHL press, New York, 2001. 20 µl of 
loading dye was added to 95µl cDNA. A 2% agarose gel (Invitrogen) was prepared 
with 50mM TBE plus EtBr (5µg/ml), with a well in the agarose large enough to 
contain the whole PCR sample volume. The sample was added to the well and 100 
base pair (bp) ladder was run in parallel for reference. Gel was run at 100V for 
1hour in 50mM TBE with EtBr added (5µg/ml). The gel was examined on a 
transilluminator (See Appendix Figure 7). The cDNA incorporated EtBr and was 
visible in the UV light. The gel containing the cDNA was carefully removed using 
a scalpel and the slice was placed in a small piece of dialysis tubing previously 
prepared by boiling and stored in water at 4°C (Appendix 8.4, Molecular Cloning- 
A Laboratory Manual). 500µl of 25mM TBE was placed in the tubing with the gel, 
bubbles were carefully removed and the other end clamped securely. The dialysis 
bag was placed in an electrophoresis chamber with the gel positioned parallel to 
the current and the current was run for approximately 1hour at 100V. The cDNA 
concentrated along the side of the tubing was carefully removed and the inside of 
the tubing was rinsed with a small volume of 25mM TBE to collect the remainder. 
The sample was placed in a 1.5ml eppendorf tube and the volume was measured. 
An equal volume of phenol chloroform (Sigma) was added and the sample 
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vortexed. The sample was spun at 8000g for 3min, the top aqueous layer was 
removed, the volume measured and placed in a clean eppendorf tube. 1/10 the 
volume of sodium acetate (3M) was added and mixed. An equal volume of 
absolute ethanol was added and the sample was mixed and placed at -50°C for 
20min. The sample was spun at 8000g for 10min taking note of where the pellet 
should be in the tube. The tube was carefully decanted and 250µl of cold 70% 
ethanol was added. The tube was spun for 2min at 8000g, decanted and any 
remaining ethanol was allowed to evaporate. 15-20 µl of RNase-free water was 
added to the sample and quickly vortexed to dissolve the cDNA. The product was 
quantitated on a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies 
Inc., Wilmington, DE, USA).  
The concentration was used to calculate the copy number/µl taking into account 
the molecular weight and length of the PCR product in base pairs. 
Example: CX3CL1 
1. length of PCR product 76bp 
2. 660 is the average molecular weight of a nucleotide,  
660 x 76= 50160 (relative molecular mass) 
3. the concentration of the cDNA was 40 ng/µl or 0.04 µg/µl 
0.04 divided by 50160 gives n =7.97448 x 10-7  where n=moles 
n x Avagadro’s number (6.022 x 1023) = number of molecules per 
litre divided by 106 gives the copy number per microlitre. 
 
7.97448 x 10-7   x   6.022 x 1023 / 106 = 4.8 x 1011    
 
 This copy number was diluted in sterile dH2O to give 1 x 108 copies per µl    
 
2.16.2 Quantitative RT-PCR 
The cDNA standard curves began with 1 X 108 copies per µl.  Serial dilutions of 
the standards were prepared in sterile dH2O down to 1 X 101. (Antibody 
preparations N3, N4, P1, P2 and P4 were previously used in the microarray 
experiments.) Quantitative real-time PCR (qRT-PCR) was carried out with the 
QuantiTect SYBR Green PCR Kit (Qiagen) in the ABI 7000 sequence detector 
(Applied Biosystems). The SYBR Green PCR Master Mix contained HotStarTaq 
DNA Polymerase, PCR buffer (contains MgCl2 to give final concentration of 
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2.5mM) and Syber Green I fluorescent dye. The real time PCR was performed in 
96 well microtitre plates. We used a final reaction volume of 25µl per well. This 
included 12.5µl of Master Mix, Primer A and Primer B at a 0.3µM concentration, 
2µl template DNA and RNA’se free water. Dilutions of standards were run in 
duplicate as were dilutions of unknown samples (See Appendix Figure 8). The 
PCR program on the ABI Prism 7000 was: 1 cycle of 10min at 95°C; 40 cycles of 
15sec at 95°C, 15sec at 58°C, 30sec at 72°C (Sample volume 25µl).  
 
Gene expression levels were calculated with the absolute quantitation method 
(Bustin 2000) and normalized to the β-actin level. All PCR reactions were carried 
out in duplicate, and repeated at least twice for each gene. The specificity of the 
PCR reactions was verified with dissociation curve analysis (See Appendix Figure 
9). 
All dilutions of standards were run in duplicate and tested on two different 
occasions. All samples were run in duplicate. β-actin copy number was determined 
for each sample three times and the mean was established. For each gene the copy 
number per µl produced in each sample was established twice (on two occasions). 
The mean and SD were determined. Each value was normalized to β-actin, 
(divided by the copy number for β-actin). This assumes that the levels of β-actin in 
the cells are constant (microarray data did not show change in expression in 
response to antibody). This is relating the value of the unknown back to a constant 
in order to compensate for the fact that slightly different amounts of RNA may 
have been added in different tests or runs. Sample 5 (normal control) was 
arbitrarily given a fold change of 1 as a reference (in order to compare). In order to 
calculate fold change for the samples, we took the copy number/µl for the 
unknown and divided by the copy number of the reference normal (given copy 
number 1). Standard DNA concentrations were measured at 260 nm and the copy 
number per µl was then calculated based on the molecular weight of the PCR 
product in question. This provides information on the relative amounts of mRNA 
used in the qRT-PCR reaction. Small differences in the amount of RNA used for 
different samples in the reaction were corrected for by normalization of all values 
to a housekeeping gene, in this case β-actin. (See Appendix 5.0 for qRT-PCR data) 
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2.17 Cell cycle analysis by propidium iodide staining of  HUVEC  
HUVEC were seeded and grown at P3 to 70-80% confluence in complete media. 
Cells were incubated with anti-β2GPI (50µg/ml) or normal control IgG (50µg/ml), 
(37°C with 5% CO2) and complete media alone as a reagent blank for 18 hours. 
Cells were trypsinised and carefully washed twice with HANKS (Sigma) and fixed 
with cold 70% ethanol on ice for 30min. Cells were washed 2X with HANKS and 
spun for 5min at 800g. The cell pellets were treated with 30µl RNase (100µg/ml) 
(Sigma) for 30min at RT. 200 µl of propidium iodide (50µg/ml) was added to each 
sample and samples were incubated at RT for 1hour. Propidium iodide 
fluorescence of stained cells was measured using a FACScanTM flow cytometer 
(Becton Dickinson). FACS analysis of cell DNA content allows identification of 
relative numbers of cells in different stages of the cell cycle. Fluorescence data is 
acquired with linear amplification and plotted on a histogram where the DNA 
content of cells is plotted on the x axis and relative number of cells on the y axis. 
Cells are devided into G0/G1, S and G2/M phases (Krishan, 1975). 
 
2.18 3H-thymidine incorporation- proliferation assay 
HUVEC at P3 were seeded in a 96 well microtitre plate and grown to 70-80% 
confluence. Cells were incubated with anti-β2GPI (50µg/ml) or normal control IgG 
(50µg/ml), (37°C with 5% CO2) and complete media alone as a reagent blank each 
in a volume of 500µl for 18hours. In addition, 1.25 µCi of 3H-thymidine (specific 
activity 70-85 Ci/mMol; Amersham International Ltd., Amersham, UK) was added 
to each sample for the 18hour incubation. After incubation, the cells were 
harvested onto glass-fibre filter mats (Wallac, Turku, Finland) using a Mach III 
harvester 96 (Tomtec, orange, USA). Conventional liquid scintillation procedures 
(Scintillant-Beta plate scint, Wallac) were used to measure the amount of 3H-
thymidine incorporated by HUVEC with a rackbeta counter (1450 Microbeta plus, 
Wallac). Results were presented as the mean counts per minute (CPM) for 
quadruplicate samples. 
 
(See Appendix for Buffers and Formulations) 
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Chapter 3 
Purification and Characterization of Anti-β2GPI 
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3.0 Introduction   
It is well documented that aPL cause activation of EC but aPL encompass a large 
group of heterogeneous antibodies with different specificities and binding 
affinities. Upregulation of adhesion molecules was taken as evidence of EC 
activation and their detection served as a measurable marker (Carlos et al., 1994). 
ICAM-1 is expressed in low levels in quiescent EC while E-Selectin is not 
constitutively expressed (Cines et al., 1998). Early in vitro studies using whole IgG 
fractions from APS patients containing high titre aCL antibodies demonstrated 
activation of HUVEC reflected in an increase in monocyte adhesion after four 
hours incubation. The same HUVEC also showed upregulation of adhesion 
molecules E-selectin, VCAM-1, and ICAM-1 (Simantov et al., 1995). In vitro 
monocyte adhesion was not induced when antibodies were in serum free media but 
did occur when purified β2GPI was added (Simantov et al., 1995). This was the 
first evidence that the procoagulant phenotype on the EC may at least in part be 
induced by antibody mediated activation and that the activation may be β2GPI 
dependent. Studies by Pierangeli et al. (1999) showed in vitro increase in adhesion 
molecules expression and enhanced in vivo adhesion of leukocytes to endothelium 
in the presence of affinity purified aPL. The Simantov paper (1995) also showed 
that IgG isolated from a rabbit immunized with purified β2GPI stimulated 
monocyte adhesion and the effect was diminished when the IgG was pre-adsorbed 
with β2GPI. But, IgG fractions from APS patients contain a number of antibodies 
including aCL, LA, anti-β2GPI and AECA. Extensive characterization of anti-
β2GPI concluded that anti-β2GPI were low affinity, monoreactive autoantibodies 
directed against β2GPI as the primary antigen (Tincani et al., 1996). Subsequent 
studies looked more specifically at polyclonal and monoclonal anti-β2GPI from 
APS patients and showed that the antibodies recognized co-factor on the EC 
surface and induced adhesion molecule upregulation that was co-factor dependent 
(Del Papa et al., 1997; George et al., 1998; Del Papa et al., 1999; Pierangeli et al., 
1999). 
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3.1 Chapter objectives 
Initially, the main objective of this project was to assess global gene expression in 
HUVEC in response to aPL. However, it was decided to be more specific and 
investigate the effect of anti-β2GPI on gene expression due to the strong 
association of these antibodies with occurrence and increased risk of thrombosis. 
In order to proceed to microarray, it was first necessary to purify patients IgG, 
affinity purify anti-β2GPI and demonstrate that we had in fact purified the 
appropriate antibodies. In short, correct protocols were developed and appropriate 
experiments were set up in order to achieve the following: 
 
• To establish satisfactory methodology for the isolation and culture of 
HUVEC for subsequent experiments. 
• To collect patient blood samples. 
• To isolate patient IgG. 
• To prepare β2GPI affinity column(s) with subsequent purification of PAPS 
patient polyclonal anti-β2GPI. 
•  To show that the affinity purified polyclonal anti-β2GPI antibody 
preparations required co-factor in order to bind to cardiolipin.  
• To show that the affinity purified polyclonal anti-β2GPI antibody 
preparations were able to bind to β2GPI and activate EC. 
• To prepare polyclonal anti-β2GPI antibody preparations from PAPS 
patients for use in microarray Experiments 1 and 2. 
 
 
3.2 Results  
3.2.1 Screening of APS patient sera for aCL and anti-β2GPI antibodies 
ACL titres in sera from 13 APS patients were measured using an aCL ELISA 
(developed in the Lupus Unit at St. Thomas’ Hospital in London) (cut-off for 
normal value, < 2 GPL u/ml, where 1 GPL unit is the binding activity of 1µg/ml of 
IgG aCL affinity purified aPL). All patients fulfilled diagnostic criteria for 
definitive APS (see Table 1.1). Anti-β2GPI titres were determined using an anti-
β2GPI ELISA kit for IgG antibodies (Genesis Diagnostics Ltd.). Anti-β2GPI were 
measured in arbitrary units where results great than 10u/ml were considered 
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positive. All patients tested showed significantly elevated levels of aCL (high 
titres) and anti-β2GPI (Table 3.1). Sample 14 was a normal control serum. A 
patient serum sample previously determined to have high titre IgG aCL was 
included in all aCL assays as a positive control.  
 
NB. For clarity, patient samples other than those used in microarray experiments 
were designated as samples, not patients. 
 
Table 3.1  aCL and anti-β2GPI antibody concentrations of 13 patients used for 
IgG purification 
 
Sample IgG aCL Anti- β2GPI 
   GPL u/ml 
 Arbitrary    
units (u/ml) 
1 552 352 
2 736 656 
3 308 184 
4 350 800 
5 557 184 
6 286 368 
7 179 89 
8 352 224 
9 252 600 
10 136 256 
11 50 124 
12 552 352 
13 140                    80 
14 <2.0  <2.0 
 
 
3.2.2 Effect of antibodies on EC activation 
Initial investigations by other groups used IgG purified from APS patients to 
ascertain the affects of aPL on EC. Preliminary experiments in this chapter use the 
same approach to begin the investigation of the effects of aPL on EC activation. 
IgG from 13 APS patient samples and normal control IgG were manually purified 
on Protein G-Sepharose columns (1ml column). Protein concentrations were 
determined using the Bicinchoninic Acid Protein assay. Protein concentrations for 
IgG preparations ranged from 3.3 to 5.8mg/ml.  
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E-selectin is not constitutively expressed by vascular EC and increased expression 
is an indicator of EC activation (Zimmerman et al., 1999). ICAM-1 is expressed 
constitutively at low levels. Purified IgG from 13 patients containing anti-β2GP1 
and normal control IgG at a protein concentration of 500µg/ml were incubated 
with HUVEC for 6 hours. Activation was measured using a HUVEC activation 
ELISA. Expression of ICAM-1 and E-selectin were calculated as the ratio of 
patient optical density (OD) to that of the normal control where the normal control 
was given a ratio of 1.0 (100% activation baseline). OD for negative control 
(unstimulated cells incubated with media only) was subtracted from all values 
before calculations were done (Figure 3.1). Results of ratios are found in Table 1 in 
the Appendix.  
 
The HUVEC activation ELISA showed upregulation of E-Selectin expression in 
response to all patient IgG preparations with the exception of patient sample 13, 
when compared to normal control IgG (500µg/ml) (Figure 3.1). Patient IgG 
contained IgG aCL and anti-β2GPI (Table 3.1) Percent upregulation of E-selectin 
ranged from 0 to 215 percent compared to normal control IgG. The HUVEC 
activation ELISA showed ICAM-1 upregulation in response to patient IgG in all 
samples (n=13). Upregulation ranged from 27 to 308 percent compared to normal 
control IgG (Figure 3.2).  
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Figure 3.1 Percent upregulation of HUVEC E-selectin expression in the 
presence of patient IgG. The percent activation of HUVEC E-selectin 
expression in the presence of patient IgG containing anti-β2GPI compared 
to normal control IgG was determined using a HUVEC activation ELISA 
assay. IgG from patient samples (n=13) and normal control IgG (n=1, 
sample 14) were incubated with cells at a concentration of 500µg/ml for 6 
hours at 37°C with 5% CO2. Unstimulated cells incubated with complete 
media only were included as a negative control. Basal OD values for 
unstimulated cells were subtracted from all OD values. Upregulation was 
calculated as the ratio of patient IgG OD to normal control IgG OD. 
Percent upregulation was calculated by comparing patient ratios to control 
IgG where normal represented a ratio of 1.0 or 100 percent baseline.  
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Figure 3.2  Percent upregulation of HUVEC ICAM-1 in the presence of 
patient IgG. The percent activation of HUVEC ICAM-1 expression in the 
presence of patient IgG containing anti-β2GPI (n=13) compared to normal 
control IgG (n=1) was determined using a HUVEC activation ELISA 
assay. Explanation as for Figure 3.1. 
 
 
3.2.3 Affinity purified anti-β2GPI and co-factor dependence 
The first polyclonal anti-β2GPI preparation was prepared from purified IgG from 
sample 1 in Table 3.1 (clinical history is given in Table 2.1). Affinity purification 
was carried out using the NHS-activated sepharose column (1ml) coupled to 
purified human β2GPI.  The antibody preparation was initially characterized by 
determining the ability of anti-β2GPI to bind to cardiolipin in the presence or 
absence of β2GPI co-factor. Dilutions of antibody were prepared in PBS containing 
10% FCS (containing the β2GPI co-factor) and the ELISA plate was blocked with 
PBS supplemented with 10% FCS for these samples. Antibody dilutions were also 
prepared in PBS containing 0.6%(w/v) gelatin in place of FCS (no co-factor) and 
the blocking step for these samples was done with the 0.6%(w/v) gelatin in PBS. 
The anti-β2GPI antibody preparation was found to be co-factor dependent (no 
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binding in the absence of β2GPI) at two concentrations of antibody (1µg/ml and 
3µg/ml) and binding was dose-dependent (Figure 3.3). Anti-β2GPI binding to 
β2GPI in the absence of co-factor was not above background levels. 
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Figure 3.3  Anticardiolipin binding activity of anti-β2GPI with and 
without co-factor. aCL binding of affinity purified antibody was tested in 
the presence and absence of co-factor β2GPI known to be present in serum. 
The antibody preparation was tested at two concentrations (1 and 3µg/ml) 
with and without β2GPI. Each test variable was tested in quadruplicate and 
the assay was done once. Anti-β2GPI bound to cardiolipin only in the 
presence of fetal calf serum (FCS) containing β2GPI.  
 
 
3.2.4 Anti-β2GPI binding to β2GPI 
The initial manipulations of affinity purified anti-β2GPI were limited in that the 
amount of antibody yield was very small, so assays were performed only once. The 
antibody affinity purified from sample 1 (Table 3.1) was shown to bind to β2GPI in 
a β2GPI ELISA, and the binding was dose dependent (Figure 3.4). A 1/50 dilution 
of the serum from sample 1 (Tables 2.1 and 3.1) gave an OD of 0.827 and 1/50 of 
normal negative control serum gave an OD of 0.223 shown in Figure 3.4. This 
assay is highly sensitive and specific for anti-β2GPI binding. 
 97
0 10 20 30 40 50 60 70
0.0
0.5
1.0
1.5
anti-β2GPI  (µg /ml)
O
D 
at
 
40
5 
n
m
 
Figure 3.4  The binding of affinity purified anti-β2GPI to β2GPI.  
Binding affinity of purified anti-β2GPI to β2GPI in solid phase was tested 
using an anti-β2GPI ELISA. The anti-β2GPI preparation was tested singly 
at four different protein concentrations (8, 15, 30 and 60µg/ml). The blue 
triangle represents the OD for normal control serum used as a negative 
control (0.223). The red diamond represents the OD for a 1/50 dilution of 
serum from sample1 (O.827) in Table 3.1 used for the preparation of the 
anti-β2GPI tested in this figure. The ODs for the controls are the mean of 
three values, the experiment was performed once.  
 
The antibody used in Figure 3.4 was purified from 5ml of serum from sample 1 
using a 1ml NHS activated sepharose column coupled to human β2GPI. The 
antibody yield after dialysis was approximately 200µl with a protein concentration 
of 300µg/ml. After subsequent purification of two more anti-β2GPI preparations 
from patient serum samples (samples 2 and 4, Table 3.1) it became apparent that 
larger volumes of patient sera would be required in order to have sufficient 
antibody yield for microarray and follow-up experiments. Over the next several 
months, 25ml of sera was collected from suitable patients with patient consent 
(Table 2.2). Subsequent IgG and antibody purification was achieved using the 
AKTAprime protein purification system.  
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3.2.5 Activation of HUVEC in response to anti-β2GPI 
Upregulation of E-selectin and ICAM-1 expression was shown in HUVEC in 
response to purified IgG from patients with APS containing anti-β2GPI (Figures 
3.1 and 3.2). In order to determine whether the affinity purified polyclonal 
antibody preparations would also activate HUVEC, we incubated HUVEC with 
two antibody preparations (Samples 1 and 4, Table 3.1) and then measured E-
selectin expression in a cell activation ELISA. Four hours incubation with antibody 
resulted in a dose-dependent increase in E-selectin expression in the presence of 
both antibody preparations when compared to normal control IgG (Figure 3.5). 
Preparations were tested at three concentrations, 8, 15 and 30µg/ml. 
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Figure 3.5   Upregulation of E-selectin in HUVEC in response to 
affinity purified anti-β2GPI antibodies.  E-Selectin expression in 
HUVEC in response to two affinity purified anti-β2GPI preparations from 
two different patient serum samples (sample 1 and sample 4 from Table 
3.1) was assessed using the HUVEC activation ELISA and compared to 
normal control IgG. The two anti-β2GPI preparations and one normal 
control IgG were tested singly at three different protein concentrations (8, 
15 and 30µg/ml). The experiment was performed once. HUVEC expression 
of E-Selectin was upregulated in the presence of anti-β2GPI in a dose 
dependent manner. 
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Similarly, upregulation of ICAM-1 expression was assessed by incubating 
HUVEC for 4 hours with one antibody preparation (Sample 4, Table 3.1). HUVEC 
demonstrated a dose dependent increase in ICAM-1 expression in response to anti-
β2GPI compared to normal control IgG (Figure 3.6). 
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Figure 3.6   Upregulation of ICAM-1 in response to affinity purified 
anti-β2GPI.  The upregulation of ICAM-1 expression was assessed using 
the HUVEC activation ELISA. The anti-β2GPI preparation (Sample 4) and 
one normal control IgG were tested singly at three different protein 
concentrations (8, 15 and 30µg/ml). The experiment was performed once. 
HUVEC expression of ICAM-1 was upregulated in response to affinity 
purified anti-β2GPI from sample 4 in a dose dependent manner compared 
to normal control IgG. 
 
 
3.2.6 IL-8 production in response to anti-β2GPI  
IL-8 is a well known pro-inflammatory chemokine produced in activated EC in 
response to a number of agents such as IL-1 and TNF-α (Kaplanski et al., 1997).  
In addition to the measurement of E-selectin and ICAM-1 expression in the cell 
ELISA, measuring IL-8 in cell supernatants of cells incubated with anti-β2GPI was 
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used as an alternative measure of EC activation. In the first experiment, expression 
of IL-8 protein in cell supernatants was measured in response to three independent 
affinity purified anti-β2GPI (25µg/ml) and compared to IL-8 concentrations in 
media alone and in response to normal control IgG (Figure 3.7). 
Figure 3.7   IL-8 concentrations in cell supernatants in response to 
affinity purified anti-β2GPI.  Three independent affinity purified anti-
β2GPI antibody preparations (25µg/ml) (Sample 4, Sample 2, and Patient 5) 
were incubated with confluent P3 HUVEC in 96 well plate for 6 hours 
(black) and 24 hours (white) at 37°C with 5% CO2. Cell supernatants were 
removed after six and twenty-four hours incubation and frozen at -70°C. 
Each value is the mean of duplicate determinations. IL-8 concentrations 
were determined using IL-8 ELISA. Complete media and normal control 
IgG (25µg/ml) were included as negative controls. This experiment was 
done once. 
 
IL-8 concentrations in the cell supernatants were checked after 6 and 24 hours 
incubation with the antibody preparations. Anti-β2GPI from Patient 5 (Table 2.2) 
stimulated substantially more IL-8 than the other two preparations (Figure 3.7). 
(Patient 5 corresponds to sample 3 in Table 3.1. Patient 5 was used in microarray 
Experiment 1). EC IL-8 production was time-dependent in response to antibody 
exposure. TNF-α (10ng/µl) was included as a positive control and results were too 
high to read from the standard curve. 
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3.2.7 IL-8 induction with and without addition of Polymixin B 
Increased IL-8 production in response to anti-β2GPI from Patient 5 (Figure 3.6) 
was measured in a second experiment. HUVEC were incubated with increasing 
concentrations of anti-β2GPI for four hours. Since LPS is a potent activator of EC, 
Polymixin B is routinely added to experiments to neutralize possible endotoxin 
contamination of reagents. IL-8 concentrations in HUVEC supernatants were 
measured in response to 4 dilutions of anti-β2GPI and normal control IgG (25, 50, 
100, and 150µg/ml) with and without the addition of Polymixin B (5µg/ml) during 
the incubation step in the protocol (Figure 3.8). The addition of Polymixin B did 
not appear to reduce the amount of IL-8 induction indicating that LPS 
contamination was negligible and not contributing to EC activation. This antibody 
preparation appeared to activate the cells in a dose-dependent manner with 
50µg/ml giving optimum activation. This antibody preparation (Patient 5) was used 
in the first Affymetrix Experiment (1) at this concentration (see Chapter 4). This 
preparation was also found to bind to β2GPI and was co-factor dependent. IL-8 
was measured in complete media as a negative control and TNF-α (10ng/µl) as a 
positive control. TNF gave values too high to read from the standard curve. 
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Figure 3.8  IL-8 up-regulation in the presence of anti-β2GPI with and 
without the addition of Polymixin B. HUVEC were incubated with 
different concentrations of affinity purified (AP) anti-β2GPI from Patient 5 
(Table 2.1) and normal control IgG for 4 hours at 37°C with 5% CO2 with 
and without the addition of Polymixin B (PMB) (5µg/ml). Cell supernatants 
were removed and frozen at -70°C. Samples were thawed and IL-8 
concentrations of the supernatants were determined using an IL-8 ELISA.  
 
 
3.2.8 Anti-β2GPI  preparations for Microarray Experiment 2 
Approximately 25ml of sera were collected from four patients with PAPS (Patients 
1-4, Table 2.2). IgG and anti-β2GPI were purified using the AKTAprime protein 
purification system. After concentration and buffer exchange the final protein 
concentrations of antibody preparations were: Patient 1, 406µg/ml: Patient 2, 
219µg/ml: Patient 3, 280µg/ml: and patient 4, 227µg/ml. In a modified aCL assay, 
all four antibody preparations (3µg/ml) were shown to bind to cardiolipin in the 
presence of co-factor (Figure 3.9). As in Figure 3.3, binding in the absence of co-
factor was not above background levels.  
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Figure 3.9  Co-factor dependent aCL activity of four anti-β2GPI 
preparations.  4 anti-β2GPI patient preparations (3µg/ml) were tested for 
binding to cardiolipin with and without the presence of co-factor (β2GPI) in 
an ELISA previously described (see 3.2.3). Antibody preparations were 
tested in duplicate and values shown represent the mean of the two ODs. 
The experiment was done once. 
 
 
It is interesting to note that the four antibody preparations at the same 
concentration show different abilities to bind to cardiolipin at the same 
concentration (Figure 3.9). This same observation was made when the same 
preparations were tested for their binding to β2GPI (Figure 3.10).  
 
All four antibody preparations were able to bind to β2GPI. Normal control IgG at 
the same concentration showed binding at background levels. However, the 
amount of antibody bound to β2GPI in the ELISA was highly variable between 
preparations at the same concentrations. This is in agreement with Del Papa et al. 
(1996) who affinity purified anti-β2GPI from 6 APS patients and all 6 showed 
different EC binding activity at the same concentrations and negligible binding 
with normal control IgG in a β2GPI ELISA (concentrations tested were from 1.5 to 
100µg/ml).  
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Figure 3.10  Binding of four anti-β2GPI to β2GPI.  Binding of four 
affinity purified anti-β2GPI to β2GPI was assessed in a β2GPI ELISA assay 
and compared to normal control IgG. Binding of four antibody preparations 
and normal control IgG were tested at concentrations of 0.75, 1.5, 3.0, 6.0, 
12.5, and 25µg/ml. was coated on the ELISA plate at a concentration of 
10µg/ml. Results were recorded as OD measured at 405 nm. These 
antibody preparations were used in Affymetrix Experiment 2.  
 
 
3.2.9  Up-regulation of E-selectin and IL-8 expression in response to anti-
β2GPI (P1-P4) 
Another way to demonstrate activation of a gene (mRNA production) is to measure 
the protein or final expression product that results from transcription and 
translation in response to a stimulus (Lockhart & Winzeler 2000). The four 
antibody preparations and the four normal control IgG’s to be used in Microarray 
experiment 2 (Patients 1-4) were tested for their ability to activate EC by 
measuring upregulation of E-selectin on the surface of the cells in the HUVEC 
ELISA (Figure 3.11). IL-8 was present in cell supernatants in higher concentration 
in response to antibody when compared to normal control IgG (Figure 3.11) 
Normal control IgG stimulated baseline amounts of E-selectin similar to incubation 
with media alone.  
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In order to check the antibody preparations for LPS contamination, E-selectin 
expression in response to antibody and normal control IgG was also tested with 
and without the addition of Polymixin B (5µg/ml). A paired t test showed no 
statistical difference between levels of E-selectin expression in the presence or 
absence of Polymixin B in three of the four anti-β2GPI peparations (P1-P3) 
indicating LPS induced activation was negligible (Figure 3.11). P4 gave a p value 
of 0.04 (p<0.05). As a precaution, Polymixin B (5µg/ml) was added to the 
HUVEC/antibody and HUVEC/normal control IgG incubation step for microarray 
Experiment 2. 
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Figure 3.11   Effect of purified anti-β2GPI on HUVEC E-selectin 
expression. The effect of the four normal control IgG and four AP anti-
β2GPI (used in microarray experiment 2) was determined using a HUVEC 
activation ELISA. Results are expressed in OD units at 405 nm. Mean ± 
SEM are shown, n=3. Antibodies were incubated with the cells for 4 hours 
(50µg/ml) at 37°C/5% CO2 with (white) and without (black) the addition of 
Polymixin B (5µg/ml). 
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IL-8 levels were determined in HUVEC supernatants after four hours incubation 
with anti-β2GPI preparations (P1, P2, P3 and P4), and normal control IgG all with 
the addition of Polymixin B (5µg/ml) (Figure 3.12). IL-8 concentration was 
increased in response to all four anti-β2GPI preparations compared to normal 
control IgG, the difference being statistically significant (p<0.03 as determined by 
two-tailed Mann Whitney U Test).   
 
Therefore, incubation of HUVEC with four anti-β2GPI preparations from four 
different PAPS patients resulted in significant upregulation of E-selectin and IL-8 
expression when compared to four normal control IgGs. 
 
 
 
Figure 3.12 Anti-β2GPI antibodies induce HUVEC activation. The 
effect of four normal control IgG and four APS-derived anti-β2GPI 
preparations (used in Microarray experiment 2) on IL-8 secretion  was 
determined by ELISA. Antibodies were incubated with cells for 4 hours at 
50µg/ml. IL-8 was measured in cell supernatants. Results show mean ± 
sem of triplicate samples from a representative experiment (one of three). * 
=p<0.03 as determined by two-tailed Mann Whitney U Test. Polymixin B 
(5µg/ml) was added to the anti-β2GPI incubation step.  
 
 
3.2.10 Effect of endotoxin on EC activation  
It was necessary to address the possibility that there was endotoxin contamination 
in the IgG and polyclonal anti-β2GPI preparations since LPS could be at least 
partially responsible for activation of pro-inflammatory genes rather than the 
antibody preparations themselves.  
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The FDA defines the endotoxin unit (EU) as the endotoxin activity of 0.2ng of 
reference endotoxin standard (Guideline on Validation of the Limulus Amebocyte 
Lysate Test as an End-Product Endotoxin Test for Human and Animal Parenteral 
Drugs, 1987). Levels of LPS in control and anti-β2GPI antibody preparations were 
measured by a Limulus Amebocyte Lysate Test (Cape Cod Associates, Mass, 
USA) and they were very low (≤4ng/ml). In preliminary experiments to test the 
effectiveness of antibody preparation to induce E-selectin expression, all control 
IgG and anti-β2GPI antibodies, which were used in the microarray experiments, 
were tested in the presence or absence of polymixin (See Figures 3.7 and 3.10).  
The addition of polymixin had no/minimal effects on control IgG or anti-β2GPI 
antibody induced E-selectin levels, but nonetheless, as a precaution, it was decided 
to include this reagent in all experiments.  
 
In order to test the effectiveness of Polymixin B (5µg/ml) on inhibiting endotoxin-
induced EC activation, confluent HUVEC were incubated with increasing 
concentrations of LPS for six hours with and without addition of the standard 
recommended concentration of Polymixin B (5µg/ml) (Figure 3.13). In the 
presence of Polymixin B, IL-8 production was not increased beyond baseline 
levels (negative controls media and media /10% FCS) up to an LPS concentration 
of 25ng/ml. Finally, other investigators in the field have routinely used this 
concentration of Polymixin B in their experiments (Raschi et al., 2003a). These 
results support the conclusion that EC activation seen in the presence of anti-β2GPI 
antibodies in the previous experiments was due to effect of antibody rather than 
endotoxin in the preparations. 
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Figure 3.13 Affect of Polymixin B on IL-8 production in the presence 
of LPS. Confluent HUVEC were incubated with increasing concentrations 
of lipopolysaccharide (LPS) (0.05-500ng/ml) for six hours at 37°C/5% C02  
with (white) and without (black) the addition of Polymixin B (5 µg/ml). IL-
8 concentrations were determined using an IL-8 ELISA. Each value is the 
mean of three replicate samples. LPS stock was 0.5mg/ml. 
 
 
3.3 Discussion 
In order to achieve the objectives for this chapter a number of protocols had to be 
established and refined. It was necessary to isolate primary HUVEC, then grow 
and retain healthy HUVEC in culture until P3 when they would be used in 
experiments. Appropriate patient serum samples had to be collected from ongoing 
clinics in the Lupus Unit at St. Thomas’ Hospital, London. IgG was purified from 
a number of patient sera, this was followed by preparation of β2GPI affinity 
columns and subsequent purification of anti-β2GPI. 
 
EC activation in response to APS patient IgG containing anti-β2GPI was confirmed 
by measuring upregulation of E-selectin and ICAM-1 on the HUVEC cell surface. 
Anti-β2GPI was affinity purified from several PAPS patient IgG samples and these 
polyclonal antibody preparations were characterized by measurement in the 
standard aCL assay with and without the addition of β2GPI co-factor and 
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measurement in a β2GPI ELISA. Iverson et al., (1998) purified anti-β2GPI from 
serum of APS patients and the antibody yield ranged from 10 to 190 µg per ml of 
serum. The first two affinity purified anti-β2GPI preparations in this study were 
each purified from 5ml of sera and the yields were in the same range. Preparations 
gave 15 µg/ml of serum (Sample 1, Table 3.1) and 90µg/ml of serum (Sample 4, 
Table 3.1) (300µg/ml in a total volume of 200µl and 450µg/ml in a total volume of 
250µl) respectively. 
 
In preliminary EC activation experiments with anti-β2GPI, polyclonal anti-β2GPI 
and monoclonal anti-β2GPI antibodies were tested at concentrations of 25-
100µg/ml (Del Papa et al., 1997, George et al., 1998). Upregulation of adhesion 
molecules in response to antibody appeared to plateau at concentrations between 
25 and 50µg/ml (George et al., 1998). In the same paper, monoclonal anti-β2GPI 
binding to β2GPI ELISA coated with 10µg/ml β2GPI plateaued at antibody 
concentrations between 25 and 50µg/ml. Binding of affinity purified anti-β2GPI 
from patients 1-4 in this study appeared to plateau at around a concentration of 25-
30µg/ml at the same concentration of β2GPI (10µg/ml)(Figure 3.10). 
 
Preliminary experiments in this study indicated anti-β2GPI induced EC activation 
occurred in a dose-dependent manner. EC activation with anti-β2GPI appeared to 
be optimal at a concentration of 50µg/ml, so it was decided to use this 
concentration in the microarray experiments. EC activation was confirmed by 
measurement of increased expression of E-selectin and ICAM-1 on the EC surface 
and increased IL-8 concentrations measured in cell supernatants after incubation 
with anti-β2GPI. 
 
As a consequence of these encouraging results, anti-β2GPI was affinity purified 
from sera of four additional PAPS patients, each of whom fulfilled the diagnostic 
criteria and had a previous history of thrombosis. These antibody preparations 
were characterized as above and shown to induce EC activation. Affinity 
purification of larger volumes of sera using the AKTAprime system meant that 
sufficient quantities of these four anti-β2GPI as well as Patient 5 (Table 2.2) were 
obtained in order to proceed to microarray (Patient 5 corresponds to patient sample 
3 in Table 3.1). 
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In conclusion, anti-β2GPI antibodies were successfully isolated and characterized 
from PAPS patient sera. These antibodies demonstrated the ability to activate EC, 
making it feasible to proceed to microarray with confidence.  
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Chapter 4 
Microarray Analysis of Global Gene Expression 
in HUVEC in Response to anti-β2GPI from 
PAPS Patients 
 112
 
4.1 Introduction 
In the previous chapter, IgG anti-β2GPI from PAPS patient sera antibodies were 
successfully affinity purified and characterized. These antibodies are strongly 
associated with VT and have been identified as an independent risk factor for 
thrombosis (Cabral et al., 1995; Martinuzzo et al., 1995; Galli et al., 2003b). 
Purified polyclonal anti-β2GPI preparations from APS patients have been used in 
numerous in vitro applications in order establish possible mechanisms of action of 
these antibodies. These studies were performed in order to identify anti-β2GPI-
dependent changes in EC phenotype that may be responsible for the prevalence of 
thrombosis in APS. It is well documented that anti-β2GPI cause EC activation. 
Anti-β2GPI antibodies have been shown to induce leukocyte adhesion molecules 
(Simantov et al., 1995; Del Papa et al., 1997; Pierangeli et al., 1999). aPL also 
upregulate TF on EC and monocytes, this increase in TF expression would clearly 
contribute to the prothrombotic EC phenotyope associated with APS (Kornberg et 
al., 1994; Cuadrado et al., 1997). EC activation has also been demonstrated in 
response to anti-β2GPI in vivo (Pierangeli et al., 2000). Recent studies have 
reported that NF-κB transcription factor pathway, MyD88 pathway, and 
p38MAPK phosphorylation are involved in EC activation by anti-β2GPI antibodies 
(Dunoyer-Geindre et al., 2002; Raschi et al., 2003; Bohgaki et al., 2004). Although 
these studies have identified a number of interesting associations between anti-
β2GPI induced EC activation and changes in EC phenotype, the extent and 
diversity of anti-β2GPI-mediated gene regulation in EC is not well characterized. 
 
The present study was undertaken in order to examine early global gene expression 
in EC in response to polyclonal patient-derived anti-β2GPI using Affymetrix 
microarray gene profiling. Such an experimental approach would be able to screen 
for changes in regulation of large numbers of genes in EC simultaneously in 
response to affinity purified anti-β2GPI. Microarray analysis can provide insights 
into those genes that may be co-regulated. Such information could lead to further 
understanding of gene interactions and provide insight into the complex 
mechanisms of EC activation in response to anti-β2GPI. As well as confirming 
changes in those anti-β2GPI regulated genes identified in previous studies, it was 
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hoped that the transcription profile obtained would identify a number of novel 
genes potentially involved in the pathology of PAPS.   
 
4.1.1 Background- Affymetrix microarray technology and data analysis  
The main goal of this project was to determine differential gene expression 
between EC exposed to anti-β2GPI and those cells exposed to normal control IgG. 
Our microarray investigations incorporated the high-density oligonucleotide 
microarray platform, made by Affymetrix Inc. Experiment 1 used the HG U133A 
chip and Experiment 2 the HG U133A_2 chip. The Affymetrix methodology uses 
expressed sequence tags (ESTs). These represent segments of DNA of known 
sequence within a gene of interest and are selected for their specificity for the 
gene. These small segments of DNA also known as oligonucleotides are used as 
probes. In the case of Affymetrix, a probe is a 25-mer oligonucleotide of known 
sequence synthesized in situ on the surface of the chip using a technology called 
photolithography. Each oligonucleotide is synthesized on a feature or specific spot 
on the chip (Affymetrix Users Manual, 2006). The Affymetrix platform 
incorporates probe sets. These are collections of probe pairs that bind to the same 
sequence or set of sequences within a gene of interest.  Affymetrix incorporates 11 
probe pairs in a set (22 probes in total) per gene, using a number of different 
probes per gene makes results more reliable. A probe pair includes the 
complementary sequence or perfect match (PM) to the selected segment of DNA 
and a mismatch oligo (MM) that contains a single base mismatch in the centre of 
the oligo to the same target region. This base substitution compensates for non-
specific hybridization of the target DNA. If the PM intensities are consistently 
higher than the MM intensities, there is a good indication that transcript for the 
corresponding gene was in fact present in the sample. The gene expression level or 
relative abundance of a transcript is obtained by taking the average hybridization 
intensity of the 11 probe pairs and this value is referred to as the signal. The 
unknown, labelled (biotinylated) fragmented cRNA, is applied to the probe array 
for hybridization and is called the target.  
 
In order to achieve reliable results in gene expression analysis studies, stringent 
quality control (QC) measures were used throughout the process in order to 
monitor sample quality and successful hybridization. To begin, the overall quality 
 114
of the RNA sample was assessed by measuring the concentration and purity and 
assessing RNA quality on a gel using the Agilent Bioanalyser. The samples were 
checked  visually twice more in the protocol by running them on a gel, the 
quantified cRNA and the fragmented cRNA were checked visually for overall 
quality and successful completion of cRNA synthesis and fragmentation.  
 
Internal control probes on the array include genes Beta-actin and GAPDH and 
these are used to assess the RNA sample quality and assay efficiency. Probes at 
opposite ends of these genes (the 3’ and 5’ends) are included on the array, the ratio 
of 5’ to 3’ intensities should be approximately 1 if the IVT reaction has been 
efficient. Other probes have a 3’ bias to ensure complete transcription. Control 
probes within the array include eukaryotic hybridization controls (bio B, C and D 
biotin-labeled cRNA). These are added to the hybridization cocktail and are 
present in gradually increasing concentrations in order to evaluate sample 
hybridization efficiency. The number of probe sets called present (%P) in relation 
to the number of probes on the array is given as a percent. (HUVEC expressed 
approximately 55% of genes. Replicate samples should have a similar %P value as 
should samples from one cell type).  
 
4.1.2 Processing the Scanned Image 
After hybridization, the array is washed to remove unbound target and scanned. 
The scanned image must be translated into numeric data that can be used for 
statistical analysis. Immediately after scanning, the probe array image (.dat file) is 
examined visually for artefacts such as high/ low intensity spots, scratches, or high 
background staining. The oligo B2 hybridization control (Biotinylated control 
oligonucleotide) is incorporated into the hybridization cocktail and the binding of 
this control is assessed visually on the image. An alternating pattern of intensities 
around the border should be visible along with the array name located in the upper 
left corner.  Using the oligo B2 as a reference, a grid is automatically placed over 
the image so that each probe corresponds to a specific location on the grid. Each 
spot on the array corresponding to a probe will be assigned an intensity value 
(single channel array). The *.cel file is created from the *.dat file where the cel file 
contains a single intensity value for each probe or feature on the grid. This data is 
filtered to remove background (electrical) noise in the system.  
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4.1.3 Detection Algorithm 
Probe pair intensities are used to generate a Detection p-value followed by a 
Present, Marginal or Absent call. Each probe pair in a set (n=11) helps to 
determine whether the measured transcript is detected (present) or not detected 
(absent). The discrimination score (R) is calculated for each probe set and takes 
into consideration intensity values for the PM probe (perfect match probe) and the 
MM (mismatch) probe. R= (PM-MM)/ (PM+MM) where a PM much higher than 
the MM in a number of the probe pairs will result in a higher discrimination score 
and a lower or more significant detection p value. A lower p-value is a reliable 
indicator that the transcript is expressed and the result is valid. The discrimination 
scores are then tested against a user-defined threshold called Tau. Scores higher 
than Tau are in favor of the transcript being present, the higher the scores are 
above Tau, the smaller the p-value and the more likely that the transcript is present. 
The one-sided Wilcoxon’s Rank test is used to determine the Detection p-value. 
(http://www.affymetrix.com/support/technical/technotes/statistical_reference_guid
e.pdf). 
 
4.1.4 Detection Calls 
The boundaries used to define Present, Marginal or Absent calls are detection p-
value cut-offs called Alpha 1 (p<0.04) and Alpha 2 (p>0.06). A p-value <0.04 is 
given a Present call, p between 0.04 and 0.06 a Marginal call and p>0.06 an 
Absent call. The process of selecting Present and Marginal genes is called 
flagging. The flagged genes are used in further calculations of expression change. 
Genes should be present in half or more than half of the samples to be considered 
significant. In Experiment 2 we stipulated that genes had to be present in 11/22 
samples or more. Signal is a quantitative measure of the relative amount of a 
transcript. It is calculated using the One-step Tukey’s Bi-weight Estimate that 
gives a weighted mean. Each probe pair contributes to the determination of signal. 
The mismatch is used to determine background or stray signal. The signal is 
estimated by subtracting the MM intensity from the PM intensity, followed by 
taking the log of the value. The mean of the intensity values for the probe set is 
calculated, converted back to linear scale and given as the signal for the 
corresponding gene. 
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Fluorescent intensities from each spot are compared across arrays within an 
experiment. In order to be able to compare data between samples (different chips 
within an experiment) the data is normalized to remove inter-array heterogeneity. 
The purpose of normalization is to minimize the effects of experimental and or 
technical differences between the samples in an experiment. This assumes that the 
majority of the transcripts are not changing in a group of samples and overall 
intensities of the arrays should be similar. This process is known as global 
normalization (incorporates all probes). This method assumes that spot intensities 
on the arrays are linearly related and that the same scaling factor can be applied to 
each spot on an array. The normalization method used in Genechip software is 
called scaling. Scaling is the adjustment of the average intensity (signal) value 
across all arrays in an experiment to a common target intensity value (usually 100). 
Each sample will have a different scaling factor.  The scaling factor is usually less 
than 1.0, a scaling factor of greater than 3 on an array will result in too much 
variation between the samples or sample degradation (Lu 2004). Scaling factors in 
the experiments reported here were consistently between 0.2 and 0.4. Affymetrix 
uses a trimmed mean including the intensities from 96% of the probe sets with the 
highest and lowest 2% of the values being eliminated to remove outliers. Flagged 
values (P and M) should be used in the calculation of the mean intensity. (The 
average intensity value (PM minus MM) for each probe pair in an array is 
calculated and compared to the means in the other samples.)  
Hybridization and corresponding fluorescent intensities are influenced by the GC 
content of the probes. GC rich probes tend to have higher intensities than those 
with AT rich probes. A non-parametric between-array normalization technique for 
Affymetrix GeneChip data that corrects for GC content is the multivariate quantile 
normalization algorithim. This algorithm compensates for dispersion of the data 
and outliers and was applied to the raw cel. file data (Bolstad et al., 2003). 
  
4.1.5 Log Transformation of Data  
When comparing differences in an experiment between two or more conditions, 
change is the qualitative measure of increase or decrease in a transcript. Once the 
data has been normalized, the change in expression is taken as the ratio of the 
intensity for the probe in the treated sample compared to the intensity for the same 
probe in the baseline or control and this gives the fold change. Assuming that the 
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majority of transcripts are unchanged, the majority of values for this ratio will 
cluster around 1.0, the data tends to be heavily skewed. Taking the log ratio gives 
more structure to the values by enabling greater discrimination between small 
differences in expression. This means the data is dispersed more evenly around 1.0 
and is more easily examined visually within the Affymetrix and Genespring 
programs. (Chapter 5, Processing microarray data- in Exploration and analysis of 
DNA Microarray and protein array data- Pg 61). Therefore, a quantitative estimate 
of the change in gene expression produced in the form of Signal Log Ratio is 
included in the analysis. 
 
The ratio of expression intensities gives the fold change. In this study, fold change 
greater than 2.0 indicated upregulated expression and < 2.0 (ratios < 0.5) indicated 
down-regulated expression. The choice of the fold change cutoff is arbitrary, 
generally from 1.5 fold or greater up and down (see 4.1.8). The Affymetrix assay is 
able to ascertain fold changes of two fold or greater 98% of the time (Wodicka et 
al., 1997).   
 
4.1.6 Significance Testing  
The one way analysis of variance (ANOVA) allows you to determine if one given 
factor (eg; antibody treatment) has a significant effect on the expression of a gene 
across two groups of samples in a study. In this study the two sample groups 
include HUVEC incubated with anti-β2GPI and HUVEC incubated with normal 
control IgG. Testing for statistical significance identified those genes that are 
differentially expressed and show similar patterns and/or levels of expression in 
treated samples when compared to untreated. Differential expression of such a 
gene would result in a significant p value in the one-way ANOVA. The one way 
analysis of variance (ANOVA) uses normalized log of ratio data and takes the 
average expression of each gene across all biological replicates. It then compares 
the mean difference for the gene between tests and controls 
(www.chem.agilent.com).  
 
4.1.7 Clustering 
Clustering of the data helps to identify patterns of regulation common to those 
genes that are altered in expression. Gene clustering approaches are applied to 
 118
microarray data in order to attempt to identify subsets of genes that display similar 
or coordinated expression patterns. The application is known as unsupervised 
pattern recognition (Boutros & Okey 2005). Clustering or unsupervised pattern 
recognition algorithms are able to identify patterns within a set of data. The three 
most common clustering algorithms are hierarchical clustering, k-means and self-
organizing maps. Unsupervised algorithms that start with the raw data generally 
provide information about patterns within the data. Hierarchical clustering assumes 
that the genes can be organized in relation to their similarity to each other. If the 
expression of a gene is altered at the same time as another (co-expression), the 
assumption may be that both genes are required in order to achieve a biological 
effect.  Co-expression of genes means that genes in a cluster display similar 
patterns of expression over several conditions. Regulation of genes that are co-
expressed may be orchestrated through a common mechanism such as signaling 
through a common pathway, for example the transcription factor NF-κB. 
Clustering may help to identify sets of genes with such associations and give rise 
to new hypotheses about the mechanisms of regulation. Genes identified as having 
differential expression can also be grouped according to their function (see Figure 
4.3).   
 
4.1.8 Selection criteria for differentially expressed genes  
This chapter presents the results of two separate microarray experiments 
undertaken in order to assess gene expression in response to anti-β2GPI. In both 
Experiments 1 and 2, genes that show changes in expression in HUVEC when 
incubated with anti-β2GPI compared to normal control IgG will be described as 
being differentially expressed. Only genes flagged as P or M by the Affymetrix 
MAS 5.0 software were included in the analysis. All expression values were 
normalized across the samples and fold change was calculated by taking the ratio 
of the mean expression for each gene in the treated samples compared to the 
controls. Non-changing genes were removed from the data before doing analysis of 
variance. Genes showing two fold change in expression (either up of down) were 
included in analysis of variance across the samples. So, those genes found to be 
statistically significant (p<0.05) were changed two fold or greater in expression.  
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Firstly, differential gene expression in Experiments 1 and 2 will be addressed 
individually. Two-fold changes in gene expression were chosen because generally 
two-fold changes in level of expression are regarded as biologically meaningful in 
more conventional biochemical assays such as Northern blot, Western Blot or 
Real-time PCR analyses. When it comes to microarray data, the two-fold cut-off is 
an arbitrary cut-off, however we restricted our analysis to this level of change in 
order to highlight those changes in gene expression that were likely to be 
biologically meaningful and also could be confirmed by other biochemical assays 
(such as those mentioned above).  
 
Those genes statistically significant genes (p<0.05) common to both experiments 
are identified. A larger number of genes within the two experiments were changed 
two fold or greater in expression, but failed to meet statistical significance due to 
the variability in expression between samples. Not all genes altered in expression 2 
fold or greater received individual comment. The focus was on those genes that 
were more highly expressed or those most likely to contribute to the thrombotic 
phenotype of PAPS based on their function.  
 
4.1.9 Chapter Objectives 
The principle objective of this chapter was to present, summarize and confirm data 
from Affymetrix microarray experiments designed in order to determine the effect 
of affinity purified anti-β2GPI on global gene expression in HUVEC when 
compared to normal control IgG. The experimental approach in order to achieve 
this objective is summarized in the following points: 
 
• Experiment 1 tested the effect of purified anti-β2GPI from Patient 5 (Table 
2.1) on differential gene expression in HUVEC. The antibody preparation 
was tested three times on three separate occasions using three different 
HUVEC donors. Each time, antibody treated cells were compared to 
normal control IgG treated cells and the samples were paired for analysis of 
the data. 
• Experiment 2 incorporated four anti-β2GPI antibody preparations from four 
additional PAPS patients and compared their regulated gene expression in 
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HUVEC to four additional normal control IgG samples. As in Experiment 
1, the experiment was repeated on three different occasions using three 
different HUVEC donors. 
• Data analysis was performed using Genespring software 
(http://www.silicongenetics.com).  
• Those genes showing 2-fold or greater increase or decrease in expression, 
and statistically significant differences in expression (p<0.05) between 
antibody treated and normal control IgG treated cells were determined for 
both Experiment 1 and 2. 
• Those genes statistically significant and changed in expression greater than 
two fold, common to both experiments were identified. 
• Quantitative RT-PCR was used to confirm altered expression in several 
novel anti-β2GPI regulated genes identified using microarray. 
• Preliminary experiments to test the effect of anti-β2GPI on DNA synthesis 
in HUVEC were performed. 
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4.2 Results 
4.2.1 Experiment 1  
 Experiment 1 tested changes in global gene expression in response to anti-β2GPI 
(treated) from Patient 5 (Table 2.1) and one normal control IgG (untreated) with 
confluent HUVEC from three different cell donors on three separate occasions.  
Cells were incubated with anti-β2GPI and normal control IgG at a concentration of 
50µg/ml for four hours. Polymixin B was not added to the cell anti-β2GPI 
incubation step in Experiment 1. 
 
After scanning the arrays, Affymetrix Microarray suite (MAS) X 5 software was 
used to generate expression values for each gene.  Chip file data was imported into 
Genespring (Agilent Technologies) for further analysis. A paired t-test was 
performed on the 6 samples, pairing anti-β2GPI treated sample to normal control 
IgG sample for each HUVEC donor. For paired comparison, all genes in the 
control samples were given the value 1.0.  In Experiment 1, 43 genes up-regulated 
2 fold or greater were statistically different (p <0.05) between treated and untreated 
cells (Table 4.1). In this experiment, no genes down-regulated 2 fold or more were 
found to be statistically different between treatments.  
 
Genes were divided into APS relevant categories; apoptosis/ anti-apoptosis, 
chemokines, metabolism, transcription factors/ signalling, adhesion molecules/ 
receptors and miscellaneous. For each gene, gene tables include the gene 
nomenclature, corresponding fold change, the number assigned to the gene by the 
National Centre for Biotechnology Information (NCBI) number, and a brief 
description.  
The results in Experiment 1 were very encouraging in that they confirmed EC 
activation in response to polyclonal patient derived anti-β2GPI and the 
upregulation anticipated in several well documented genes, was in fact confirmed 
(ICAM-1 and VCAM-1, Table 4.1). 
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Table 4.1  Experiment 1- Anti- β2GPI antibody-induced gene expression in 
HUVEC (p<0.05, n=43). 
 
Gene Fold 
Induction 
Accession 
Number 
Gene Description 
Apoptosis/ anti-apoptosis 
RIPK2 3.6 AF027706 receptor-interacting serine-threonine kinase 2 
TNFAIP8 2.6 NM_014350 tumor necrosis factor, alpha-induced protein 8 
TRIB3 2.5 NM_021158 tribbles homolog 3 (Drosophila) 
IFIH1 2.1 NM_022168 Interferon induced with helicase c domain 1 
    
Adhesion Molecules/ Receptors 
    
ICAM 6.05 NM_000201 intercellular adhesion molecule 1 (CD54) 
VCAM 5.0 NM_001078 vascular cell adhesion molecule 1 
IL18R1 3.5 NM_003855 interleukin 18 receptor 1  
TNFAIP3 3.4 NM_006290 tumor necrosis factor, alpha-induced protein 3 
IFNGR1 2.1 AF056979 interferon gamma receptor 1 
    
Cytokines/ Chemokines 
    
CXCL2 14.6 M57731 Chemokine (C-X-C motif) ligand 2 
CX3CL1 6.3 NM_002996 Fractalkine 
CCL7 2.4 NM_006273 Chemokine (C-C motif) ligand 7 
CCL2 2.0 S69738 chemokine (C-C motif) ligand 2 
Metabolism 
   
    
ASNS 2.4 NM_001673 Asparagine synthase 
CTH 2.3 AL384572 Cystathionase (cystathionine gamma-lyase) 
ABCG1 2.1 U34919 ATP-binding cassette, sub-family G (WHITE), member 1 
CBR3 2.0 NM_001236 Carbonyl reductase 3 
Transcription Factors/ signaling 
    
CEBPD 3.6  M83667 CCAAt/enhancer binding protein (C/EBP) 
NFKBIA 3.4 NM_020529 Nuclear factor of kappa light polypeptide gene enhancer in 
B- cells inhibitor, alpha 
VEGF 3.2 AF022375 Vascular endothelial cell growth factor 
PMAIP1 3.2 NM_021127 Phorbol-12-myristate-13-acetate-induced protein 1  
NKX31 3.1 AF247704 Transcription factor related, locus 1 Drospophila 
SOD2 3.0 W46388 Superoxide dimutase 2, mitochondrial 
HIVEP2 
 
2.9 AL023584 Human immunodeficiency virus type 1 enhancer binding 
protein 
IL-6 2.9 NM_000600 Interleukin 6 
BCL3 2.8 NM_005178 B-cell CLL/lymphoma 3 
RND1 2.7 U69563 Rho family GTPase 1 
EFNA1 2.5 NM_004428 Ephrin-A1 
RAPGEF5 2.4 NM_012294 Rap guanine nucleotide exchange factor (GEF)5 
CEBPD 2.3 AL564683 CCAAT/enhancer binding protein (C/EBP), beta 
ZBTB10 2.25 NM_023929 Zinc finger and BTB domain containing 10 
MAP3K1 2.2 AA361361 Mitogen-activated protein kinase kinase kinase 1 
DSCR1 2.15 NM_004414 Down syndrome critical region gene1 
ATF3 2.15 NM_001674 Activating transcription factor 3 
JUNB 2.1 NM_002229 Jun B proto-oncogene 
NFKB1 2.1 M55643 Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 
RELB 2.1 NM_006509 v-rel reticuloendotheliosis viral oncogene homolog B 
KLF9 2.0 NM_001206 Kruppel-like factor 9 
Miscellaneous 
 
TNFAIP2 5.0 NM_006291 Tumor necrosis factor, alpha-induced protein 2 
DD1T4 2.58 NM_019058 DNA inducible transcript 4 
C8orf4 2.4 NM_020130 Chromosome 8 open reading frame 4 
N4BP3 2.1 AW139448 Nedd4 binding protein 3 
SDC4 2 NM_002999 Syndecan 4 ( amphiglycan ryudican) 
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The majority of those genes induced in Experiment 1 (p<0.05) (Table 4.1) were 
transcription factors and genes coding for signalling molecules. Of note, both 
NFκB1 (nuclear factor of kappa light polypeptide gene enhancer in B cells) and 
one of its inhibitors NFκBIA were induced. The NFκB1 pathway is induced in 
response to pro-inflammatory stimuli and this will be referred to later in the 
discussion. Chemokines not previously associated with the syndrome included 
CXCL2, CXCL1, CCL2 and CCL7. Differential expression of TNF associated 
proteins TNFAIP8, TNFAIP3 and TNFAIP2 provided further evidence that anti-
β2GPI activate EC through inflammatory activation pathway(s). CTH is required 
for amino acid biosynthesis and metabolism and its’ expression was upregulated. 
 
The data in Table 4.1 has been presented in a different format in Figure 4.1. Gene 
trees are tree-like structures made up of branches that visually display similarities 
in gene expression as a dendrogram. Smaller branches are displayed within larger 
ones until eventually all branches are joined within one stem.  The larger the 
branch, the more distantly related are the genes. Condition trees are gene trees that 
group similar samples (conditions) together based on similar expression profiles 
(http://www.microarray.okstate.edu/files/Genespring-tutorial.pdf). Figure 4.1 
shows the 46 genes (p<0.05) from Experiment 1. The software has clustered the 
genes according to similarities in expression (not function) on the vertical axis. 
Each column on the horizontal axis represents a condition or sample (antibody 
treated versus normal control IgG treated) and the results pertain to one Affymetrix 
chip. The data is shown using coded colours for differences in gene expression. 
There are different formats available within the Genespring software, 4.1 A is 
defined as heatmap where red indicates up-regulation in expression. Figure 4.1 B is 
defined as default interpretation where red indicates up-regulation in gene 
expression, blue and yellow little or no change. The dendrograms clearly 
differentiate between anti-β2GPI treated and normal control IgG treated samples. 
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             A                                                 B 
Figure 4.1  Hierarchical clustering of HUVEC genes changed two-fold 
or more in expression (p<0.05, paired t-test) by treatment with anti-
β2GPI antibodies in Experiment 1.  In three independent experiments 
with three different HUVEC donors, the anti-β2GPI antibody preparation 
from Patient 5 (Table 2.2) induced significant change in expression in 43 
genes when treated samples were compared to one normal control IgG 
(N1). Genes have been clustered according to similarities in patterns of 
expression (vertical axis) as well as per condition (horizontal axis). Each 
row represents a gene and each column represents an experimental 
condition. Branches are color-coded for anti-β2GPI antibody treated (blue) 
and normal control IgG (green) treated samples. A shows the clustering in 
heatmap format. B is colored by changes in expression where red indicates 
up-regulation and blue indicates little or no change. No down-regulated 
genes reached statistical significance in this experiment. 
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4.2.2 Experiment 2 
In three independent experiments on different HUVEC isolate populations, cells 
were incubated for four hours with either anti-β2GPI antibodies (P1, P2, P3, P4) or 
normal control IgG (N1, N2, N3, N4). Polymixin B (50µg/ml) was added to the 
incubation step in all replicate experiments. In the second of the three experiments, 
one patient sample (P2) and one normal control IgG sample (N4) were not 
included in the experiment because of insufficient RNA sample. Therefore, 
Experiment 2 consisted of 22 Affymetrix chips in total and all were included in the 
analysis. Genes included in the analysis had to be present in at least 11/22 of the 
samples (at least half). The approach to the statistical analysis of the data for 
Experiment 2 is included in Chapter 2.  
 
The genechips incorporate 22,283 oligonucleotides that are representative of 
18,400 human gene transcripts. Chips were scanned and cel. data was imported 
into Genespring. Genes defined as Present or Marginal by Affymetrix Mas 5.0 
software and present in at least 11/22 samples were selected from all genes and 
numbered 13,727. From these 13,727 genes, those differentially expressed and 
statistically significant (p<0.05) when grouped by treatment type were determined 
by using non-parametric one way ANOVA. Those genes numbered 1792. Those 
genes changed in expression two fold or great up or down were selected as being 
of biological relevance (see 4.1.8). Of those 1792 genes, (anti-β2GPI treated versus 
normal control IgG treated) a total of 101 genes were statistically significant 
(p<0.05) and upregulated by at least 2 fold or more by anti-β2GPI antibodies 
(Table 4.2). 14 anti-β2GPI antibody-regulated genes were downregulated in EC 2 
fold or greater (p<0.05) (Table 4.3).  
 
As in Experiment 1, genes in Experiment 2 were devided manually into APS 
relevant functional categories: apoptosis/ anti-apoptosis, chemokines, metabolism, 
transcription factors/ signalling, adhesion molecules/ receptors and miscellaneous.  
In Experiment 2, of particular note is the high level of induction of the chemokines 
of both C-C and C-X-C sub-groups. Sub-groups of chemokines are based on 
structural, not functional similarities. The most highly anti-β2GPI-induced gene 
was CCL20 (macrophage inflammatory protein-3 alpha or MIP-3) up 27 fold in 
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expression compared to normal control IgG treated cells. Other chemokines 
included CXCL3, Fractalkine (CX3CL1), CXCL5, CXCL2 and CXCL1 (human 
melanoma growth stimulating factor). A number of these inflammatory 
chemokines not previously associated with APS are angiogenic mitogenic factors.  
Genes classically associated with pro-inflammatory cytokine TNFα signaling such 
as TNFAIP6 (up 21 fold), TNFAIP2, TNFAIP8, TNFAIP3 were up-regulated. 
Functional groups containing the largest numbers of genes were transcription 
factors/signaling molecules reflecting complex mechanisms of EC activation, and 
adhesion molecules (Table 4.2). 
 
Also in Experiment 2, expression of the anti-apoptotic genes BCL2A1 (up 14 fold) 
and BIRC3 was increased. Induced cell receptors included Tenascin C, OLR1 
(oxLDL receptor) and IL-18 receptor 1 (IL18R1). Other induced genes of interest 
included growth factors CSF2 (GM-CSF, up 12 fold), CSF3 (G-CSF, up 7 fold), 
IL-6, IL-1β IL-8 and FGF18. 
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Table 4.2   Anti-β2GPI antibody-induced gene expression in HUVEC  
 
          
Gene               Fold induction     Accession no.                       Gene description 
 
Apoptosis/anti-apoptosis 
 
 
 
BCL2A1 14.4 NM_004049 BCL2-related protein A1   
TNAIP8 3.8 NM_014350 tumor necrosis factor, alpha-induced protein 8   
TNFAIP3 3.6 NM_006290 tumor necrosis factor, alpha-induced protein 3   
TRAF1 3.5 NM_005658 TNF receptor-associated factor   
BIRC3 3.4 U37546 baculoviral IAP repeat-containing 3   
CARD15 3.0 NM_022162 caspase recruitment domain family, member 15   
RIPK2 2.5 AF027706 receptor-interacting serine-threonine kinase 2   
TRIB3 2.3 NM_021158 tribbles homolog 3 (Drosophila)   
      
Adhesion molecules/receptors 
   
TNFAIP6 21.3 NM_007115 tumor necrosis factor, alpha-induced protein 6   
TNFRSF1 5.0 NM_002546 tumor necrosis factor receptor superfamily, 
member 11b       
LLT1 4.7 NM_013269 C-type lectin domain family 2, member D   
BDKRB2 4.7 NM_000623 bradykinin receptor B2    
TNC 4.5 NM_002160 tenascin C (hexabrachion)   
TNFRSF9 4.4 NM_001561 tumor necrosis factor receptor superfamily, member 9   
OLR1 4.4 AF035776 oxidised low density lipoprotein (lectin-like) receptor 1
  
  
IL18R1 4.3 NM_003855 interleukin 18 receptor 1    
E-Selectin 3.8 NM_000450 selectin E (endothelial adhesion molecule 1)   
ICAM 3.4 NM_000201 intercellular adhesion molecule 1 (CD54)   
ICOSL 3.1 AL355690 inducible T-cell co-stimulator ligand   
CCRL2 3.0 AF015524 chemokine (C-C motif) receptor-like 2   
PDZK3 2.8 AF338650 PDZ domain containing 3    
CD69 2.6 L07555 CD69 antigen (p60, early T-cell activation antigen)   
IFRG28 2.5 NM_022147 28kD interferon responsive protein   
JAG1 2.3 U61276 jagged 1 (Alagille syndrome)    
PTHLH 2.2 BC005961 parathyroid hormone-like hormone   
EB13 2.2 NM_005755 Epstein-Barr virus induced gene 3   
VCAM 2.2 NM_001078 vascular cell adhesion molecule 1   
CD83 2.1 NM_004233 CD83 antigen (immunoglobulin superfamily)   
PDGFRA 2.1 NM_006206 platelet-derived growth factor receptor, alpha polypeptide
   
 
HRH1 2.1 D28481 histamine receptor H1   
IL1R1 2.1 NM_000877 interleukin 1 receptor, type I   
      
Coagulation 
    
F3 3.3 NM_001993 coagulation factor III (tissue factor)   
   
   
Cytokines/chemokines 
 
 
  
>10 fold 
     
CCL20 27.0 NM_004591 Macrophage inflammatory protein- MIP-3   
CXCL3 14.7 NM_002090 chemokine (C-X-C motif) ligand 3   
CSF2 11.6 M11734 colony stimulating factor 2 (granulocyte-macrophage)   
CX3CL1 10.5 NM_002996 Fractalkine   
 
5-10 fold      
CSF3 6.9 NM_000759 colony stimulating factor 3 (granulocyte)   
IL6 6.0 NM_000600 interleukin 6 (interferon, beta 2)    
CXCL5 5.6 AK026546 chemokine (C-X-C motif) ligand 5   
IL1Beta 5.1 NM_000576 interleukin 1, beta   
 
2-5 fold      
CXCL2 4.1 M57731 Chemokine (C-X-C motif) ligand 2   
FGF18 4.1 NM_003862 fibroblast growth factor 18   
CXCL1 4.0 NM_001511 chemokine (C-X-C motif) ligand 1   
LIF 3.6 NM_002309 leukemia inhibitory factor (cholinergic differentiation factor)   
CXCL10 3.3 NM_001565 chemokine (C-X-C motif) ligand 10   
CXCL11 2. 3 AF030514 chemokine (C-X-C motif) ligand 11   
LTB 2.3 NM_002341 lymphotoxin beta (TNF superfamily, member 3)   
IL8 2.2 AF043337 interleukin 8   
CCL5 2.1 NM_002985 chemokine (C-C motif) ligand 5   
CCL8 2.1 AI984980 chemokine (C-C motif) ligand 8   
PBEF1 2.0 BF575514 pre-B-cell colony enhancing factor 1   
CSF1 2.0 M37435 colony stimulating factor 1    
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Metabolism     
SLC7A5 4.7 AB018009 solute carrier family 7 (cationic amino acid transporter) 
PPAP2B 4.2 AB000889 phosphatidic acid phosphatase type 2B  
ASNS 3.5 NM_001673 asparagine synthetase  
INDO 3.3 M34455 indoleamine-pyrrole 2,3 dioxygenase  
GCH1 2.9 NM_000161 GTP cyclohydrolase 1 (dopa-responsive dystonia) 
S100A3 2.8 NM_002960 S100 calcium binding protein A3 
SDC4 2.6 NM_002999 syndecan 4 (amphiglycan, ryudocan)  
MSCP 2.5  BE677761 solute carrier family 25, member 37 
GFPT2 2.5 NM_005110 glutamine-fructose-6-phosphate transaminase 2 
MT1X 2.3 NM_002450 metallothionein 1X 
MTIE 2.3 BF217861 metallothionein 1E (functional) 
PDLM4 2.3 AF153882 PDZ and LIM domain 4 
LIPG 2.3 NM_006033 lipase, endothelial 
KCNMB1 2.2 U61536 potassium large conductance calcium-activated channel 
OASL 2.2 NM_00373 2'-5'-oligoadenylate synthetase-like 
 
 
Miscellaneous 
 
TNFAIP2 9.7 NM_006291 tumor necrosis factor, alpha-induced protein 2 
DD1T4 2.8 NM_019058 DNA-damage-inducible transcript 4 
IFIT3 2.5 NM_001549 interferon-induced protein with tetratricopeptide repeats 3 
IFIT2 2.3 BE888744 interferon-induced protein with tetratricopeptide repeats 2 
MOX2 2.2 H23979 CD200 antigen 
ZC3HV1 2.2 NM_020119 zinc finger CCCH-type, antiviral 1 
CDC42 2.1 AI754416 CDC42 effector protein (Rho GTPase binding) 3 
MSCP 2.1 NM_018579 solute carrier family 25, member 37 
AIMI 2.1 U83115 absent in melanoma 1 
CHST5 2.1 N32257 carbohydrate metabolism N-acetylglucosamine metabolism 
 
  
NAV3 2.0 NM_014903 neuron navigator 3 
ST5 2.0 NM_005418 suppression of tumorigenicity 5 
FLJ23231 2.0 NM_025079 zinc finger CCCH-type containing 12A 
    
Transcription factors/signaling 
 
 
NKX31 6.3 AF247704 transcription factor related, locus 1 (Drosophila) 
SOD2 5.7 AL050388 superoxide dismutase 2, mitochondrial 
CEBPD 5.6 NM_005195 CCAAT/enhancer binding protein (C/EBP), delta 
HIVER2 4.4 AL023584 human immunodeficiency virus type I enhancer binding protein 2 
DSCR1 3.7 NM_004414 Down syndrome critical region gene 1 
RAPGEF5 3.4 NM_012294 Rap guanine nucleotide exchange factor (GEF) 5 
STC2 3.2 BC000658 stanniocalcin 2 
NCF4 2.9 NM_013416 neutrophil cytosolic factor 4, 40kDa 
APOL3 2.7 NM_014349 apolipoprotein L3 
SNFT 2.6 NM_018664 Jun dimerization protein p21SNFT 
RND1 2.6 U69563 Rho family GTPase 1 
MAP3K8 2.6 NM_005204 Mitogen-activated protein kinase kinase kinase 8 
FOXF1 2.5 NM_001451 forkhead box F1 
IRF1 2.5 NM_002198 interferon regulatory factor 1 
MSC 2.4 AF060154 musculin (activated B-cell factor-1) 
RGS2 2.3 NM_002923 regulator of G-protein signalling 2, 24kDa 
STAT5A 2.2 NM_003152 signal transducer and activator of transcription 5A 
MEOX1 2.2 NM_004527 Mesenchyme homeo box1 
NFKB1 2.2 M55643 nuclear factor of kappa light polypeptide gene enhancer   
ISG20 2.2 NM_002201 interferon stimulated exonuclease gene 20kDa 
ABTB2 2.2 AL050374 ankyrin repeat and BTB (POZ) domain containing 2 
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A smaller panel of anti-β2GPI antibody-regulated genes were down-regulated in 
EC 2 fold or greater (Table 4.3). None of these genes has previously been reported 
to be anti-β2GPI antibody-regulated genes in EC. The majority of the 14 down-
regulated genes encode signaling and transcription factors/signaling molecules. 
Two receptor/adhesion molecules were also down-regulated. GJA4 (connexin 37) 
is a gap junctional protein and OCLN (Occludin) is a structural protein of tight 
junctions. ID2 (inhibitor of DNA binding and differentiation) was down-regulated. 
  
Table 4.3  Anti-β2GPI antibody mediated down-regulation of gene expression 
in HUVEC 
 
           
Gene        Fold reduction  Accession no.                       Gene description 
Adhesion molecules/receptors 
GJA4 2.9 NM_002060 gap junction protein, alpha 4, 37kDa (connexin 37) 
OCLN 2.1 U53823 occludin  
 
Cytokine/Chemokine 
BDNF 2.1 NM_001709 brain-derived neurotrophic factor 
    
Metabolism 
  
GFOD1 2.0 NM_018988 glucose-fructose oxidoreductase domain containing 1 
    
Miscellaneous 
13CDNA
73 2.2 NM_023037 hypothetical protein CG003  
    
Transcription Factors/ Signaling 
MEOX2 3.1 NM_005924 mesenchyme homeo box 2 
 
MAF 3.0 NM_005360 v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 
BMP4 2.8 D30751 bone morphogenetic protein 4 
TXB1 2.8 AF012130 T-box 1  
ID2 2.3 NM_002166 inhibitor of DNA binding 2 
DACH1 2.2 NM_004392 dachshund homolog 1 (Drosophila) 
RUNX1T
1 2.2 NM_004349 runt-related transcription factor 1 
MAFB 2.0 NM_005461 v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
ZNF365 2.0 NM_014951 zinc finger protein 365  
 
As in Experiment 1, genes altered in expression 2 fold or greater (p<0.05) in 
Experiment 2 were clustered according to similarities in patterns of expression and 
presented in a dendrogram (Figure 4.2). The expression patterns for all 22 
Affymetrix chips are represented and Genespring software has divided the samples 
into antibody and normal control IgG treated samples. As branches indicate, 
samples were further divided into the three replicate experiments for treated and 
untreated samples. 
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Figure 4.2  Hierarchical clustering of 
HUVEC genes changed two-fold or 
more in expression (p<0.05) by 
treatment with anti-β2GPI antibodies.
In three independent experiments on 
different HUVEC preparations, cells 
were incubated for four hours with either 
anti-β2GPI antibodies (P1, P2, P3, P4) or 
normal control IgG (N1, N2, N3, N4). 
mRNA was isolated and processed for 
microarray hybridization and analysis. A 
genetree and condition tree have been 
created in GeneSpring software by 
average linkage hierarchical clustering 
using the Pearson Correlation. Each 
column represents results from an 
individual microarray chip (n=22), each 
horizontal row represents a gene. Genes 
have been clustered according to 
similarities in patterns of expression 
(vertical axis) as well as per condition 
(horizontal axis). Branches are color-
coded for anti-β2GPI antibody treated 
(blue) and control IgG (green) treated 
samples. Colored bars below figure also 
indicate location of results from the three 
independent experiments. Differences in 
expression level between anti-β2GPI 
antibody treated HUVEC and those 
incubated with normal control IgG are 
clearly distinguishable on the heat map. 
Genes with high expression levels in red, 
intermediate level expression black and 
low level expression green.  
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4.2.3 Genespring GO-ontology functional classification 
There are a number of ways to classify those genes differentially expressed in 
microarray analysis. For Experiments 1 and 2, genes were manually assigned to a 
functional category as an exercise in order to become familiar with those genes 
identified in the analysis. Clustering techniques group genes that share common 
patterns of expression together. Gene ontologies (GO) on the other hand, group 
genes together based on gene attributes such as biological process or function, 
cellular components, or molecular function for genes and their protein products 
(http://www.silcongenetics.com).    
The 101 genes (p<0.05) induced in expression in Experiment 2 were also classified 
using the Genespring GO-ontology program. In this program, differentially 
expressed genes are classified according to known functions or predicted functions 
based on patterns in expression similar to genes of known function (Figure 4.3).  
 
Figure 4.3   Pie Chart of 101 up-regulated genes in Experiment 2. The 
101 genes up-regulated in Experiment 2 were divided into functional 
groups using the GO-ontology program in Genespring software. The 
number of genes in each functional category was given as a percentage. 
The largest group of genes accounted for 39% of the total and these genes 
were associated with an inflammatory response (seen in red). The second 
largest functional group of 18% of the total could be attributed to 
transcription factors and signaling. Intriguingly, the smallest functional 
group was attributed to coagulation. 
 
12%
7%
18%
13%
10%
39%
1% 
Proliferation
Inflammatory Response
Apoptosis/ anti-Apoptosis
Transcription Factors/
Signaling
Metabolism
Miscellaneous
Coagulation
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This Genespring ontology program segregated the 101 2 fold or greater induced 
genes (p<0.05) into 7 functional groups: inflammatory response (39% of total), 
transcription factors/signalling (18%), metabolism (13%), proliferation (12%), 
miscellaneous (10%), apoptosis (7%), and coagulation (1%).  
 
Table 4.4 GO ontology- genes up-regulated two fold or more with 
functions associated with an inflammatory response. 
          
    Gene                 Fold change 
CCL20 26.95 chemokine (C-C motif) ligand 20 
TNFAIP6 21.32 tumor necrosis factor, alpha-induced protein 6 
CX3CL1 10.52 chemokine (C-X3-C motif) ligand 1 
IL1B 5.115 interleukin 1, beta 
BDKRB2 4.729 bradykinin receptor B2 
IL1B 4.353 interleukin 1, beta 
CXCL2 4.14 chemokine (C-X-C motif) ligand 2 
CXCL1       4.0 chemokine (C-X-C motif) ligand 1 
SELE 3.77 selectin E (endothelial adhesion molecule 1) 
CXCL10 3.337 chemokine (C-X-C motif) ligand 10 
APOL3 2.753 apolipoprotein L, 3 
RIPK2 2.504 receptor-interacting serine-threonine kinase 2 
CXCL11 2.333 chemokine (C-X-C motif) ligand 11 
CXCL11 2.261 chemokine (C-X-C motif) ligand 11 
CCL5 2.121 chemokine (C-C motif) ligand 5 
HRH1 2.075 histamine receptor H1 
RIPK2 2.068 receptor-interacting serine-threonine kinase 2 
IL1R1 2.046 interleukin 1 receptor, type I 
 
Table 4.5 GO ontology genes up-regulated two fold or more with 
function associated with cell proliferation. 
 
            Gene                 Fold change 
IL6 6.0 interleukin 6 (interferon, beta 2) 
IL 1B 5.1 interleukin 1, beta 
TNFRSF9 4.4 tumor necrosis factor receptor superfamily, member 9 
PTHLH 2.2 parathyroid hormone-like hormone 
FGF18 4.1 fibroblast growth factor 18 
PBEF1 2.0 pre-B-cell colony enhancing factor 1 
CSF1 2.0 colony-stimulating factor (CSF-1) Human macrophage specific  
CXCL10 3.3 chemokine (C-X-C motif) ligand 10 
ISG20 2.2 interferon stimulated gene 20kDa 
PDGFRA 2.1 platelet-derived growth factor receptor, alpha polypeptide 
CSF3 6.9 colony stimulating factor 3 (granulocyte) 
LIF 3.6 leukemia inhibitory factor (cholinergic differentiation factor) 
CXCL1 4.0 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 
JAG1 2.3 jagged 1 (Alagille syndrome) 
CXCL5 5.6 chemokine (C-X-C motif) ligand 5 
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Table 4.6 GO ontology- genes upregulated two fold or more with 
function associated with chemotaxis. 
 
                      Gene        Fold change 
CCL20 26.95 chemokine (C-C motif) ligand 20 
CX3CL1 10.52 chemokine (C-X3-C motif) ligand 1 
CXCL2 4.14 chemokine (C-X-C motif) ligand 2 
CXCL1 4.105 chemokine (C-X-C motif) ligand 1  
CXCL10 3.337 chemokine (C-X-C motif) ligand 10 
CXCL11 2.333 chemokine (C-X-C motif) ligand 11 
CCL5 2.121 chemokine (C-C motif) ligand 5 
 
 
 
GO-ontology grouped the largest number of genes into those involved in the 
inflammatory response (Table 4.4). The second largest functional group included 
transcription factors and those genes involved in cell signaling. 
 
Of interest, genes involved in cell proliferation were designated as a separate 
functional category (Table 4.5). Of the 101 genes, those involved in chemotaxis 
were further segregated by GO-ontology (Table 4.6). Neither of these two 
functional groups has been generally recognized as making a significant 
contribution to the pathology of PAPS or indeed APS.  
 
 
4.2.4 Common genes found to be upregulated by anti-β2GPI antibodies in 
Experiments 1 and 2. 
Those genes common to both Experiments 1 and 2 (p<0.05) and changed in 
expression by two fold or more are listed in Table 4.7. Fold changes given are 
those that were found in Experiment 2. Collectively, these genes are representative 
of those significant genes induced in expression two fold or more in response to 
five independent polyclonal anti-β2GPI antibody preparations. A total of 6 
independent HUVEC donors were used in the experiments. Such biological 
replicates are necessary to compensate for variable expression between cells of the 
same type from different individuals. It has been recommended that each 
microarray experiment should be repeated three times (as in Experiment 2) in order 
to increase the reliability of data and compensate for both biological and technical 
variability (Leung & Calvalieri, 2003). 
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Importantly, VCAM-1 and ICAM-1 long recognized as aPL mediated proteins are 
present in the list. NF-κB is conspicuously present as the key transcription factor in 
inflammatory responses. Genes not previously associated with PAPS included 
CX3CL1, DSCR1 and RND1. Transcription factors included SOD2, CEBPD, 
HIVEP2, RAPGFF5 and RND1. 
 
Table 4.7 Differentially expressed and statistically significant (p<0.05) genes 
common to Experiments 1 and 2 (n=22). 
 
 Fold Change/ Gene 
10.52 CX3CL1   Fractalkine 
9.667 TNFAIP2 tumor necrosis factor, alpha-induced protein 2 
6.323 NKX3-1 NK3 transcription factor related, locus 1 (Drosophila) 
6.017 IL6 interleukin 6 (interferon, beta 2) 
5.583 CEBPD Human NF-IL6-beta protein mRNA, complete cds. 
4.306 IL18R1 interleukin 18 receptor 1 
4.14 CXCL2 chemokine (C-X-C motif) ligand 2 
3.519 ASNS asparagine synthetase 
3.415 RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 
3.408 HIVEP2 Human DNA sequence from clone RP1-67K17 on chromosome 6q24.1-24.3. 
3.339 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 
3.322 DSCR1 Down syndrome critical region gene 1 
3.197 ICAM1 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor 
2.894 PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
2.785 DDIT4 DNA-damage-inducible transcript 4 
2.692 SOD2 superoxide dismutase 2, mitochondrial 
2.591 RND1 Rho family GTPase 1 
2.565 SDC4 syndecan 4 (amphiglycan, ryudocan) 
2.504 RIPK2 receptor-interacting serine-threonine kinase 2 
2.301 TRIB3 chromosome 20 open reading frame 97 
2.21 NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1  
2.164 VCAM1 vascular cell adhesion molecule 1 
 
All genes differentially expressed and changed two fold in expression common to 
Experiments 1 and 2 are listed in Table 4.8 (n=63). Statistically significant genes 
found in both experiments (from Table 4.7) are designated in red bold script. 
Statistically significant genes from Experiment 2 also changed in expression two-
fold or more in Experiment 1 but not statistically significant in Experiment 1 are 
designated in bold blue. Black represents two fold in both, not statistically 
significant in either experiment. 
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Table 4.8 Genes common to Experiments 1 and 2 showing two-fold 
differential expression (n=63). 
 
CCL20 chemokine (C-C motif) ligand 20 
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 
CXCL3 chemokine (C-X-C motif) ligand 3 
CSF2 colony stimulating factor 2 (granulocyte-macrophage) 
BCL2A1 BCL2-related protein A1 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 
CX3CL1 chemokine (C-X3-C motif) ligand 1 
SOD2 superoxide dismutase 2, mitochondrial 
CXCL5 chemokine (C-X-C motif) ligand 5 
IL6 interleukin 6 (interferon, beta 2) 
CEBPB AL564683 Homo sapiens FETAL LIVER Homo sapiens cDNA clone  
CXCL2 chemokine (C-X-C motif) ligand 2 
KIAA0146 KIAA0146 protein 
CXCL1 chemokine (C-X-C motif) ligand 1  
NKX3-1 NK3 transcription factor related, locus 1 (Drosophila) 
IL18R1 interleukin 18 receptor 1 
SELE selectin E (endothelial adhesion molecule 1) 
MGC5618 Homo sapiens hypothetical protein MGC5618 
MGC4504 hypothetical protein MGC4504 
CCL8 IL-8 
MSC musculin (activated B-cell factor-1) 
SERPINB2 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 
TRAF1 TNF receptor-associated factor 1 
CCL3 chemokine (C-C motif) ligand 3 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 
ICAM1 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor 
BIRC3 IAP homolog C; interacts with TRAF1 and TRAF2 in yeast two hybrid system 
RND1 Rho family GTPase 1 
HIVEP2 Human DNA sequence from clone RP1-67K17 on chromosome 6q24.1-24.3, 
F3 coagulation factor III (thromboplastin, tissue factor) 
IL1B interleukin 1, beta 
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 
TNFAIP8 tumor necrosis factor, alpha-induced protein 8 
DSCR1 Down syndrome critical region gene 1 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 
PLN phospholamban 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
RIPK2 receptor-interacting serine-threonine kinase 2 
STC2 stanniocalcin 2 
CCRL2 chemokine (C-C motif) receptor-like 2 
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 
SOCS3 suppressor of cytokine signaling 3 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
SDC4 syndecan 4 (amphiglycan, ryudocan) 
ASNS asparagine synthetase 
ISG20 interferon stimulated gene 20kDa 
LTB lymphotoxin beta (TNF superfamily, member 3) 
PDE5A phosphodiesterase 5A, cGMP-specific 
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CSF1 (CSF-1) precursor; Human macrophage-specific colony-stimulating factor  
CDH19 cadherin 19, type 2 
PAX4 paired box gene 4 
GLRA1 glycine receptor, alpha 1 (startle disease/hyperekplexia, stiff man syndrome) 
IRF1 interferon regulatory factor 1 
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) 
DDIT4 DNA-damage-inducible transcript 4 
PDZK3 Homo sapiens PDZ domain-containing protein AIPC (AIPC)  
FLJ13236 Homo sapiens mRNA; cDNA DKFZp564D042 (from clone DKFZp564D042). 
CD69 CD69 antigen (p60, early T-cell activation antigen) 
COL10A1 H.sapiens type X collagen gene. 
TRIB3 chromosome 20 open reading frame 97 
VCAM1 vascular cell adhesion molecule 1 
GPR88 G-protein coupled receptor 88 
IL1A interleukin 1, alpha 
 
 
It was interesting to note the large number of genes differentially induced 2 fold or 
greater common to both experiments (n=63). The experimental protocol for both 
was identical, but the statistical analysis applied each set of data was different. 
Genes common to both potentially previously associated with APS included IL-6, 
IL-8, E-selectin, ICAM-1, VCAM-1 and TF. 
 
The genes in Table 4.7 are listed in descending magnitude of fold change. The 
most highly upregulated gene in either experiment was CCL20. Importantly, E-
selectin is included, since it is not constitutively expressed and functions as an 
indicator of EC activation (Cines et al., 1998). BCL2A1 and BIRC3 each have 
anti-apoptotic function and both are induced by NF-κB in response to 
inflammatory mediators. TF (F3), the one gene with the functional signature of 
coagulation is also present. CD 69 is a leukocyte receptor induced on subsets of T 
and B cells when they are activated. It is highly expressed in leukocyte infiltrates 
in various chronic inflammatory diseases and has been recently shown to down-
regulate autoimmune reactivity by TGF-β induction in collagen mediated RA 
(Sancho et al., 2003).  
 
4.2.4 Genes different between antibody preparations 
Genespring software was used to determine if there were any genes that were 
statistically different between antibody preparations (P1-P4). The analysis was 
applied to the genes that were differentially expressed and statistically significant 
between treated and untreated samples (n=1792). The control samples were 
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removed from the analysis at this point so that only the differences in antibody 
preparations would be identified.  
 
Of the 1792 genes tested, the one way ANOVA identified 131 genes statistically 
different between the four antibody preparations (p<0.05). Table 4.9 lists the 
number of genes out of the total of 131 that were the same or different between 
preparations. Anti-β2GPI from Patient 1 showed the greatest variation when 
compared to the other three preparations (181 in red).  
 
Figures 4.1 and 4.2 show hierarchical cluster analysis of upregulated and 
downregulated genes in Experiments 1 and 2. Genes were clustered according to 
their patterns of expression (vertical axis) and also per condition on the horizontal 
axis (shows similarities between total gene expression profiles in different 
samples). It is important to note that in the dendrogram similarities in the level of 
gene expression are grouped (see branching) according to independent experiment 
(that is per separate HUVEC population rather than per antibody preparation. This 
implies that the greatest source of variation, in terms of genes regulated by anti-
β2GPI antibody, is determined by individual HUVEC populations rather than 
between individual anti-β2GPI antibody preparations. Since only 131 genes were 
found to be statistically different between the four anti-β2GPI, inter-experiment 
variation probably masked more subtle differences in the 
upregulation/downregulation of genes by anti-β2GPI antibody from different 
patients. 
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Table 4.9 Genes statistically different (p<0.05) between the four anti-β2GPI 
antibody preparations in Experiment 2 (n=131). 
 
 
  Different The same Total 
P1 P1 P2 80 51 131 
 
P1 P3 37 94 131 
 
P1 P4 64 67 131 
 
  181   
P2 P1 P2 80 51 131 
 P3 P2 52 79 131 
 P4 P2 39 92 131 
   171   
P3 P1 P3 37 94 131 
 P2 P3 52 79 131 
 P4 P3 23 108 131 
   112   
P4 P1 P4 64 67 131 
 P2 P4 39 92 131 
 P3 P4 23 108 131 
   126   
 
Table 4.9 shows the variation between antibody preparations (P1-P4) taking into 
account the number of genes common and different between preparations out of a 
total of 131 statistically different (p<0.05) between the four preparations. 
 
 
4.3 Confirmation of Microarray Data by Quantitative Real-time PCR. 
4.3.1 Background for qRT-PCR 
Quantitative RT-PCR (reverse transcription- polymerase chain reaction, qRT-PCR) 
is the most sensitive method for detection and quantitation of mRNA currently 
available. qRT-PCR has become the method of choice for validating changes in 
gene expression determined in array analysis. A study by Dallas et al., (2005) 
indicated the strong correlation between qRT-PCR and microarray data (r=0.89) 
when identical transcripts were targeted by the two methods. (The two alternative 
methods used are Northern blot analysis and RNase protection assay that measure 
end product.) There are four different real time PCR chemistries available but 
SYBR Green is the simplest and most economical format for use in real time 
reactions and can be used for microarray validation (Bustin 2000). SYBR Green is 
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incorporated into double stranded DNA and when this occurs light is emitted. 
Fluorescence increases as the amount of PCR product (amplicon) accumulates. At 
the beginning of a PCR reaction DNA amplification proceeds at a constant 
exponential rate (amplicon should double in every cycle) and in qRT-PCR the 
logarithmic phase is where measurements of fluorescence are taken. Later in the 
cycle the rate of reaction plateaus and very little product is formed. The 
disadvantage of SYBR Green is that the dye can be incorporated into any dsDNA 
including primer dimers and any contaminating genomic DNA resulting in over-
estimation of product. In order to reduce false increases in fluorescence, the qRT-
PCR master mix incorporates hot start Taq polymerase which has no activity at 
RT. This prevents formation of double stranded products during setting up of the 
assay which would cause a false increase in fluorescence. CT threshold cycle is the 
point where Fluorescence is first detected above background noise and the 
threshold should occur around the 25th PCR cycle.  
 
The 7 RNA samples used for qRT-PCR analysis were; P1 (sample 1), P2 (sample 
2), P4 (sample 3), N3 (sample 4), N4 (sample 5), P5 (sample 6) and TNF (sample 
7) (P1- P5, Table 2.2).  cDNA was synthesized from each RNA sample. PCR using 
primers for β-Actin was carried out on cDNA samples after RT-PCR to ensure 
successful cDNA synthesis and the PCR products were run on a 1% agarose gel in 
parallel to 100 bp ladder in order to visualize the reaction (Figure 4.4). DNA 
standards for selected genes were prepared as described (Chapter 2, 2.16.1). 
Standards were run on a 1% gel to demonstrate fragment sized relative to the 
100bp ladder (Figure 4.5).  
 
We used the standard curve or absolute method for quantitation of mRNA. Using 
PCR, a DNA standard was prepared for each gene of interest using cDNA in which 
the target genes were expressed. All dilutions of standards were run in duplicate 
and tested on two different occasions. All samples were run in duplicate. β-actin 
copy number was determined for each sample three times and the mean was 
established. For each gene the copy number per µl produced in each sample was 
established twice (on two occasions). The mean and SD were determined for each 
determination. Each value was then normalized to β-actin, (divided by the copy 
number for β-actin). This assumes that the levels of β-actin in the cells was 
 140
constant (microarray data did not show change in expression in response to anti-
β2GPI antibody). This is relating the value of the unknown back to a constant in 
order to compensate for the fact that slightly different amounts of RNA may have 
been added in different tests or runs. Sample 5 (normal control) was arbitrarily 
given a fold change of 1 as a reference (in order to compare). In order to calculate 
fold change for the samples, the copy number/µl for the unknown was taken and 
divided by the copy number of the reference normal (given copy number 1). Our 
qRT-PCR was an independent validation using RNA from different cells than the 
microarray. P5 was the exception to this and cDNA was prepared form the RNA 
used for the microarray analysis. 
 
 
                                                                                  
 
                                          1     2     3    4   5     6    7    8   9    10    11 
 
 
 
Figure 4.4 cDNA derived β-Actin PCR products.  β-actin primers were 
used for PCR on all cDNA synthesis reactions to ensure that cDNA 
synthesis was successful before proceeding to PCR for gene standards.  All 
show that the cDNA synthesis has been successful since β-actin primers 
produced a PCR product (100bp product). Lane 1 shows 100 base pair 
ladder. cDNAs are; Lanes 2 and 3 are TNF induced RNA, Lane 4 is  P1, 
Lanes 5 and 6 are P2, Lane 7 is P3, lane 8 is P5, Lane 9 is N3, Lane 10 is 
the reagent blank and lane 11 is N4.  
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                                          1         2       3        4      5       6       7        8 
 
Figure 4.5  Standards for quantitative RT-PCR. Standards for 
quantitative RT-PCR were run on a 1% agarose gel in parallel with a 100 
bp standard (Lane 1). The standards on the gel are as follows; Lane 2- 
SOD2 (85bp), Lane 3- FGF18 (113 bp), Lane 4 -CX3CL1 (76bp), Lane 5- 
ID2 (bp), Lane 6- CSF3 (75 bp), Lane 7- TNC (100 bp), and Lane 8- E-
selectin (77 bp) showing faint expression due to small amount of sample 
applied to the gel.  
 
The efficiencies of the PCR reactions were calculated for each gene where 100 % 
efficiency was doubling of PCR product in each consecutive cycle. Efficiency was 
calculated from the slope of the standard curve using the equation Efficiency = 
[10(-1/slope)] -1 (Bustin 2000). PCR efficiencies for all genes were between 90 and 
100 % (data not shown).  
 
Table 4.10 gives the fold changes in expression corresponding to the genes of 
interest, comparing microarray values and those obtained using qRT-PCR. It is not 
unusual for levels of fold induction to be higher for qRT-PCR than those 
determined in microarray analysis (Dallas et al., 2005). Quantitative PCR is able to 
detect larger differences in fold change due to the high sensitivity of the 
technology to small changes in copy number whereas microarray is restricted by 
the limited ability of the software to measure differences in fluorescence. 
However, the correlation between qRT-PCR and microarray was confirmed by 
Dallas et al. and found to be very strong (r=0.89) (Dallas et al., 2005).  
 
Of those genes selected for qRT-PCR analysis, CX3CL1 was the most highly 
induced gene in microarray. This result was duplicated by qRT-PCR with all 4 
preparations measuring the highest fold induction for CX3CL1 of those genes 
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tested. Anti-β2GPI from Patient 5 appeared to induce substantially larger amounts 
of mRNA for CX3CL1 and E-selectin than the other 3. It would be tempting to 
speculate that this patient’s antibodies may be more potent in their ability to 
activate EC as reflected in her considerable clinical history associated with PAPS 
(Table 2.2).Overall, P1, P2 and P3 appear to have a similar impact on transcription 
levels for all genes with the possible exception of P2 (CSF3 and TNC) when 
measured by qRT-PCR. TNF induced high levels of induction of all genes but 
FGF18 (Table 4.10). ID2 was down-regulated 2.3 fold by microarray analysis and 
this was very similar to the level of down-regulation by qRT-PCR (Table 4.1 and 
Fig. 4.7b). ID2 was down-regulated by three of the four anti-β2GPI (Table 4.10) 
(Raw real time PCR data is found in the Appendix 5.0).  
 
Table 4.10 qRT-PCR derived fold changes for genes of interest compared to 
values in microarray in response to patient derived anti-β2GPI, normal 
control IgG and TNF positive control. 
 
 
Gene Exp. 2, 
fold 
change in 
Micro-
array 
P1  
* 
 
P2 
* 
 
P4 
* 
 
P5 
* 
 
N 3 
* 
  
N 4 
* 
  
TNF 
* 
 
CX3CL1 10.5 86 97 93 255 3 1.0 9940 
CSF3 6.9 15 5 15 6 2 1.0 21 
SOD2 5.7 29 22 18 11 1.9 1.0 412 
E-selectin 3.8 28 23 29 68 .3 1.0 852 
FGF18 4.1 7 8 4 3 .74 1.0 1.0 
TNC 4.5 7 15 7 2 1.0 1.0 16.0 
ID2 2.3    ↓ 1.04 2.6    
↓ 
2.6   
↓ 
3.1   
↓ 
1.14 1.0 1.2 
* Fold change in qRT-PCR in response to four anti-β2GPI. 
The microarray data was confirmed by qRT-PCR for all genes tested (Figure 4.7).  
In summary, qRT-PCR analysis was carried out for selected novel anti-β2GPI 
antibody regulated genes, covering a range of different fold levels of regulation. 
Genes included in this analysis were; CSF3, CX3CL1, FGF18, SOD2 and 
Tenascin C plus E-selectin as a positive control gene. We also included the down-
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regulated gene ID2 in these experiments. All six upregulated genes (CSF3, 
CX3CL1, E-Selectin, FGF18, Tenascin C and SOD2) were also found to be 
upregulated by RT-PCR analysis. Levels of fold upregulation were variable but 
highest fold upregulation was found for CX3CL1 which was the highest fold 
upregulated gene of the 6 selected genes by microarray analysis (Figure 4.6a). ID2 
was downregulated 2.3 fold by microarray analysis and this was very similar to the 
level of downregulation by real-time PCR analysis (Figure 4.6b).   
 
In addition, increased mRNA levels of E-selectin and IL-8 following anti-β2GPI 
antibody treatment detected by microarray analysis were consistent with increased 
protein levels following antibody treatment as measured by ELISA (Figures 3.11 
and 3.12).  
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Figure 4.6 Anti-β2GPI antibodies induce HUVEC activation.  Cells 
were incubated with either control normal IgG (N3, N4) or different anti-
β2GPI antibody preparations (P1, P2, P4, P5), or TNFα for four hours and 
total RNA isolated and processed for real-time PCR analysis. Antibody 
preparations N3, N4, P1, P2 and P4 were previously used in the microarray 
experiments. Gene expression levels were normalised to the β-actin mRNA 
level. The results show fold change in expression level relative to control 
normal IgG (N3) level and represent the mean of duplicate samples from 2 
independent experiments. (a) shows data for SOD2, CX3CL1 and E-
selectin. TNFα induced expression of these genes but fold induction levels 
were off scale and omitted from the figure, (b) shows data for CSF, FGF, 
Tenascin C (TNC) and ID2. TNFα-regulated changes in levels of 
expression are included for comparison. 
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4.4 Preliminary Data- Anti-β2GPI effect on DNA synthesis in HUVEC 
Since a number of genes identified in this study were angiogenic, it was decided to 
see if anti-β2GPI had a proliferative effect on HUVEC. Proliferation assays were 
performed in two ways, propidium iodide staining followed by FACS analysis to 
determine the proportion of cells in different stages of the cell cycle (Figure 4.7) 
and incorporation of 3H-thymidine (Figure 4.8). The propidium iodide experiment 
was done twice and the 3H-thymidine incorporation experiment was done once. 
Approximately 6% more of the total cells were detected in S and G2 when cells 
were incubated with anti-β2GPI compared to normal control IgG. Results were 
consistent for the three experiments performed. Preliminary data suggested that 
anti-β2GPI may stimulate DNA synthesis in EC when compared to normal control 
IgG and AECA control antibody. Results were not statistically significant but 
suggest a trend towards an increase in anti-β2GPI treated cells. Further experiments 
are needed to determine if anti-β2GPI does indeed significantly induce EC 
proliferation in vitro. 
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Figure 4.7 Propidium iodide staining and FACS analysis of HUVEC 
after incubation with anti-β2GPI. Passage 3 HUVEC were grown to 70-
80% confluence in complete media and incubated for 18 hours (37°C with 
5% CO2) with anti-β2GPI from P1, P3, N1 and N2 as well as AECA control 
antibody anti-Ribosomal P (all at 50µg/ml). Cells were trypsinized and 
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stained with propidium iodide (50µg/ml) followed by FACS analysis. 
Percent of total HUVEC between S and G2 in cell cycle gated as M2 and 
M3 combined (M2+M3) are shown in Figure 4.8. Data from two 
experiments was combined, each column represents the mean of four 
determinations with error bars for SEM.  
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Figure 4.8  Incorporation of 3H-thymidine in HUVEC in the presence 
of anti-β2GPI. Passage 3 HUVEC were grown to 70-80% confluence in 
complete media and incubated for 18 hours (37°C with 5% CO2) with anti-
β2GPI from P1, P3, P4 and N as well as control antibody anti-Ribosomal P 
(all at 50µg/ml). Each sample was tested in quadruplicate and the results 
represent the mean of four values (CPM). N is combined data for 2 normal 
control IgG (N1 and N2). Error bars represent SEM. The experiment was 
done once. 
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4.5 Discussion  
Experiment 1 and 2 used the same experimental design and protocol, the difference 
being experiment 1 tested the effect of affinity purified polyclonal anti-β2GPI from 
1 patient and 1 normal control IgG on global gene expression in HUVEC. 
Experiment 2 tested and compared anti-β2GPI induced expression in HUVEC in 
response to four additional affinity purified polyclonal anti-β2GPI and four normal 
control IgG preparations. In total, 5 anti-β2GPI preparations were tested and 
HUVEC from 6 different donors were used in the experiments.  
 
In Experiment 2, following gene chip hybridization and scanning, HUVEC were 
found to express 13,727 out of 18,400 transcripts (approximately 58% of genes in 
the array). This observation was consistent across all samples in the three separate 
experiments within Experiment 2 and arrays in Experiment 1. This observation is 
important if gene expression between biological replicates is to be meaningful.  
The number of genes expressed in a cell type should be consistent. Genes that were 
significantly changed (p<0.05, up or down) two fold or more were filtered and 
categorized as anti-β2GPI antibody-regulated genes. Importantly, the majority of 
genes represent those not previously reported in association with anti-β2GPI.  
 
Genes were divided into APS relevant categories; apoptosis/ anti-apoptosis, 
chemokines, metabolism, transcription factors/ signalling, adhesion molecules/ 
receptors and miscellaneous and classified using the information provided by 
Affymetrix annotation on line (www.Affymetrix.com). Gene tables within the 
chapter replace the Affymetrix accession numbers with the corresponding 
identification number assigned to each gene by the NCBI.  
 
Experiment 1 confirmed the anti-β2GPI induced expression of ICAM-1 and 
VCAM-1 in response to anti-β2GPI using microarray technology supporting the 
findings other in vitro studies (Simantov et al., 1995; Del Papa et al., 1997; 
Pierangeli et al., 1999).  Up-regulated chemokines and cytokines included CXCL2, 
Fractalkine (CX3CL1), CCL7 and IL-6. Genes that were induced two fold or 
greater in expression, previously associated with APS, but that did not pass the 
stringency of the paired t-test included E-selectin, TF and IL-8. A total of 231 
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genes showed differential expression of two fold or more in Experiment 1. 
Expression of vascular endothelial cell growth factor (VEGF) was statistically 
significant and induced 3 fold. VEGF is one of the most potent inducers of EC 
proliferation and angiogenesis (Ferrara & vis-Smyth 1997). Upregulation of this 
gene in response to anti-β2GPI was of interest because VEGF was found to be 
present in increased concentrations in the plasma of APS patients (Williams et al., 
2000). A recent paper by Cuadrado et al. (2006) showed that monocytes from 
PAPS patients express more VEGF and VEGF receptor flt-1 when compared to 
normal control monocytes. IgG from PAPS patients induced monocyte VEGF 
expression in a dose dependent fashion through the p38MAPK activation pathway 
(Cuadrado et al., 2006).  
 
The majority of genes common to both experiments 1 and 2 (p<0.05, n=25) were 
transcription factors and signalling molecules (Table 4.7). Recent studies have 
identified several important signaling cascades that may be activated in response to 
anti-β2GPI binding. They are the NF-κB pathway (Dunoyer-Geindre et al., 2002) 
and MyD88 signaling through TLR4 followed by subsequent NF-κB pathway 
activation (Raschi et al., 2003a). The p38 MAPK pathway has been implicated in 
the regulation of TF in EC and monocytes and may be activated in response to 
anti-β2GPI (Branger et al., 2003; Bohgaki et al., 2004). NF-κB was up in Exp. 2 
(p<0.05) and Exp. 1(2 fold criteria only). Transcription factor SOD2 was induced 
(p<0.05) in both experiments and it is known to be activated, at least in part, 
through NF-κB via the Protein Kinase C pathway (Rakkola, Matikainen & Nyman, 
2007). RIPK2 (a serine threonine kinase) was up in both experiments (p<0.05) and 
is known to be a potent activator of NF-κB as well as an inducer of apoptosis 
(Munz et al., 2002). 
 
Of novel interest is the induction of Down Syndrome Critical Region 1 (DSCR1) 
(p<0.05) in both Experiments 1 and 2.  The VEGF-regulated expression of DSCR1 
expression has recently been described (Hesser et al., 2004).  Increased expression 
of VEGF was statistically significant in Experiment 1. VEGF was also induced in 
Experiment 2 but did not meet the two-fold up selection criteria. DSCR1 regulates 
expression of inflammatory markers on EC by blocking calcineurin (CnA) 
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signaling which in turn blocks the de-phosphorylation of nuclear factor of 
activated T cell transcription factor. Expression of DSCR1 reduces the expression 
of TF, E-selectin and COX-2 and may provide a negative feedback loop to reduce 
expression of inflammatory genes following EC activation. Other CnA target 
genes include IL-8 and GM-CSF (Hesser et al., 2004). 
  
Rho GTPase 1 was increased in both experiments (p<0.05). It is one of a family of 
23 signaling proteins that control the polymerization, branching and bundling of 
actin filaments in the cell cytoskeleton. This in turn directs cellular processes of 
motility and phagocytosis and Rho GTPase binding (Jaffe & Hall 2005). Induction 
of Rho GTPase results in the activation of the MAPK signaling pathway and a 
number of transcription factors. In turn, this triggers production of pro-
inflammatory cytokines (Jaffe & Hall 2005). Increased expression of this enzyme 
may contribute to changes in the EC membrane, increased vascular permeability 
and increased targeting of inflammatory cells. 
 
CCL20 (macrophage inflammatory protein-3α or MIP-3α) was the most highly 
induced gene in Experiment 2, up 27 fold in expression. Its function is thought to 
involve the recruitment of memory T cells and dendritic cells to sites of 
inflammation in diseases such as dermatitis and arthritis.  CCL20 is highly 
expressed in colonic tissue from patients with inflammatory bowel disease and 
evidence suggests that it acts as an antimicrobial peptide (Yang et al., 2003). Its 
expression can be strongly induced by proinflammatory cytokines such as TNF-α, 
IL-1β or Escherichia coli LPS. This chemokine is a specific ligand for the CCR6 
chemokine receptor expressed by most B cells, subsets of T cells and dendritic 
cells (Perez-Canadillas et al., 2001). Its production has been associated with a 
number of different epithelial cells types, (inflammation of intestinal epithelial 
cells), and fibroblasts but interestingly, not EC. CCL20 induced VEGF expression 
in human gingival fibroblasts (Hosokawa et al., 2005). EC induced anti-β2GPI 
expression of CCL20 may be partially responsible for perpetuating the recruitment 
of cells involved in the autoimmune response to the EC surface. 
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Fractalkine (CX3CL1) is the only CX3 chemokine to have been described in the 
literature and its expression was upregulated 10.5 fold in response to anti-β2GPI. 
CX3CL1 acts as an adhesion molecule and chemoattractant and is expressed on 
endothelial cells that have been activated by inflammatory cytokines such as TNF-
α. Its receptor, CX3CR1 is expressed on vascular smooth muscle cells (SMC), 
natural killer cells (NK), and macrophages. Soluble CX3CL1 causes migration of 
these cells while the membrane bound protein binds cells bearing CX3CR1 with 
high affinity, even under shear stress. CX3CL1 allows adhering leukocytes to 
bypass the integrins ICAM-1 and VCAM-1, potentially facilitating the 
extravasation of circulating leukocytes (Umehara et al., 2004). Interestingly, 
CX3CL1 has been shown to enhance the integrin-dependent adhesion and 
transmigration of CX3CR1+ monocytes. In addition, samples from human 
coronary atherosclerotic plaques contain CX3CL1 mainly expressed by 
mononuclear cells (differentiating monocytes). CX3CL1 has been also been shown 
to mediate chemotaxis of vascular smooth muscle cells in vitro via its receptor 
CX3CR1 (Lucas et al., 2003). 
 
Surprisingly, but perhaps reassuringly, TF is the only gene directly involved in 
coagulation that has been shown to be upregulated in this study (Table 4.1).  This 
result implicitly reinforces the longstanding belief that TF is a major contributing 
factor to thrombosis in APS. TF was the only gene directly involved in coagulation 
found to be upregulated (p<0.05) in Experiment 2. Numerous studies have reported 
increased TF expression on monocytes and EC in the presence of aPL (anti-β2GPI) 
and this has been considered to be directly relevant to disease pathology in APS  
(Branch et al., 1993; Cuadrado et al., 1997; Kornberg et al., 1997). Indeed PAPS 
patients with thrombosis express increased TF on their monocytes (Dobado-
Berrios et al., 1999).  Plasma levels of TF are increased in patients with APS 
(Cuadrado et al., 1997; Amengual et al., 1998). A recent study by Szotowski et al. 
(2005) has identified a soluble isoform of alternatively spliced human (asHTF) 
responsible for procoagulant activity in cell supernatants which is released from 
EC in response to TNFα and IL-6 (Szotowski et al., 2005).  
As in Experiment 1, the list of up-regulated genes includes some other previously 
identified anti-β2GPI-induced genes such as E-selectin, ICAM-1, and VCAM-1 but 
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the majority of the genes we have identified represent anti-β2GPI-induced genes 
not previously reported. 
 
Adhesion molecules and receptors common to Experiments 1 and 2, (p<0.05) 
included ICAM-1, VCAM-1 and IL18R1. Chemokines included CX3CL1, CXCL1 
and 2. A number of inflammatory genes activated by NF-κB pathway included IL-
1β, TNF-α, IL-6, and IL-8 (Tak & Firestein 2001). A total of 63 genes were 
changed two fold or greater in expression and common to both Experiments 1 and 
2 (Table 4.8). 
 
While the GO-ontology program in Genespring designated a number of anti-
β2GPI-regulated genes a proliferative function, a literature search for the 
association of aPL with vascular EC and myeloid cell lines yields very few papers. 
Isolated case reports present evidence of mitogenic activity in smooth muscle cells, 
fibroblasts and EC as part of the pathology in APS associated hypertension and 
intra-renal vascular disease (Durand et al., 1994). A woman with SLE and aPL 
presented with reactive angioendotheliomatosis (RAE) and histopathology of a 
skin lesion revealed marked expansion of the dermal microvasculature with 
intravascular EC proliferation and thrombosis (Creamer, Black, & Calonje, 2000). 
The possible contribution of selected genes identified in this study to cellular 
proliferation in PAPS is further addressed in the general discussion. GO-ontolgy 
was used to further discriminate those genes involved in chemotaxis of leukocytes 
(Table 4.5).  
 
qRT-PCR analysis was carried out for selected novel anti-β2GPI antibody 
regulated genes, covering a range of different fold levels of regulation. Genes 
included in this analysis were; CSF3, CX3CL1, FGF18, SOD2 and Tenascin C 
plus E-selectin as a positive control gene. The down-regulated gene ID2 was also 
incuded in these experiments. The results of these experiments are shown in Figure 
2.  All six up-regulated genes (CSF3, CX3CL1, E-Selectin, FGF18, Tenascin C 
and SOD2) were also found to be upregulated by qRT-PCR. Levels of fold 
upregulation were variable, but highest fold upregulation was found for CX3CL1 
that was the highest fold upregulated gene of the 6 selected genes selected for 
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microarray analysis (Figure 4.5a). Levels of fold induction for microarray 
Experiment 2 and corresponding qRT-PCR fold changes are given in Tables 4.6 
and 4.7).  In experiments 1 and 2 the largest group of up-regulated genes were 
transcription factors, and those genes involved in cell signaling. Ideally, our 
experimental protocol would have incorporated different time points to look at 
changes in gene expression over time. When a ligand makes contact with its 
receptor, the resulting signal can be amplified many times and a number of 
different and/or interacting signaling pathways may be activated. We chose the 
four hour time point to look at early gene expression in HUVEC in response to 
anti-β2GPI. This was early gene expression in the sense that in vivo, the EC are 
continually exposed to circulating anti-β2GPI. By looking at the four hour time 
point, activation of numerous genes would have already occurred and declined 
resulting in a number of autocrine mechanisms of gene regulation. Of interest, 
Simantov et al. (1995) reported a 4 hour time lag before increased evidence of 
monocyte adhesion in the presence of aPL (APS IgG). In conclusion, our qRT-
PCR analysis confirmed those changes in gene expression identified by microarray 
analysis.  
 
Combined results of Experiments 1 and 2 identified a number of novel anti-β2GPI 
induced genes. Of particular interest were high levels of chemokines and growth 
factors that could potentially contribute to the diverse spectrum of clinical 
phenomenon and systemic effects seen in APS and PAPS. Upregulation of large 
numbers of transcription factors and signaling molecules indicate a complex 
activation mechanism in EC in response to these antibodies. Many of these may 
contribute to further autocrine meachanisms of activation and regulatory 
mechanisms.  
 
In this study, microarray results revealed a transcription profile largely 
predominated by pro-inflammatory genes. Past opinion has defined the thrombosis 
in PAPS as being typified by non-inflammatory lesions (Lie et al., 1996) and such 
a description has been included in the diagnostic criteria of the disease (Wilson et 
al., 1999). Reassuringly, a number of genes previously associated with APS were 
identified and TF upregulation was confirmed. It is interesting to note that results 
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of another microarray experiment designed to identify differential PBMC genomic 
markers in APS patients with and without thrombosis in association with aPL did 
not in fact identify genes involved in coagulation (Potti et al., 2006). This may 
imply that the pro-inflammatory genes induced by anti-β2GPI are in fact 
responsible for the development of the pro-thrombotic EC phenotype. 
 
In conclusion, combined results of Experiments 1 and 2 identified a number of 
novel anti-β2GPI induced genes. Of particular interest were high levels of 
chemokines and growth factors that could potentially contribute to the diverse 
spectrum of clinical phenomenon and systemic effects seen in APS and PAPS. 
Upregulation of large numbers of transcription factors and signaling molecules 
indicate a complex activation mechanism in EC in response to these antibodies. 
Many of these may contribute to further autocrine mechanisms of activation and 
regulatory mechanisms. 
 154
 
 
 
 
 
Chapter 5 
General Discussion 
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5.1 Introduction 
The most striking feature of this study was the extent and diversity of anti-β2GPI 
antibody regulated genes in EC. The results revealed induction of a complex pro-
inflammatory as well as a pro-adhesive and pro-coagulant milieu by these 
antibodies, which potentially could be responsible, at least in part, for inducing 
and/or sustaining the vasculopathy of the syndrome. A number of angiogenic 
chemokines not previously associated with the syndrome were differentially 
expressed as well as several growth factors necessary for recruitment and 
proliferation of a number of cells involved in the inflammatory response. The 
relatively large number of anti-β2GPI antibody regulated genes identified also 
suggested activation of a signaling transduction cascade(s) as well as autocrine 
routes of activation following anti-β2GPI antibody binding to HUVEC. The 
possible contributions that some of the most highly upregulated genes may make to 
the pathology of PAPS are discussed in this chapter. 
 
 
5.2 Adhesion molecules and inflammation 
The endothelium normally acts as a selective barrier between blood and underlying 
tissue. It maintains blood flow, vascular integrity and supports normal hemostasis. 
However, the endothelium can be damaged by substances in the blood or physical 
stresses which result in changes in EC function. EC activation may be the result of 
turbulent blood flow, nitric oxide synthase (NOS), induced expression of 
inflammatory cytokines such as IL-1β and TNFα or infection. The first in vivo 
evidence of EC activation is the upregulation of selectins (P-selectin and E-selectin 
in that order) and integrins (ICAM-1 and VCAM-1) on activated EC (Cines et al., 
1998). 
 
In vivo, expression of these molecules enables the adhesion of leukocytes to the EC 
surface. After EC activation, newly expressed E-selectin loosely binds neutrophils 
as they roll along the endothelium carried by the flowing blood. The subsequent 
expression of ICAM-1 in combination with chemokine IL-8 on the extracellular 
matrix results in their firm adhesion. In addition, IL-8 activates surface receptors 
LFA-1 and Mac-1 on the neutrophil surface, and their expression results in firm 
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adhesion (tethering) to the EC surface. The chemokine IL-8 was upregulated 2 fold 
in Experiment 2 (Table 4.4). The recruitment and activation of monocytes 
succeeds that of neutrophils. In the presence of inflammatory cytokines such as 
TNF-α and IL1-β, monocytes migrate through the endothelium into the intima of 
the vessel wall where they differentiate into macrophages. This study has 
confirmed previously reported anti-β2GPI mediated upregulation of adhesion 
molecules E-selectin, ICAM-1 and VCAM-1 using microarray (Simantov et al., 
1995; George et al., 1998a). It is possible that persistent exposure of the 
endothelium to anti-β2GPI in vivo may result in the upregulation of adhesion 
molecules, subsequent recruitment and differentiation of monocytes into 
macrophages and chronic inflammation. This ongoing process may contribute to 
the proadhesive and prothrombotic EC phenotype associated with PAPS. 
 
 
5.3 Accelerated atherosclerosis 
Roughly one third of PAPS patients have atherosclerosis and a direct association of 
aPL with the pathogenesis of accelerated atherosclerosis in APS patients has been 
reported (Pierangeli et al., 2000; George, Harats & Shoenfeld, 2001). 
Immunoperoxidase staining has identified high concentrations of β2-GPI localised 
within atherosclerotic plaques, especially in subendothelial regions (George et al., 
1998b). It has been suggested that anti-β2GPI could contribute to the accelerated 
arterial disease seen in PAPS patients by stimulating upregulation of leukocyte 
adhesion molecules (Simantov et al., 1995; George et al., 1998a). Other cytokines 
and adhesion molecules found to be upregulated by anti-β2GPI antibodies may also 
have a role in the development of atherosclerosis. Monocytes have been shown to 
strongly express IL-18 in atheromatous lesions in situ (Mallat et al., 2001) and EC 
expression of IL-18R was increased 4.3 fold in this study. Gerdes et al. suggested 
an IL-18 mediated paracrine proinflammatory pathway involving monocytes, EC 
and smooth muscle cells in association with atherogenesis (Gerdes et al., 2002). 
CX3CL1 and its receptor CX3CR1 are expressed in the atherosclerotic lesions of 
humans and mice (Lucas et al., 2003) and in CX3CL1-deficient mice there is a 
major reduction of atherosclerosis (Teupser et al., 2004). 
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Clot formation and atherogenesis involve the sustained recruitment of 
mononuclear cells to the endothelial surface. Atherosclerotic lesion formation is 
initiated by the adherence of monocytes to adhesion molecules on the surface of 
activated EC. These monocytes differentiate into scavenger receptor bearing 
macrophages that absorb oxidized low density lipoprotein (oxLDL) forming foam 
cells characteristic of the lesions. These cells migrate into the sub-endothelium and 
contribute to plaque formation. Anti-β2GPI bind to β2GPI-oxLDL complexes and 
have been shown in vitro to enhance oxLDL uptake into monocytes/macrophages 
potentially accelerating the lesion formation (Hasunuma et al., 1997). ACL were 
reported to cross-react with anti-oxLDL antibodies and Vaarala and co-workers 
suggested that there may be a connection between this finding and the accelerated 
arterial disease observed in APS patients (Vaarala et al., 1993). It has been 
reported recently that β2-GPI inhibits LDL oxidation and cholesterol accumulation 
by macrophages in vitro and may therefore confer a protective effect by preventing 
the uptake of cholesterol (Hasunuma et al., 1997). If β2GPI confers a protective 
effect against atherosclerosis, antibodies to β2GPI may indeed interfere with this 
protective process.  
 
OxLDL is a risk factor for the development and progression of atherosclerosis. 
Initially it impairs endothelial relaxation (vasodilation) by reducing the expression 
of NOS and induces generation of reactive oxygen species (Morawietz et al., 
2001).   It also increases adhesion molecule expression and endothelial apoptosis 
(Morawietz et al., 2001). Expression of oxLDL receptor OLR1 was upregulated 
over four fold in this study (Table 4.1). Human OLR1 gene encodes the 
endothelium derived lectin-like oxidized low density lipoprotein receptor involved 
in the binding, internalisation and proteolytic degradation of oxLDL suggesting 
that it may play a significant role in atherogenesis and acute myocardial infarction 
(Kume et al., 1998; Mango et al., 2003). OLR1 expression is induced in vitro by 
inflammatory cytokines such as TNF-α and in vivo by pro-atherogenic conditions 
like hypertension, hyperlipidaemia, and diabetes mellitus (Kume et al., 1998). It 
acts as a mediator of endothelial dysfunction favouring superoxide generation, 
inhibiting nitric oxide production, and enhancing endothelial adhesiveness for 
monocytes. An increase in OLR1 expression could result in the increase in binding 
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of oxLDL and subsequent foam cell development and migration and would clearly 
contribute to atherosclerosis.  
 
Endothelin-1 (ET-1) is increased in cardiovascular diseases and increased levels 
are found in the plasma of patients with APS (Atsumi et al., 1998). ET-1 is a 
potent vaso-constrictor, expression is induced by aPL and ET-1 induces expression 
of OLR-1 (LOX-1) in EC (Morawietz et al., 2001). One downregulated gene GJA4 
(connexin 37) is an EC specific gap junction protein and interestingly 
polymorphisms in this protein have been associated with the development of 
arteriosclerotic plaques in human subjects. One allelic form of the gene (codon 
1019, C to T substitution) is significantly associated with smooth muscle cell 
proliferation and thickening of the carotid intima (Boerma et al., 1999). It has been 
proposed that GJA4 polymorphism may provide a link between chronic 
inflammation and development of atherosclerosis. Down-regulation of the gene in 
response to anti-β2GPI may mirror this effect although the mechanism is unclear 
(Boerma et al., 1999). 
 
5.4 Proliferation 
The GO-ontology program in Genespring classified a number of anti-β2GPI 
regulated genes into the functional category of proliferation. A number of 
chemokines such as IL-8 and growth factors such as FGF18 (fibroblast growth 
factor) and VEGF were upregulated by anti-β2GPI antibodies in the present study 
and may contribute to the hyperplasia associated with PAPS. APS is associated 
with EC proliferation and fibrosis characterized by intimal hyperplasia within the 
lumen of micro-capillaries typically within the kidney (Frampton et al., 1991). It is 
also associated with cardiac lesions involving thickening of heart valves with 
deposition of aPL in the subendothelial layers (Nesher et al., 1997). Histologic 
examination of renal biopsies from 16 patients with PAPs showed small vessel 
vaso-occlusive lesions associated with myofibroblastic intimal cellular 
proliferation and thrombosis, five patients showed endothelialized channels 
indicating recanalizing thrombosis and EC proliferation (Nochy et al., 1999). In 
addition to intrarenal arteries and arterioles, intimal hyperplasia has been noted in 
PAPS patients in lung, skin and brain (Amigo & Garcia-Torres 2000).  
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Chemokines induced by anti-β2GPI in this study included CCL20, CXCL3, 
CX3CL1 (fractalkine), CXCL5, CXCL2 and CXCL1. All are involved in 
recruitment, chemotaxis and proliferation of mononuclear cells and/or 
granulocytes. These findings are consistent with a number of in vitro and in vivo 
studies reporting that anti-β2GPI antibodies increased monocyte adhesion to EC 
(Simantov et al., 1995; Del Papa et al., 1995; Pierangeli et al., 1999). Moreover, 
placental biopsies from APS patients had a higher concentration of inflammatory 
cells particularly macrophages (Stone et al., 2006) and an association has been 
found between neutrophil recruitment and fetal loss in APS (Girardi et al., 2003).  
Other growth related genes of interest with increased expression included growth 
factors CSF2 (GM-CSF, up 12 fold) and CSF3 (G-CSF, up 7 fold). These factors 
may also contribute to proliferation, concentration and homing of white blood cells 
(Barreda, Hanington & Belosevic, 2004). 
 
 
5.5 Angiogenesis 
A number of genes identified in this study are associated with angiogenesis and 
this process involves the proliferation of vascular EC. Development of new vessels 
(neovascularization) may contribute to plaque formation and plaque growth. It is 
more common at sites where there has been infiltration of inflammatory cells such 
as macrophages and lymphocytes (Khurana et al., 2005). Angiogenesis is evident 
in renal lesions in APS patients. This is associated with renal artery lesions, 
stenosis, thrombi, microagiopathy and hypercellularity of EC and mononuclear 
cells. Intriguingly all five of the CXC chemokines upregulated in response to anti-
β2GPI in this study are proangiogenic in function (CXCL3, CXCL2, CXCL1, 
CXCL5, CXCL8) (Streiter et al., 2005). 
   
VEGF is the most potent stimulator of angiogenesis. VEGF acts in combination 
with G-CSF to mobilize EC progenitor cells from the bone marrow (Ferrara et al., 
1997). Recently described, DSCR1 is a calcineurin inhibitor and its expression is 
induced by VEGF (Hesser et al., 2004). Induced genes with inhibitory functions 
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are of interest because they may represent endogenous feedback mechanisms that 
shut down the inflammatory response. DSCR1 is an example of one such gene.   
 
 
5.6 Signaling Pathways 
Regulation of many of the anti-β2GPI antibody induced genes occurs through NF-
κB signaling and this pathway has been shown previously to be involved in anti-
β2GPI antibody mediated effects in EC (Dunoyer-Geindre et al., 2002). Of note, 
both NFκB1 and one of its inhibitors NFκBIA were induced in this study. To date 
the mechanisms of signal transduction upstream of NFκB1 not been characterized. 
Anti-β2GPI - induced translocation of NF-κB to the cell nucleus results in a pro-
inflammatory and pro-thrombotic EC phenotype similar to that seen in response to 
LPS and pro-inflammatory cytokines IL1-β and TNF-α. This observation is 
supported by the large number of pro-inflammatory genes upregulated in this 
study. LPS, IL1-β and TNF-α induced activation pathways are mediated by the 
TNF-receptor associated factor (TRAF) adapter family (Meroni et al., 2000). LPS 
and IL-1 interact with toll-like receptor 4 (TLR4) and IL1 receptor (IL-1R) 
respectively and both of these receptors share a common cytoplasmic signaling 
domain, the toll/IL-1R receptor domain (TIR). 
 
Investigations by Raschi et al. (2003a) indicated that anti-β2GPI - mediated EC 
activation potentially involves a member of the TLR/IL-1 receptor family and 
activation occurs through a mechanism different from that induced by TNF-α 
(Raschi et al., 2003). Their group made the association between the TLR/myeloid 
differentiation protein (MyD88) dependent signaling pathway and anti-β2GPI- 
dependent NF-κB induced gene expression. Dominant negatives of MYD88 and 
TRAF6 completely abrogated anti-β2GPI–induced NF-κB activation in a 
microvascular EC line (Raschi et al., 2003a).  
 
Thrombin is a serine protease whose functions include involvement in coagulation, 
cell proliferation and inflammation. Thrombin acts through a specific thrombin 
receptor on the EC surface. A recent microarray study has identified a number of 
thrombin-induced genes in HUVEC. These included ICAM-1, IL-8, CXCL3, 
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CXCL1, and BIRC3. VCAM-1, CXCL2, CCL20, CSF2 and CD69 were up-
regulated but did not reach statistical significance in that study (Okada et al., 
2006). Interestingly, all of these genes were induced by anti-β2GPI in this study. 
CCL20 was one of the more highly induced genes in response to thrombin. CCL20 
(macrophage inflammatory protein-3α or MIP-3α) was the most highly induced 
gene in Experiment 2: up 27 fold in expression in this study. Since the expression 
of CCL20 can be strongly induced by pro-inflammatory cytokines such as TNF-α, 
IL-1β or Escherichia coli LPS (Perez-Canadillas et al., 2001), this observation 
indicates some common elements of activation in EC in response to a number of 
pro-inflammatory mediators and these should include anti-β2GPI antibodies.  
 
However, the anti-β2GPI antibody induced gene panel described in this study is 
largely distinct to those described in gene profiling studies on HUVEC with 
different cytokines or LPS (Zhao et al., 2001; Mayer et al., 2004).  Nonetheless, a 
small subset of anti-β2GPI antibody-induced genes (for example, E-selectin, IL-8, 
VCAM-1), have been shown to be induced by cytokine and/or LPS-induced gene 
profiling of HUVEC (Zhao et al., 2001; Mayer et al., 2004).  Genes induced by 
LPS include plasminogen activator inhibitor and monocyte chemotractant protein. 
Both of these genes exert a procoagulant effect on EC and interestingly neither of 
these genes was up-regulated by anti-β2GPI (Zhao et al., 2001). In addition, 
phosphorylation of p38MAPK is known to be increased in the presence of aPL 
(Vega-Ostertag et al., 2005) and is involved in the transcription and expression of 
TF, IL-6 and IL-8, and all three of which genes were induced in this study. The 
p38MAPK signaling pathway has been shown to have a role in anti-β2GPI 
mediated signaling in HUVEC and monocytes, and this pathway may also 
contribute to the regulation of some of the genes identified in our study (Raschi et 
al., 2003a; Bohgaki et al., 2004).  
 
 
5.7 Possible receptors for β2GPI  
β2GPI has been reported to bind to cells in a number of different ways. For 
example, it can bind to anionic membrane molecules such as heparan sulphate and 
it has also been reported to bind as a ligand to the annexin II receptor (Meroni et 
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al., 2005; Zhang et al., 2005).  Annexin II receptor is the receptor for plasminogen 
/plasminogen activator inhibitor. Annexin II receptor is not a trans-membrane 
protein so must therefore be associated with an adaptor protein in order to convey 
signal to the cells. It has been proposed that similar sequence homology between 
bacterial/viral peptides (natural ligands for TLRs) and β2GPI may be responsible 
for the binding of β2GPI to TLR4 alone or in combination with another receptor. It 
has been postulated that anti-β2GPI may bind to Annexin II in combination with 
TLR co-receptor, crosslinking the TLRs via F(ab)2 binding and resulting in cellular 
activation (Zhang et al., 2005).  
 
In support of this hypothesis, an in vivo study by Pierangeli et al. (2007) looked at 
the effects of aPL on thrombus formation and white cell adhesion in a mouse 
model with a polymorphism in TLR4 gene. This polymorphism is associated with 
impaired response to LPS (Shoenfeld et al., 2006). Injection of APS IgG induced 
formation of significantly larger thrombi and induced more white cell adhesion in 
wild type mice when compared to those with the TLR4 mutation or injection of 
normal control IgG (Pierangeli et al., 2007). These results suggest a possible 
association between β2GPI and the TLR family. Since β2GPI displays molecular 
mimicry with microbial pathogens, it seems possible that β2GPI may associate 
with TLRs (Shoenfeld et al., 2006).  
 
Annexin II is also a high affinity receptor for Tenascin C, a component of the 
extracellular matrix that functions as an adhesion molecule, shown in this study to 
be upregulated by anti-β2GPI antibody (Chung et al., 1996).   
 
An important question in relation to the findings in this study is their relevance to 
the in vivo situation. Is there evidence in vivo for the presence of increased 
expression of any or all of these genes in APS patients? aPL activate endothelium 
both in vitro and in in vivo experimental models by inducing a pro-
inflammatory/coagulant phenotype. A recent study, measuring a limited number of 
parameters of EC function, concluded that aPL antibodies were unable to support a 
full-blown endothelial perturbation in vivo (Meroni et al., 2004). There is evidence 
however, from other studies, for increased circulating levels of TF, IL-6, TNFα 
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(Forastiero, Martinuzzo, & de Larranaga 2005) and VCAM-1 in APS patients 
(Kaplanski et al., 2000). This study suggests that increased levels of some 
cytokines might, at least in part, be EC derived and therefore evidence of 
endothelial perturbation in vivo. It will be interesting to address whether there are 
increased plasma levels of some of the cytokines/chemokines newly identified in 
this study as anti-β2GPI antibody EC regulated genes in APS patients. 
 
In order to determine an association between aPL and β2GPI in vivo, it was 
necessary to establish whether β2GPI was expressed on EC throughout the 
vasculature. Indeed, preliminary studies revealed that β2GPI was expressed on 
HUVEC (Del Papa et al., 1995) while both human monoclonal and affinity 
purified polyclonal IgG anti-β2GPI antibody preparations recognized β2GPI 
adherent to EC in placental vessels (La Rosa et al., 1994). In order to explain the 
wide range of clinical associations between anti-β2GPI and vasculopathy 
associated with both macro and microvasculature, it was necessary to determine 
whether or not β2GPI is expressed on EC of different anatomical origin. 
Expression of β2GPI on both human brain microvascular EC (HBMEC) and 
dermal EC (HDMEC) was confirmed and it seems likely that β2GPI is 
constitutively expressed (Meroni et al., 2003).  
 
EC are recognized for their heterogeneous phenotypes within different parts of the 
vasculature and within organ systems (Cines et al., 1998). Decrease in blood flow, 
injury to the vessel wall (EC damage) and a change in pro-coagulant/anticoagulant 
balance create a pro-thrombotic EC phenotype. Differences in EC phenotype and 
signaling pathways unique to portions of the vascular bed give rise to focal 
thrombotic lesions such as those seen in APS (Rosenberg & Aird 1999). An 
extensive and interesting study by Chi et al. (2003) used global gene expression 
profiling in order to determine differences in gene expression between EC from a 
variety of anatomical sites. Not surprisingly, their results confirmed distinct 
differences in EC gene expression patterns between large and microvascular 
vessels, between arterial and venous EC and identified organ specific differences 
as well. The heterogeneity of EC phenotype within the vasculature combined with 
different binding and activation characteristics of patient derived polyclonal anti-
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β2GPI antibodies could help to explain the diverse clinical pathology observed in 
patients with PAPS.  
 
The largest subset of differentially expressed genes that were identified in this 
study were those genes involved in the inflammatory response. Vascular 
thrombosis is a common feature of pathologic inflammation in the vasculature and 
numerous in vitro experiments have linked coagulation with inflammatory 
processes (Kaplanski et al., 1997). It is tempting to speculate that a combination of 
increased adhesion molecules, pro-inflammatory cytokines and chemokines in 
addition to increased TF expression could strongly support development of 
thrombosis and contribute to the advancement of atherosclerotic lesions in 
response to anti-β2GPI antibodies. For example, circulating anti-β2GPI in 
susceptible individuals may stimulate an on-going chronic activation of EC, in the 
cerebral circulation for example, or in conjunction with impaired circulation in a 
leg vein or capillaries in the extremities. Up-regulation of chemotactic chemokines 
and adhesion molecules on the EC surface will encourage recruitment and 
activation of leukocytes and platelets. Monocytes and EC, already primed to 
produce TF will produce even more. This would result in more platelet activation, 
thrombin generation and localized clot formation within either the venous and/or 
arterial circulation. This scenario presents a very plausible explanation for the 
increased incidence of thrombosis in PAPS patients.  
 
It is not uncommon for the value of microarray analysis to be diminished by being 
defined as a “fishing expedition”. It is in fact just that, but its value lies in its 
ability to screen for significant changes in expression in vast numbers of genes in 
the human genome in relation to different biological samples and variables. In the 
present report, rigorous experimental design and replication, access to well-defined 
primary tissues/clinical sources and robust statistical analysis have contributed to 
the generation of meaningful and reliable data. This observation was further 
strengthened by our validation of previous findings by other investigators. The 
microarray approach interrogates the expression levels of a large number of known 
genes so there is no bias for or against those genes thought to be involved in EC 
biology and PAPS.  
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5.8 Limitations of the study 
• This study was restricted to the analysis of gene expression in response to 
anti-β2GPI after a four hour incubation time. Analysis of differential gene 
expression at a number of time points would be potentially more 
informative. However, the four hour data provides a reference point on 
which to base future studies. 
• Well-characterized, readily attainable, macrovascular HUVEC were used 
as the source of EC in this study. In addition, it would have been interesting 
and useful to use cells such as microvascular EC that would be more 
biologically appropriate to the pathology of APS.  
• Normal control IgG was used as negative control antibody throughout the 
study. Another specific AECA could have been used in addition to normal 
control.  
• An additional control that would have been valuable in this investigation 
would be IgG from patients with history of thrombosis and no aPL. 
   
 
5.9 Future perspectives 
Further experiments, utilizing our panel of anti-β2GPI antibody-regulated genes 
and specific inhibitors and/or dominant negatives of important signaling 
components will map particular signal transduction pathways to induction of 
specific genes. One possibility however that has to be considered is that our 
regulated genes may include some or many genes not regulated by anti-β2GPI 
antibody directly but rather indirectly by autocrine cytokine/chemokine production 
produced by EC cells shortly after anti-β2GPI antibody exposure. Clearly, many 
cytokines/chemokines are induced and they could themselves then induce gene 
expression in EC by binding to high affinity receptors on the EC. This possibility 
should be addressed in future studies aimed at investigating the signal transduction 
mechanisms responsible for anti-β2GPI antibody mediated gene regulation in EC. 
Future studies should aim to identify specific genes responsible for the functional 
effects of anti-β2GPI antibodies on EC.  
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It would be valuable to map the specific signal transduction pathways responsible 
for mediating gene expression, by using specific inhibitors of the different 
pathways. Mapping of the signaling pathways could identify potential molecular 
targets for future therapeutic approaches in APS. Potential cell receptors such as 
Annexin II or TLR4 could be targeted with their specific ligands and the resultant 
gene expression could be compared with that obtained with anti-β2GPI antibodies. 
Specific genes within the panel could be targeted using siRNA. Down regulation 
of a specific gene may be seen to inhibit anti-β2GPI mediated monocyte adhesion 
or other EC functions including angiogenesis and apoptosis.  
 
EC from different vascular beds (microvascular) could be used to see if there are 
differences in antibody-mediated gene expression in EC that may be more relevant 
to disease pathology. It may be possible to obtain samples of relevant tissue from 
APS patients such as placental tissue (trophoblasts), kidney biopsies, heart valves 
or skin biopsies. RT-PCR or fluorescent microscopy could be used to compare 
gene expression in these tissues compared to normal tissue. 
 
This study did not identify large differences in gene expression profiles between 
the different anti-β2GPI antibody preparations. As previously discussed, the largest 
differences in gene expression were between EC from different donors and not due 
to the individual antibody preparations. Even though the corresponding patients 
had differences in their clinical histories, there were also similarities. It would be 
interesting to look at gene expression profiles in response to anti-β2GPI in patients 
with aPL and a history of purely venous or arterial thrombosis or recurrent 
pregnancy loss as well as SLE patients to see if there were differences in antibody 
induced gene expression. Also, anti-β2GPI antibodies from patients with aPL but 
no history of APS symptoms would be a useful source for comparison in gene 
expression studies. 
 
Fitting with disease criteria, many of the genes identified in this study are involved 
in the mechanisms of inflammation, proliferation and angiogenesis.  New evidence 
suggests that aPL-mediated pregnancy loss and IUGR may be the result of 
complement activation and recruitment of inflammatory cells. Subsequent increase 
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in expression of TNFα and other inflammatory mediators shifts the cytokine 
balance from TH2 associated with normal pregnancy outcome to TH1 and the 
innate immune response (Berman et al., 2005). In the present study however, anti-
β2GPI were able to activate EC in the absence of complement in vitro and induce 
expression of a number of proinflammatory genes. Taken together, these findings 
suggest a more significant inflammatory component in the etiology of PAPS (and 
APS) than previously thought. 
 
In conclusion, by using microarray gene profiling we have confirmed and extended 
the analysis of anti-β2GPI antibody regulated genes and identified a panel of genes 
that may be responsible for EC phenotype in PAPS. Characterization of the 
expression levels in vivo in APS patients and the signal transduction cascades 
responsible for induction or downregulation of this gene panel should provide 
important new information relevant to understanding the role of anti-β2GPI 
antibodies in APS pathology. Most importantly, therapeutic targeting of one or 
more pathological induced genes could contribute to lessening of disease severity. 
It may also be possible to link upregulation of one or more gene- regulated plasma 
markers in APS to patients at greater risk of developing thrombosis or accelerated 
arterial disease or at the very least gene(s) products may act as important 
biomarkers of the disease. Moreover, these findings could have wider implications 
for other diseases, such as SLE, where anti-β2GPI have been described.  
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1.0 Appendix:  Buffers and Formulations 
1.1 Reagents for aCL ELISA 
 
1. PBS 
3 PBS tablets 
600 ml deionized water 
pH 7.4 
2. 10% ABS-PBS solution 
20 ml adult bovine serum (Sigma) 
180 ml PBS 
3. Substrate Buffer- Magnesium Carbonate pH 9.8 
0.6g NaHC03 
0.025g MgCl2.6H20 
100 ml dH20 
 
1.2 Coating buffer for anti-β2GPI ELISA 
Coating Buffer- 0.05M Carbonate Buffer pH 9.6 
1.59g Na2C03 (anhydrous) MW 105.89 
2.93g NaHC03 MW 84.01 
Dissolved in 1l of deinoised water. 
 
1.3 Storage solution for umbilical cords 
For 8 pots; 
 
1) 360ml H20 (sterile  water) 
2) 40ml Hanks buffer (Sterile, Sigma) 
3) 15ml bicarb/phenol red (Bicarb: 44g/l, add 0.1% phenol red (Sigma) 
4) 10ml 1M HEPES 
5) 5ml gentamycin (7.5mg/ml in PBS)  
 
Cord pots can be obtained from Scientific Labs (www.scientificlabs.com)  
Cat; SL57588 (250ml, metal cap plain label) 
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1.4 Reagents for IgG and anti-β2GPI purification 
1. Binding Buffer 
20 mM NaP04,  pH 7.0 
2.76 g NaP04         FW = 138.0 
Dissolved in 1L dH20. 
2. Elution Buffer 
0.1M Glycine-HCl,  pH 2.7 
1.115g Glycine-HCl    FW=111.5 
Dissolved in 100 ml dH20 
3. Neutrallization Buffer 
1 M Tris-HCl,  pH 9.0 
15.76g Tris-HCl     FW=157.6 
Dissolve in 100 ml dH20. 
 
1.5 Reagents for preparation of β2GPI affinity purification columns 
1. Coupling Buffer  
0.2M NaHC03  FW= 84.0 13.36g dissolved in 200 ml dH20. 
0.5M NaCl   FW=58.44 5.844g dissolved in 200 ml dH20. 
pH 8.3 
2. Inactivation of HP (blocking of free binding sites) 
Buffer A   
0.5M ethanolamine   (.054 ml)) 
0.5 M NaCl     (2.922 g). 
in 100 ml dH20   pH 8.3 
Buffer B 
0.1M acetate  (0.6 ml acetic acid) 
0.5M NaCl    (2.922 g) 
in 100 ml dH20  pH 4.0 
3. Storage Buffer 
20 mM NaH2P04    FW=120.0 (0.12 g in 50 ml dH20) 
0.1% NaN3    0.05g 
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2.0 Reagents and equipment required for HUVEC isolation and culture 
• Collagenase Enzyme- working concentration 100mg/ml (Sigma 500 mg 
reconstituted in 5.0 ml sterile deionized water, aliquoted and frozen at –
70°C. 
• Fetal Calf Serum- Endotoxin tested (Biowest) 
• 0.1% gelatin (Sigma 2% stock, diluted in sterile deionized water, store at 
4°C.) 
• DMEM- Dulbecco’s Eagle’s Medium- Sigma (contains 1000 mg glucose/l, 
L-glutamine, NaHCO3, pyridoxine HCl) 
• DMEM + 10% Fetal Calf Serum (Biowest) 
• Fungizone (Gibco- 250 µg/ml stock- working concentration 2.5 µg/ml, add 
5 ml of stock to 500 ml of media) 
• L-Glutamine (Sigma- 200 mM stock- working concentration 2mM- add 5 
ml to 500 ml) 
• Penicillin and Streptomycin (Sigma P4333- 5mLs stock in 500 ml media- 
final concentration 100 u/ml Penicillin/ 100 µg/ml Streptomycin) 
• Medium 199- Gibco BRL- 25mM Hepes, 500 ml. 
• Medium 199 +10% FCS + Pen/Strep- complete media 
• Hanks Balanced Salt Solution (Sigma) 
• 0.5 %Trypsin-EDTA (Sigma- T3924) 
• Large and small tissue culture flasks (75 and 250 ml) 
• Sterile 50ml Falcon tubes 
• Sterile 20ml syringes 
• Sterile 20ml universals 
• Sterile 5ml and 10ml pipettes 
• Bone marrow needles (2 per cord) 
• String, gloves 
• Scissors and clamps 
• 0.22µm Millipore filters 
• Class 2 tissue culture hood for human work 
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3.0 Contents of Qiagen RNeasy Mini Kit (50 columns) 
Catalog no. 74104 74106 
Number of preps 50 
RNeasy Mini Spin Columns (pink) 50  
Collection Tubes (1.5 ml) 50  
Collection Tubes (2 ml)* 50  
Buffer RLT*† 45 ml  
Buffer RW1† 45 ml  
Buffer RPE‡ (concentrate) 11 ml  
RNase-Free Water 10 ml  
 
Two-Cycle Target Labeling 
■ Two-Cycle Target Labeling and Control Reagents, Affymetrix, P/N 900494 
A convenient package containing required labeling and control reagents to perform 
30 two-cycle labeling reactions. Each of these components may be ordered 
individually (described below) as well as in this complete kit. 
 
Contains: 
■ 1 IVT Labeling Kit (Affymetrix, P/N 900449) 
■ 1 Two-Cycle cDNA Synthesis Kit (Affymetrix, P/N 900432) 
■ 2 Sample Cleanup Modules (Affymetrix, P/N 900371) 
■ 1 Poly-A RNA Control Kit (Affymetrix, P/N 900433) 
■ 1 Hybridization Control Kit (Affymetrix, P/N 900454) 
■ MEGAscript® High Yield Transcription Kit, Ambion Inc, P/N 1334 
 
 
4.0 Sterilization 
All sterilization procedures were carried out by autoclaving at 15lb/in2 for 20 
minutes at 121ºC using a Rodwell Series 32 autoclave. 
 
 
 
 
 
 
 
 
 196
Appendix  Table 1   Activation of E-selectin and ICAM-1 in HUVEC induced 
by incubation with IgG from APS patients. 
 
 
      Ratio Ratio 
Sample E-selectin ICAM Pt IgG to  Pt IgG to 
  OD  OD N Cont IgG N Cont IgG 
      E-Selectin ICAM-1 
1 0.683 0.794 3.15 4.08 
2 0.593 0.786 2.34 3.97 
3 0.65 0.858 2.84 4.96 
4 0.564 0.681 2.09 2.53 
5 0.589 0.654 2.31 2.16 
6 0.469 0.679 1.28 2.51 
7 0.538 0.734 1.87 3.26 
8 0.516 0.676 1.68 2.46 
9 0.514 0.66 1.66 2.25 
10 0.561 0.682 2.07 2.55 
11 0.531 0.675 1.81 2.35 
12 0.449 0.589 1.1 1.27 
13 0.432 0.595 0.957 1.36 
NIgG         14 0.437 0.569              1.0                1.0 
Negative 
control   
 0.321 
 
 0.496 
     
TNF Positive 
control  
 0.836 
 
 0.879 
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A 
          B 
Appendix Figure 1A and 1B  Elution of IgG and anti-β2GPI using 
AKTAprime. Plot of elution (acid pH 2.7) of PAPS patient (A) IgG from 
Sepharose HiTrap G Protein S column and (B) anti-β2GPI from NHS 
activated sepaharose column coupled to β2GPI (B) using the UV recorder 
(AKTAprime). The x axis represents time in minutes, the y axis represents 
OD at  
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Appendix Table 2   Determination of RNA content in confluent HUVEC.  
RNA concentration in HUVEC was determined. HUVEC were checked for 
viability using trypan blue exclusion test. One well of confluent HUVEC (six well 
tissue culture plate) yielded enough RNA for an Affymetrix chip (approximately 5 
µg). 
 
 
 
Ratio of 
Purity 
Total RNA 
    In  µg 
Viability  
1 well    
810,000 2.44 4.7 98% 
2 wells    
1,600,000 2.273 12 99% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 2   Gel electrophoresis of HUVEC RNA. RNA was 
extracted from confluent HUVEC grown in a six well tissue culture Plate. 
A: RNA was extracted from one well (approximately 1 x 106 cells) B: RNA 
was extracted from two wells. Both A and B show two ribosomal bands, 
28S and 18S. DNA ladder was included to indicate proper running of gel, 
not for sizing. 
 
2000kb 
1500kb 
 
1000kb 
28S 
 
18S 
1kb DNA 
Ladder A         B 
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Appendix Figure 3   RNA for Affymetrix microarray analysis. Quality 
of Qiagen purified RNA was checked on a RNA 6000 Nano Assay gel chip 
before proceeding with protocol for preparation of fragmented cRNA. 
Samples shown are 8 samples processed in the first part of Experiment 1. 
 
Appendix Figure 4   Fragmented cRNA for hybridization to 
Affymetrix chips. Successful fragmentation of cRNA was checked on a 
RNA 6000 Nano Assay gel chip before proceeding to preparation of the 
hybridization cocktail. Fragmented cRNA should range from 35-200 bp in 
length as seen in this figure. 
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Appendix Figure 5    Scan of cRNA prepared for Affymetrix run on 
gel. Scan shows marker on left and the distribution cRNA transcripts for 
one sample determined by their size. The right of the figure shows a smear 
of cRNA ranging from 50 to 3000 bp long. 
 
Appendix Figure 6   Scan of fragmented cRNA. Scan shows marker on 
left and distribution of cRNA transcripts after fragmentation for one 
sample. Fragment sizes range from 35-200 bp in length. 
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Appendix Figure 7   Gel purification of cDNA standards for qRT-PCR.  
A. cDNA standards for SOD2 (1) and ID2 (2) were run on a 2% agarose 
gel containing EtBR for visualization. 100 bp ladder (L) was run in parallel. 
B. Bands of gel containing standards were carefully cut out and placed in 
dialysis tubing.  
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5.0 qRT-PCR Raw Data 
SOD2 
 
  Mean copy no /µl SD SEM 
Sample 1 7502000000 7.75E+09 3872790747 
Sample 2 5927250000 5.81E+09 2906988286 
Sample 3 1469650000 1.59E+09 794830918.6 
Sample 4 552400000 5.57E+08 278685417 
Sample 5 49267500 50106585 25053292.32 
Sample 6 1338675000 1.48E+09 738974157.6 
Sample 7 25413500000 2.85E+10 14239950453 
 
Normalised to β-actin 
    
 Β-actin SOD2 normalised values fold change 
Sample 1 97200000 7.5E+09 77.18106996 29.4515475 
Sample 2 103840000 5.93E+09 57.08060478 21.781405 
Sample 3 31680000 1.47E+09 46.39046717 17.7021522 
Sample 4 108200000 5.52E+08 5.105360444 1.94815601 
Sample 5 18800000 49267500 2.620611702 1 
Sample 6 44860000 1.34E+09 29.84117254 11.3871019 
Sample 7 23566666.67 2.54E+10 1078.366337 411.494132 
 
CX3CL1 
 
 Mean copy no/ul SD SEM 
Sample 1 9280000 6393762.586 3196881.293 
Sample 2 11080000 5610805.052 2805402.526 
Sample 3 3255000 1099014.71 549507.3551 
Sample 4 396450.8425 584553.6704 292276.8352 
Sample 5 20787.015 16128.51314 8064.256572 
Sample 6 12630000 5817806.001 2908903.001 
Sample 7 259000000 55506756.35 32046840.72 
 
 
 
 
Normalised to β-actin    
 β-actin CX3CL1 normalised values fold change 
Sample 1 97200000 9280000 0.095473251 86 
Sample 2 103840000 11080000 0.106702619 97 
Sample 3 31680000 3255000 0.102746212 93 
Sample 4 108200000 396450.8425 0.003664056 3 
Sample 5 18800000 20787.015 0.001105692 1 
Sample 6 44860000 12630000 0.281542577 255 
Sample 7 23566666.67 259000000 10.99009901 9940 
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ID2 
 
 
 Mean copy no/ul SD SEM 
Sample 1 201411.78 24493.5 12246.7485 
Sample 2 88383.0675 13331.07 6665.535831 
Sample 3 25691.43 13055.9 6527.949307 
Sample 4 267034.885 54205.99 27102.99708 
Sample 5 40423.0875 12571.49 6285.742562 
Sample 6 30678.1875 22661.23 11330.6127 
Sample 7 59304.93 45800.91 22900.45681 
 
 
 β-actin ID2 normalised values fold change 
Sample 1 97200000 201411.8 0.002072138 0.963711342 
Sample 2 103840000 88383.07 0.000851147 0.395851923 
Sample 3 31680000 25691.43 0.000810967 0.377165077 
Sample 4 108200000 267034.9 0.002467975 1.14780763 
Sample 5 18800000 40423.09 0.002150164 1 
Sample 6 44860000 30678.19 0.000683865 0.318052487 
Sample 7 23566666.67 59304.93 0.002516475 1.170364139 
 
 
E-selectin 
 
 
 Mean copy no/ul SD SEM 
Sample 1 17100000 2412468 1206233.808 
Sample 2 15150000 2595509 1297754.471 
Sample 3 5947500 1844639 922319.3138 
Sample 4 213473.7 68326.23 34163.11395 
Sample 5 119067.9 61973.79 30986.89255 
Sample 6 19450000 6605301 3302650.451 
Sample 7 1.27E+08 41119501 23740354.77 
 
 
 
 β-actin SELE normalised values fold change 
Sample 1 97200000 17100000 0.176 27.777498 
Sample 2 1.04E+08 15150000 0.146 23.036221 
Sample 3 31680000 5947500 0.188 29.642345 
Sample 4 1.08E+08 213473.7 0.002 0.3115161 
Sample 5 18800000 119067.9 0.006 1 
Sample 6 44860000 19450000 0.434 68.457907 
Sample 7 23566667 1.27E+08 5.400 852.66766 
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TNC 
 
 
 Mean copy no/ul SD SEM 
Sample 1 88723 19442 9721 
Sample 2 219358 67154 33577 
Sample 3 30406 16975 8488 
Sample 4 15517.00333 4275 2468 
Sample 5 2598 384 192 
Sample 6 12053.5 3574 2063 
Sample 7 52299 29900 14950 
 
 
 β-actin TNC normalised values fold change 
Sample 1 97200000 88723 0.000912783 6.6045402 
Sample 2 103840000 219358 0.002112463 15.284946 
Sample 3 31680000 30406 0.000959782 6.9446039 
Sample 4 108200000 15517 0.00014341 1.0376608 
Sample 5 18800000 2598 0.000138205 1 
Sample 6 44860000 12053.5 0.000268691 1.9441453 
Sample 7 23566666.67 52299 0.002219195 16.057214 
 
 
 
FGF18 
 
 Mean copy no/ul SD SEM 
Sample 1 41685 7531 3766 
Sample 2 49754 7102 3551 
Sample 3 7964 406 203 
Sample 4 13838 3549 1775 
Sample 5 1093 328 164 
Sample 6 7201 2107 1054 
Sample 7 28949 10834 5417 
 
 
 
 
 
 β-actin FGF normalised values fold change 
Sample 1 97200000 41685 0.000428857 7.4 
Sample 2 103840000 49754 0.000479138 8.2 
Sample 3 31680000 7964 0.000251383 4.3 
Sample 4 108200000 13838 0.000127893 2.2 
Sample 5 18800000 1093 5.81328E-05 1.0 
Sample 6 44860000 7201 0.000160514 2.8 
Sample 7 23566666.67 28949 0.001228392 21.1 
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CSF3 
 
 Mean copy no/ul SD SEM 
Sample 1 749421 114924 57462 
Sample 2 261875 25089 12544 
Sample 3 252702 33728 16864 
Sample 4 42088 5766 2883 
Sample 5 9884 3179 1590 
Sample 6 149550 96403 48202 
Sample 7 16280 12637 6318 
 
 
 β-actin CSF normalised values fold change 
Sample 1 97200000 749421 0.00771 14.67 
Sample 2 103840000 261875 0.00252 4.80 
Sample 3 31680000 252702 0.00798 15.17 
Sample 4 108200000 42088 0.00039 0.74 
Sample 5 18800000 9884 0.00053 1.00 
Sample 6 44860000 149550 0.00333 6.34 
Sample 7 23566666.67 16280 0.00069 1.31 
 
 
 
 
 
 
 
Appendix Figure 8   qRT-PCR standard curve for β-actin.  Standard was run in 
duplicate for 1 x 108 – 1x 100 copy number. 
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Appendix Figure 9   Dissociation curve for ID2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
